{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "schemaVersion": "4.0.0",
  "instanceType": "StudyDocument",
  "id": "USDM-M14-359-20251208193910",
  "name": "Protocol Extraction: M14-359",
  "sourceDocument": {
    "documentId": "DOC-28ACEDF428D666A3",
    "filename": "NCT02264990_M14-359.pdf",
    "sha256Hash": "28acedf428d666a301244cf1cec6e578c66e266a294fed7c54d571a072dba039",
    "byteSize": 3757803,
    "uploadTimestamp": "2025-12-08T19:39:10.315230",
    "pageCount": 154
  },
  "extractionMetadata": {
    "extractionTimestamp": "2025-12-08T19:39:10.429105",
    "pipelineVersion": "3.1",
    "primaryModel": "gemini-2.5-pro",
    "agentCount": 16,
    "successfulAgents": [
      "study_metadata",
      "arms_design",
      "endpoints_estimands_sap",
      "adverse_events",
      "safety_decision_points",
      "concomitant_medications",
      "biospecimen_handling",
      "laboratory_specifications",
      "informed_consent",
      "pro_specifications",
      "data_management",
      "site_operations_logistics",
      "quality_management",
      "withdrawal_procedures",
      "imaging_central_reading",
      "pkpd_sampling"
    ],
    "failedAgents": [],
    "qualitySummary": {
      "study_metadata": {
        "overallScore": 0.9964539007092198,
        "fromCache": true
      },
      "arms_design": {
        "overallScore": 0.9968434343434344,
        "fromCache": true
      },
      "endpoints_estimands_sap": {
        "overallScore": 0.9957886676875957,
        "fromCache": true
      },
      "adverse_events": {
        "overallScore": 0.9400000000000001,
        "fromCache": true
      },
      "safety_decision_points": {
        "overallScore": 1.0,
        "fromCache": true
      },
      "concomitant_medications": {
        "overallScore": 0.9791987179487179,
        "fromCache": true
      },
      "biospecimen_handling": {
        "overallScore": 0.9786559139784946,
        "fromCache": true
      },
      "laboratory_specifications": {
        "overallScore": 0.9993556701030929,
        "fromCache": true
      },
      "informed_consent": {
        "overallScore": 0.9400000000000001,
        "fromCache": true
      },
      "pro_specifications": {
        "overallScore": 0.9238174868609651,
        "fromCache": true
      },
      "data_management": {
        "overallScore": 0.8827574750830566,
        "fromCache": true
      },
      "site_operations_logistics": {
        "overallScore": 0.9978753541076487,
        "fromCache": true
      },
      "quality_management": {
        "overallScore": 0.9390601503759398,
        "fromCache": true
      },
      "withdrawal_procedures": {
        "overallScore": 0.9400000000000001,
        "fromCache": true
      },
      "imaging_central_reading": {
        "overallScore": 0.9600000000000001,
        "fromCache": true
      },
      "pkpd_sampling": {
        "overallScore": 0.9800000000000001,
        "fromCache": true
      }
    },
    "averageQualityScore": 0.9656129231998855
  },
  "study": {
    "instanceType": "Study",
    "id": "M14-359",
    "name": "M14-359",
    "officialTitle": "A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers",
    "version": "4",
    "provenance": {
      "section_number": null,
      "page_number": 1,
      "text_snippet": "Veliparib\nM14-359 Protocol Amendment 4\nEudraCT 2014-002565-30"
    },
    "studyPhase": {
      "code": "C15602",
      "decode": "Phase 3",
      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "A Randomized, Open-Label, Multicenter, Phase 3\nTrial Comparing Veliparib Plus Carboplatin and\nPaclitaxel Versus Investigator’s Choice of Standard"
      }
    },
    "studyType": {
      "code": "C98388",
      "decode": "Interventional",
      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 5,
        "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and\ntolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard\nchemotherapy in subjects receiving first cytotoxic chemotherapy for advanced or metastatic\nnon-squamous NSCLC who are current or former smokers."
      }
    },
    "studyIdentifiers": [
      {
        "id": "NCT02264990",
        "scopeId": "clinicaltrials.gov",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "NCT02264990"
        }
      },
      {
        "id": "2014-002565-30",
        "scopeId": "eudract",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "EudraCT 2014-002565-30"
        }
      }
    ],
    "studyProtocolVersions": [
      {
        "versionNumber": "4",
        "versionDate": "2018-05-09",
        "amendmentNumber": "4",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "M14-359 Protocol Amendment 4\n...\nDate: 09 May 2018"
        }
      },
      {
        "versionNumber": "3",
        "versionDate": "2015-07-17",
        "amendmentNumber": "3",
        "provenance": {
          "section_number": "1.1",
          "page_number": 2,
          "text_snippet": "Amendment 3 17 July 2015"
        }
      },
      {
        "versionNumber": "2",
        "versionDate": "2014-12-10",
        "amendmentNumber": "2",
        "provenance": {
          "section_number": "1.1",
          "page_number": 2,
          "text_snippet": "Amendment 2 10 December 2014"
        }
      },
      {
        "versionNumber": "1",
        "versionDate": "2014-10-20",
        "amendmentNumber": "1",
        "provenance": {
          "section_number": "1.1",
          "page_number": 2,
          "text_snippet": "Amendment 1 20 October 2014"
        }
      },
      {
        "versionNumber": "Original",
        "versionDate": "2014-07-10",
        "provenance": {
          "section_number": "1.1",
          "page_number": 2,
          "text_snippet": "Original 10 July 2014"
        }
      }
    ],
    "studyPopulation": {
      "targetDisease": {
        "name": "Non-Squamous Non-Small Cell Lung Cancer",
        "stage": "Metastatic or Advanced"
      },
      "ageRange": {
        "minAge": 18,
        "maxAgeNoLimit": true,
        "unit": "years"
      },
      "sex": {
        "allowed": [
          {
            "code": "C20197",
            "decode": "Male",
            "provenance": {
              "section_number": null,
              "page_number": 5,
              "text_snippet": "Subject randomization will be stratified by... by gender (male versus female) and by ECOG performance status (0 versus 1)."
            }
          },
          {
            "code": "C16576",
            "decode": "Female",
            "provenance": {
              "section_number": null,
              "page_number": 5,
              "text_snippet": "Subject randomization will be stratified by... by gender (male versus female) and by ECOG performance status (0 versus 1)."
            }
          }
        ]
      },
      "performanceStatus": {
        "scale": "ECOG",
        "allowedValues": [
          0,
          1
        ],
        "provenance": {
          "section_number": null,
          "page_number": 7,
          "text_snippet": "9. Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 – 1."
        }
      },
      "keyInclusionSummary": {
        "values": [
          "Subject must be ≥ 18 years of age.",
          "Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC.",
          "Subjects must be current smokers or former smokers.",
          "Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 – 1.",
          "Subject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as defined by RECIST (version 1.1).",
          "Adequate bone marrow, renal and hepatic function."
        ],
        "provenance": {
          "section_number": null,
          "page_number": 6,
          "text_snippet": "Diagnosis and Main Criteria for Inclusion/Exclusion: \nDiagnosis: Metastatic or advanced non-squamous Non-Small Cell Lung Cancer\nMain Inclusion:"
        }
      },
      "keyExclusionSummary": {
        "values": [
          "Subjects with squamous NSCLC.",
          "Subjects with an untreated EGFR mutation (exon 19 deletion or L858R mutation in exon 21) and/or ALK gene rearrangement.",
          "Subject has a known hypersensitivity to paclitaxel or platinum compounds.",
          "Subjects with peripheral neuropathy ≥ grade 2.",
          "Subject has previously been treated with a PARP inhibitor.",
          "Subject must have no history of brain metastases or evidence of CNS tumors at screening assessment."
        ],
        "provenance": {
          "section_number": null,
          "page_number": 8,
          "text_snippet": "Diagnosis and Main Criteria for Inclusion/Exclusion (Continued): \nMain Exclusion:"
        }
      },
      "provenance": {
        "section_number": "1.2",
        "page_number": 4,
        "text_snippet": "Study Population: \nSubjects receiving first cytotoxic chemotherapy for Metastatic or Advanced Non-Squamous Non-Small \nCell Lung Cancer (NSCLC) who are current or former smokers."
      }
    },
    "studyMilestones": {
      "estimatedDurations": {
        "screeningPeriodDays": 28,
        "treatmentPeriodDescription": "Up to 6 cycles of initial therapy (21-day cycles), followed by optional maintenance pemetrexed therapy until toxicity or radiographic progression occurs."
      },
      "provenance": {
        "section_number": "5.2",
        "page_number": 33,
        "text_snippet": "Subjects must meet all inclusion criteria and none of the exclusion criteria within 28 days of randomization."
      }
    },
    "studyDesignInfo": {
      "designType": "Parallel Assignment",
      "randomization": {
        "isRandomized": true,
        "allocationRatio": "1:1",
        "provenance": {
          "section_number": null,
          "page_number": 5,
          "text_snippet": "Subjects will be randomized in a 1:1 ratio to a maximum of 6 cycles of carboplatin/paclitaxel plus 120 mg BID of veliparib or a maximum of 6 cycles of Investigator's choice of platinum doublet chemotherapy"
        }
      },
      "blinding": {
        "blindingType": "Open-label",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "A Randomized, Open-Label, Multicenter, Phase 3 Trial"
        }
      },
      "targetEnrollment": 595,
      "plannedSites": 150,
      "countries": {
        "values": [
          "USA",
          "Japan",
          "Australia",
          "New Zealand",
          "Canada"
        ],
        "provenance": {
          "section_number": "5.5.2.3",
          "page_number": 63,
          "text_snippet": "Table 8. Study Drug Storage Conditions\nStudy Drug Country Storage Conditions\nVeliparib All countries, except\nAustralia/New Zealand/Japan\nStore at 15° to 25°C (59° to 77°F)\nVeliparib Australia/New Zealand Store below 25°C\nVeliparib Japan Store at 15° to 30°C"
        }
      },
      "provenance": {
        "section_number": "1.2",
        "page_number": 4,
        "text_snippet": "Study Sites: 150\n...\nNumber of Subjects to be Enrolled: 595"
      }
    },
    "therapeuticArea": {
      "value": "Oncology",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "Chemotherapy for Metastatic or Advanced\nNon-Squamous Non-Small Cell Lung Cancer (NSCLC)"
      }
    },
    "indication": {
      "value": "Non-Small Cell Lung Cancer",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "Chemotherapy for Metastatic or Advanced\nNon-Squamous Non-Small Cell Lung Cancer (NSCLC)"
      }
    },
    "sponsorName": {
      "value": "AbbVie Inc.",
      "provenance": {
        "section_number": "1.2",
        "page_number": 4,
        "text_snippet": "AbbVie Inc. Protocol Number: M14-359"
      }
    },
    "isPivotal": true,
    "extensionAttributes": [
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "1.0",
          "title": "Title Page"
        }
      }
    ]
  },
  "domainSections": {
    "studyDesign": {
      "moduleId": "arms_design",
      "instanceType": "StudyDesign",
      "data": {
        "id": "M14-359-arms-design",
        "instanceType": "StudyDesign",
        "name": "M14-359 Study Design",
        "provenance": {
          "section_number": "5.1",
          "page_number": 30,
          "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for advanced or metastatic non-squamous NSCLC who are current or former smokers."
        },
        "studyArms": [
          {
            "id": "ARM01",
            "instanceType": "StudyArm",
            "name": "Veliparib + Carboplatin + Paclitaxel",
            "label": "Veliparib Arm",
            "description": "Veliparib administered orally twice daily on Days -2 through 5, with Carboplatin and Paclitaxel administered intravenously on Day 1 of each 21-day cycle for a maximum of 6 cycles. Suitable subjects are encouraged to receive maintenance pemetrexed.",
            "armType": {
              "code": "C174266",
              "decode": "Experimental",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 298,
            "provenance": {
              "section_number": "5.5.1",
              "page_number": 59,
              "text_snippet": "Veliparib 120 mg BID Days –2 through 5; carboplatin AUC 6 mg/mL•min administered on Day 1; and paclitaxel 200 mg/m2 administered on Day 1 of each 21-day cycle;"
            },
            "interventions": [
              {
                "id": "INT01",
                "instanceType": "StudyIntervention",
                "name": "Veliparib",
                "type": "Drug",
                "role": {
                  "decode": "Investigational"
                },
                "dosingRegimen": {
                  "dose": 120,
                  "doseUnit": "mg",
                  "frequency": "BID",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "Fixed"
                },
                "formulation": "Capsule",
                "strength": "40 mg",
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "Veliparib 120 mg BID Days –2 through 5; carboplatin AUC 6 mg/mL•min administered on Day 1; and paclitaxel 200 mg/m2 administered on Day 1 of each 21-day cycle;"
                },
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 80,
                      "doseUnit": "mg",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –1 AUC 5 175 mg/m2 80 mg BID"
                      }
                    },
                    {
                      "level": -2,
                      "dose": 40,
                      "doseUnit": "mg",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –2 AUC 4 150 mg/m2 40 mg BID"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG01",
                      "condition": "Grade 3/4 toxicity not attributable to carboplatin/paclitaxel or underlying disease",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until toxicity resolves to grade 1 or lower or to baseline",
                      "provenance": {
                        "section_number": "5.7.1",
                        "page_number": 71,
                        "text_snippet": "For any subject who experiences grade 3/4 toxicity which is not attributable to carboplatin/paclitaxel or the underlying disease, the veliparib dose is to be held until the toxicity resolves to grade 1 or lower or to baseline if grade 2 is present at the time of study entry. Upon resuming veliparib treatment, the dose is to be reduced one dose level."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Dose reduction beyond 40 mg BID",
                    "Grade >= 2 seizure attributed to veliparib",
                    "Discontinuation of both carboplatin and paclitaxel"
                  ],
                  "provenance": {
                    "section_number": "5.7.1",
                    "page_number": 70,
                    "text_snippet": "The following are guidelines for dose reduction, delay and discontinuation of veliparib:"
                  }
                }
              },
              {
                "id": "INT02",
                "instanceType": "StudyIntervention",
                "name": "Carboplatin",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 6,
                  "doseUnit": "mg/mL*min",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "AUC-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "Veliparib 120 mg BID Days –2 through 5; carboplatin AUC 6 mg/mL•min administered on Day 1; and paclitaxel 200 mg/m2 administered on Day 1 of each 21-day cycle;"
                },
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 5,
                      "doseUnit": "mg/mL*min",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –1 AUC 5 175 mg/m2 80 mg BID"
                      }
                    },
                    {
                      "level": -2,
                      "dose": 4,
                      "doseUnit": "mg/mL*min",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –2 AUC 4 150 mg/m2 40 mg BID"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG02",
                      "condition": "Grade 3/4 Febrile Neutropenia",
                      "toxicityGrade": 3,
                      "action": "Reduce",
                      "targetLevel": -1,
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Grade 3/4 Febrile Neutropenia Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                      }
                    },
                    {
                      "id": "TRIG03",
                      "condition": "Grade 3/4 nausea, vomiting, or stomatitis",
                      "toxicityGrade": 3,
                      "action": "Reduce",
                      "targetLevel": -1,
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Grade 3/4 nausea, vomiting despite standard supportive care, or grade 3/4 Stomatitis Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                      }
                    },
                    {
                      "id": "TRIG04",
                      "condition": "Grade 4 Thrombocytopenia",
                      "toxicityGrade": 4,
                      "action": "Reduce",
                      "targetLevel": -1,
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Grade 4 Thrombocytopenia Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Stomatitis not resolved to grade 1 or less within 3 weeks"
                  ],
                  "provenance": {
                    "section_number": "5.7.2",
                    "page_number": 71,
                    "text_snippet": "For carboplatin and/or paclitaxel dose modifications, the Investigator should follow procedures as defined in the locally approved product label or applicable Summary of Product Characteristics (SmPC). Suggested dose reductions for carboplatin/paclitaxel if above information is not available are summarized in Appendix G."
                  }
                }
              },
              {
                "id": "INT03",
                "instanceType": "StudyIntervention",
                "name": "Paclitaxel",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 200,
                  "doseUnit": "mg/m²",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "BSA-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "Veliparib 120 mg BID Days –2 through 5; carboplatin AUC 6 mg/mL•min administered on Day 1; and paclitaxel 200 mg/m2 administered on Day 1 of each 21-day cycle;"
                },
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 175,
                      "doseUnit": "mg/m²",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –1 AUC 5 175 mg/m2 80 mg BID"
                      }
                    },
                    {
                      "level": -2,
                      "dose": 150,
                      "doseUnit": "mg/m²",
                      "provenance": {
                        "section_number": "5.7",
                        "page_number": 70,
                        "text_snippet": "Dose Level –2 AUC 4 150 mg/m2 40 mg BID"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG05",
                      "condition": "Grade 2 Neuropathy",
                      "toxicityGrade": 2,
                      "action": "Reduce",
                      "targetLevel": -1,
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Grade 2 Neuropathy No Change Reduce to Dose Level –1."
                      }
                    },
                    {
                      "id": "TRIG06",
                      "condition": "Grade 3/4 Neuropathy",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -2,
                      "holdCriteria": "Until recovery to Grade 2",
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Grade 3/4 Neuropathy No Change Hold until recovery to Grade 2. Reduce to Dose Level –2."
                      }
                    },
                    {
                      "id": "TRIG07",
                      "condition": "Bilirubin > 1.5 × ULN with increased ALT above ULN",
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until recovery",
                      "provenance": {
                        "section_number": null,
                        "page_number": 113,
                        "text_snippet": "Bilirubin > 1.5 × ULN with increased ALT above ULN No Change Hold until recovery, then reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Stomatitis not resolved to grade 1 or less within 3 weeks"
                  ],
                  "provenance": {
                    "section_number": "5.7.2",
                    "page_number": 71,
                    "text_snippet": "For carboplatin and/or paclitaxel dose modifications, the Investigator should follow procedures as defined in the locally approved product label or applicable Summary of Product Characteristics (SmPC). Suggested dose reductions for carboplatin/paclitaxel if above information is not available are summarized in Appendix G."
                  }
                }
              },
              {
                "id": "INT04",
                "instanceType": "StudyIntervention",
                "name": "Pemetrexed",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 500,
                  "doseUnit": "mg/m²",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "BSA-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "Maintenance therapy after completion of up to 6 cycles of either veliparib/carboplatin/paclitaxel or Investigator's choice of chemotherapy. Maintenance therapy consists of pemetrexed or no maintenance therapy (observational). Maintenance pemetrexed will be administered as 500 mg/m2 on Day 1 of each 21-day cycle."
                }
              }
            ]
          },
          {
            "id": "ARM02",
            "instanceType": "StudyArm",
            "name": "Investigator's Choice of Standard Chemotherapy",
            "label": "Investigator's Choice Arm",
            "description": "Investigator's choice of one of three standard platinum doublet chemotherapy regimens for a maximum of 6 cycles. Suitable subjects are encouraged to receive maintenance pemetrexed.",
            "armType": {
              "code": "C174267",
              "decode": "Active Comparator",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 297,
            "provenance": {
              "section_number": "5.5.1",
              "page_number": 59,
              "text_snippet": "Investigator's choice of standard doublet chemotherapy (one of the following three options, to be administered on Day 1 of each 21-day cycle):\no Carboplatin AUC 6 mg/mL•min + paclitaxel 200 mg/m2\no Cisplatin 75 mg/m2 + pemetrexed 500 mg/m2\n○ Carboplatin AUC 6 or AUC 5 mg/mL•min + pemetrexed 500 mg/m2"
            },
            "interventions": [
              {
                "id": "INT02",
                "instanceType": "StudyIntervention",
                "name": "Carboplatin",
                "type": "Drug",
                "role": {
                  "decode": "Comparator"
                },
                "dosingRegimen": {
                  "dose": 6,
                  "doseUnit": "mg/mL*min",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "AUC-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "o Carboplatin AUC 6 mg/mL•min + paclitaxel 200 mg/m2"
                }
              },
              {
                "id": "INT03",
                "instanceType": "StudyIntervention",
                "name": "Paclitaxel",
                "type": "Drug",
                "role": {
                  "decode": "Comparator"
                },
                "dosingRegimen": {
                  "dose": 200,
                  "doseUnit": "mg/m²",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "BSA-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "o Carboplatin AUC 6 mg/mL•min + paclitaxel 200 mg/m2"
                }
              },
              {
                "id": "INT04",
                "instanceType": "StudyIntervention",
                "name": "Pemetrexed",
                "type": "Drug",
                "role": {
                  "decode": "Comparator"
                },
                "dosingRegimen": {
                  "dose": 500,
                  "doseUnit": "mg/m²",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "BSA-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "o Cisplatin 75 mg/m2 + pemetrexed 500 mg/m2\n○ Carboplatin AUC 6 or AUC 5 mg/mL•min + pemetrexed 500 mg/m2"
                }
              },
              {
                "id": "INT05",
                "instanceType": "StudyIntervention",
                "name": "Cisplatin",
                "type": "Drug",
                "role": {
                  "decode": "Comparator"
                },
                "dosingRegimen": {
                  "dose": 75,
                  "doseUnit": "mg/m²",
                  "frequency": "Day 1 of each cycle",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "doseCalculationBasis": "BSA-based"
                },
                "provenance": {
                  "section_number": "5.5.1",
                  "page_number": 59,
                  "text_snippet": "o Cisplatin 75 mg/m2 + pemetrexed 500 mg/m2"
                }
              }
            ]
          }
        ],
        "studyEpochs": [
          {
            "id": "EPOCH01",
            "instanceType": "StudyEpoch",
            "name": "Screening",
            "description": "Eligibility assessment and baseline evaluations performed within 28 days of randomization.",
            "epochType": {
              "code": "C48262",
              "decode": "Screening",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 1,
            "durationDays": 28,
            "provenance": {
              "section_number": "5.2",
              "page_number": 33,
              "text_snippet": "Subjects must meet all inclusion criteria and none of the exclusion criteria within 28 days of randomization."
            }
          },
          {
            "id": "EPOCH02",
            "instanceType": "StudyEpoch",
            "name": "Treatment",
            "description": "Subjects receive up to 6 cycles of assigned platinum doublet therapy (21-day cycles). Following completion, suitable subjects are strongly encouraged to receive maintenance pemetrexed.",
            "epochType": {
              "code": "C101526",
              "decode": "Treatment",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 2,
            "provenance": {
              "section_number": "5.1",
              "page_number": 30,
              "text_snippet": "Subjects will be randomized in a 1:1 ratio to a maximum of 6 cycles of carboplatin/paclitaxel plus 120 mg BID of veliparib or a maximum of 6 cycles of Investigator's choice of platinum doublet chemotherapy (carboplatin/paclitaxel, cisplatin/pemetrexed, or carboplatin/pemetrexed). Following completion of platinum doublet therapy, maintenance pemetrexed is strongly encouraged for all subjects who are suitable candidates."
            }
          },
          {
            "id": "EPOCH03",
            "instanceType": "StudyEpoch",
            "name": "Follow-up",
            "description": "After cessation of therapy, physician visits and quality of life measures will be performed q9 weeks until 1 year, then q12 weeks until radiographic progression or death. Survival information is reported at 2-month intervals.",
            "epochType": {
              "code": "C99158",
              "decode": "Follow-up",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 3,
            "provenance": {
              "section_number": "5.1",
              "page_number": 31,
              "text_snippet": "After cessation of therapy, physician visits and quality of life measures will be performed q9 weeks until one year after randomization (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death."
            }
          }
        ],
        "studyCells": [
          {
            "id": "CELL01",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": "5.2",
              "page_number": 33,
              "text_snippet": "Subjects must meet all inclusion criteria and none of the exclusion criteria within 28 days of randomization."
            }
          },
          {
            "id": "CELL02",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": "5.2",
              "page_number": 33,
              "text_snippet": "Subjects must meet all inclusion criteria and none of the exclusion criteria within 28 days of randomization."
            }
          },
          {
            "id": "CELL03",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT01",
              "INT02",
              "INT03",
              "INT04"
            ],
            "provenance": {
              "section_number": "5.5.1",
              "page_number": 59,
              "text_snippet": "Veliparib 120 mg BID Days –2 through 5; carboplatin AUC 6 mg/mL•min administered on Day 1; and paclitaxel 200 mg/m2 administered on Day 1 of each 21-day cycle;"
            }
          },
          {
            "id": "CELL04",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT02",
              "INT03",
              "INT04",
              "INT05"
            ],
            "provenance": {
              "section_number": "5.5.1",
              "page_number": 59,
              "text_snippet": "Investigator's choice of standard doublet chemotherapy (one of the following three options, to be administered on Day 1 of each 21-day cycle):\no Carboplatin AUC 6 mg/mL•min + paclitaxel 200 mg/m2\no Cisplatin 75 mg/m2 + pemetrexed 500 mg/m2\n○ Carboplatin AUC 6 or AUC 5 mg/mL•min + pemetrexed 500 mg/m2"
            }
          },
          {
            "id": "CELL05",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": "5.1",
              "page_number": 31,
              "text_snippet": "After cessation of therapy, physician visits and quality of life measures will be performed q9 weeks until one year after randomization (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death."
            }
          },
          {
            "id": "CELL06",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": "5.1",
              "page_number": 31,
              "text_snippet": "After cessation of therapy, physician visits and quality of life measures will be performed q9 weeks until one year after randomization (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death."
            }
          }
        ],
        "designMetadata": {
          "id": "DESIGN01",
          "designType": {
            "code": "C82639",
            "decode": "Parallel",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          "isRandomized": true,
          "allocationRatio": "1:1",
          "randomizationDetails": {
            "randomization_type": "central",
            "randomization_method": "IRT",
            "provenance": {
              "section_number": "5.5.4",
              "page_number": 65,
              "text_snippet": "All subjects in the study will be randomized using an IRT system."
            }
          },
          "blindingType": "Open-label",
          "whoIsBlinded": [],
          "isPlaceboControlled": false,
          "isActiveControlled": true,
          "provenance": {
            "section_number": "5.1",
            "page_number": 30,
            "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for advanced or metastatic non-squamous NSCLC who are current or former smokers."
          },
          "stratificationFactors": [
            {
              "id": "STRAT01",
              "name": "Smoking status",
              "levels": [
                {
                  "level_id": "STRAT01-L1",
                  "level_name": "Current"
                },
                {
                  "level_id": "STRAT01-L2",
                  "level_name": "Former"
                }
              ],
              "is_irt_stratification": true,
              "provenance": {
                "section_number": "5.1",
                "page_number": 30,
                "text_snippet": "Subject randomization will be stratified by smoking status (current versus former)"
              }
            },
            {
              "id": "STRAT02",
              "name": "Investigator's preferred platinum doublet therapy",
              "levels": [
                {
                  "level_id": "STRAT02-L1",
                  "level_name": "carboplatin/paclitaxel"
                },
                {
                  "level_id": "STRAT02-L2",
                  "level_name": "cisplatin/pemetrexed"
                },
                {
                  "level_id": "STRAT02-L3",
                  "level_name": "carboplatin/pemetrexed"
                }
              ],
              "is_irt_stratification": true,
              "provenance": {
                "section_number": "5.1",
                "page_number": 30,
                "text_snippet": "by the Investigators' preferred platinum therapy (carboplatin/paclitaxel versus cisplatin/pemetrexed versus carboplatin/pemetrexed)"
              }
            },
            {
              "id": "STRAT03",
              "name": "Gender",
              "levels": [
                {
                  "level_id": "STRAT03-L1",
                  "level_name": "Male"
                },
                {
                  "level_id": "STRAT03-L2",
                  "level_name": "Female"
                }
              ],
              "is_irt_stratification": true,
              "provenance": {
                "section_number": "5.1",
                "page_number": 30,
                "text_snippet": "by gender (male versus female)"
              }
            },
            {
              "id": "STRAT04",
              "name": "ECOG performance status",
              "levels": [
                {
                  "level_id": "STRAT04-L1",
                  "level_name": "0"
                },
                {
                  "level_id": "STRAT04-L2",
                  "level_name": "1"
                }
              ],
              "is_irt_stratification": true,
              "provenance": {
                "section_number": "5.1",
                "page_number": 30,
                "text_snippet": "and by ECOG performance status (0 versus 1)."
              }
            }
          ]
        }
      },
      "_agentDocumentation": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical"
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical"
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical"
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json"
      }
    },
    "endpointsEstimandsSAP": {
      "moduleId": "endpoints_estimands_sap",
      "instanceType": "EndpointsEstimandsSAP",
      "data": {
        "id": "M14-359-endpoints-estimands-sap",
        "instanceType": "EndpointsEstimandsSAP",
        "name": "M14-359 Endpoints, Estimands & SAP",
        "documentType": "protocol",
        "protocol_endpoints": {
          "objectives": [
            {
              "id": "objective-001",
              "instanceType": "Objective",
              "name": "Primary Objective",
              "text": "To assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in Lung Subtype Panel (LSP) positive subjects with metastatic or advanced NSCLC.",
              "level": {
                "code": "C85826",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-001"
              ],
              "provenance": {
                "section_number": "4.0",
                "page_number": 29,
                "text_snippet": "The primary objective of the study is to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in LSP positive subjects with metastatic or advanced NSCLC."
              }
            },
            {
              "id": "objective-002",
              "instanceType": "Objective",
              "name": "Secondary Objectives",
              "text": "To assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival in the entire study population; to compare progression-free survival (PFS) and objective response rate (ORR) between the two treatment arms in LSP positive subjects or in the entire study population.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006"
              ],
              "provenance": {
                "section_number": "4.0",
                "page_number": 29,
                "text_snippet": "The secondary objectives of the study are to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in the entire study population with metastatic or advanced NSCLC; to compare progression-free survival (PFS) and to compare objective response rate (ORR) between the two treatment arms in LSP positive subjects or in the entire study population."
              }
            },
            {
              "id": "objective-003",
              "instanceType": "Objective",
              "name": "Tertiary Objectives",
              "text": "To compare duration of overall response (DOR), ECOG performance status and Quality of Life (QoL) between the two treatment arms in LSP positive subjects or in the entire study population.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-007",
                "endpoint-008",
                "endpoint-009"
              ],
              "provenance": {
                "section_number": "4.0",
                "page_number": 29,
                "text_snippet": "The tertiary objectives are to compare duration of overall response (DOR), ECOG performance status and Quality of Life (QoL) between the two treatment arms in LSP positive subjects or in the entire study population."
              }
            }
          ],
          "endpoints": [
            {
              "id": "endpoint-001",
              "instanceType": "Endpoint",
              "name": "Overall Survival (OS) in LSP+ subgroup",
              "label": "Primary Efficacy Endpoint",
              "text": "Time from randomization to death from any cause in subjects positive for the Lung Subtyping Panel (LSP) signature.",
              "purpose": "To assess the effect of treatment on survival in the LSP+ population.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Collection of survival information",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The primary efficacy endpoint is overall survival (OS) in LSP+ subgroup."
              }
            },
            {
              "id": "endpoint-002",
              "instanceType": "Endpoint",
              "name": "Overall Survival (OS) in all subjects",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to death from any cause in all randomized subjects.",
              "purpose": "To assess the effect of treatment on survival in the entire study population.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Collection of survival information",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The secondary efficacy endpoints are: progression free survival (PFS) in LSP+ subgroup, objective response rate (ORR) in LSP+ subgroup, OS in all subjects, PFS in all subjects, and ORR in all subjects."
              }
            },
            {
              "id": "endpoint-003",
              "instanceType": "Endpoint",
              "name": "Progression-Free Survival (PFS) in LSP+ subgroup",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to the first documentation of radiographic progression per RECIST 1.1 or death from any cause, whichever occurs first, in LSP+ subjects.",
              "purpose": "To assess the effect of treatment on disease progression or death in the LSP+ population.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST version 1.1",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The secondary efficacy endpoints are: progression free survival (PFS) in LSP+ subgroup, objective response rate (ORR) in LSP+ subgroup, OS in all subjects, PFS in all subjects, and ORR in all subjects."
              }
            },
            {
              "id": "endpoint-004",
              "instanceType": "Endpoint",
              "name": "Progression-Free Survival (PFS) in all subjects",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to the first documentation of radiographic progression per RECIST 1.1 or death from any cause, whichever occurs first, in all randomized subjects.",
              "purpose": "To assess the effect of treatment on disease progression or death in the entire study population.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST version 1.1",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The secondary efficacy endpoints are: progression free survival (PFS) in LSP+ subgroup, objective response rate (ORR) in LSP+ subgroup, OS in all subjects, PFS in all subjects, and ORR in all subjects."
              }
            },
            {
              "id": "endpoint-005",
              "instanceType": "Endpoint",
              "name": "Objective Response Rate (ORR) in LSP+ subgroup",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of subjects with a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 in LSP+ subjects.",
              "purpose": "To assess tumor response in the LSP+ population.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST version 1.1",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The secondary efficacy endpoints are: progression free survival (PFS) in LSP+ subgroup, objective response rate (ORR) in LSP+ subgroup, OS in all subjects, PFS in all subjects, and ORR in all subjects."
              }
            },
            {
              "id": "endpoint-006",
              "instanceType": "Endpoint",
              "name": "Objective Response Rate (ORR) in all subjects",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of subjects with a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 in all randomized subjects.",
              "purpose": "To assess tumor response in the entire study population.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST version 1.1",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The secondary efficacy endpoints are: progression free survival (PFS) in LSP+ subgroup, objective response rate (ORR) in LSP+ subgroup, OS in all subjects, PFS in all subjects, and ORR in all subjects."
              }
            },
            {
              "id": "endpoint-007",
              "instanceType": "Endpoint",
              "name": "Duration of Overall Response (DOR)",
              "label": "Exploratory Endpoint",
              "text": "Time from first documentation of CR or PR until disease progression or death in subjects who achieved a response.",
              "purpose": "To assess the durability of tumor response.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST version 1.1",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The tertiary efficacy endpoints are duration of response, ECOG performance status and Quality of Life (QoL) in LSP+ subgroup and in all subjects."
              }
            },
            {
              "id": "endpoint-008",
              "instanceType": "Endpoint",
              "name": "ECOG Performance Status",
              "label": "Exploratory Endpoint",
              "text": "Change from baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status.",
              "purpose": "To assess the impact of treatment on patient functional status.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25284",
                "decode": "Ordinal Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "ECOG Performance Status Scale",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The tertiary efficacy endpoints are duration of response, ECOG performance status and Quality of Life (QoL) in LSP+ subgroup and in all subjects."
              }
            },
            {
              "id": "endpoint-009",
              "instanceType": "Endpoint",
              "name": "Quality of Life (QoL)",
              "label": "Exploratory Endpoint",
              "text": "Change from baseline in health-related quality of life as measured by the NFLSI-17 and EQ-5D-5L questionnaires.",
              "purpose": "To assess the impact of treatment on patient-reported quality of life.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "NFLSI-17 and EQ-5D-5L",
              "assessor": "Patient",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.3.3",
                "page_number": 53,
                "text_snippet": "The tertiary efficacy endpoints are duration of response, ECOG performance status and Quality of Life (QoL) in LSP+ subgroup and in all subjects."
              }
            }
          ],
          "estimands": [
            {
              "id": "estimand-001",
              "instanceType": "Estimand",
              "name": "Primary Estimand for OS in LSP+ Subgroup",
              "text": "Treatment effect on Overall Survival comparing Veliparib plus Carboplatin/Paclitaxel versus Investigator's Choice of standard chemotherapy in the LSP+ subgroup, regardless of intercurrent events such as discontinuation of study treatment or initiation of subsequent anti-cancer therapy.",
              "endpoint_id": "endpoint-001",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Veliparib plus Carboplatin and Paclitaxel"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98389",
                    "decode": "Active Comparator Arm"
                  },
                  "description": "Investigator's Choice of standard chemotherapy"
                },
                "provenance": {
                  "section_number": "5.1",
                  "page_number": 30,
                  "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for advanced or metastatic non-squamous NSCLC who are current or former smokers."
                }
              },
              "population": {
                "analysis_population_id": "population-002",
                "description": "All randomized subjects who are positive for the Lung Subtyping Panel (LSP) signature.",
                "provenance": {
                  "section_number": "8.1.2.1",
                  "page_number": 83,
                  "text_snippet": "The primary efficacy analysis will be a comparison of OS distributions between the 120 mg of veliparib BID + carboplatin/paclitaxel and Investigators' choice of platinum therapy groups in LSP + subgroup."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-001",
                "description": "Overall Survival (time from randomization to death from any cause).",
                "provenance": {
                  "section_number": "8.1.2.1",
                  "page_number": 83,
                  "text_snippet": "Time to death for a given subject will be defined as the number of days from the date that the subject was randomized to the date of the subject's death. All events of death will be included, regardless of whether the event occurred while the subjects was still taking study drug, or after the subject discontinued study drug."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-001",
                  "name": "Initiation of subsequent anti-cancer therapy",
                  "description": "Subject receives a new anti-cancer therapy after discontinuing study treatment.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "To evaluate the effect of the overall treatment strategy, including any subsequent therapies, which reflects clinical practice.",
                  "provenance": {
                    "section_number": "8.1.2.1",
                    "page_number": 83,
                    "text_snippet": "All events of death will be included, regardless of whether the event occurred while the subjects was still taking study drug, or after the subject discontinued study drug."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-001",
                "sens-002",
                "sens-003"
              ],
              "provenance": {
                "section_number": "8.1.4",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95%CI) using Cox proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, Investigator's choice of platinum therapy, and smoking status) as the covariates."
              }
            },
            {
              "id": "estimand-002",
              "instanceType": "Estimand",
              "name": "Secondary Estimand for OS in All Subjects",
              "text": "Treatment effect on Overall Survival comparing Veliparib plus Carboplatin/Paclitaxel versus Investigator's Choice of standard chemotherapy in all randomized subjects, regardless of intercurrent events.",
              "endpoint_id": "endpoint-002",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Veliparib plus Carboplatin and Paclitaxel"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98389",
                    "decode": "Active Comparator Arm"
                  },
                  "description": "Investigator's Choice of standard chemotherapy"
                },
                "provenance": {
                  "section_number": "5.1",
                  "page_number": 30,
                  "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for advanced or metastatic non-squamous NSCLC who are current or former smokers."
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "All randomized subjects.",
                "provenance": {
                  "section_number": "8.1.5.3",
                  "page_number": 86,
                  "text_snippet": "For all subjects, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95% CI) using the Cox Proportional hazard model..."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-002",
                "description": "Overall Survival (time from randomization to death from any cause).",
                "provenance": {
                  "section_number": "8.1.2.1",
                  "page_number": 83,
                  "text_snippet": "Time to death for a given subject will be defined as the number of days from the date that the subject was randomized to the date of the subject's death."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-002",
                  "name": "Initiation of subsequent anti-cancer therapy",
                  "description": "Subject receives a new anti-cancer therapy after discontinuing study treatment.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "To evaluate the effect of the overall treatment strategy, including any subsequent therapies.",
                  "provenance": {
                    "section_number": "8.1.2.1",
                    "page_number": 83,
                    "text_snippet": "All events of death will be included, regardless of whether the event occurred while the subjects was still taking study drug, or after the subject discontinued study drug."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [],
              "provenance": {
                "section_number": "8.1.5.3",
                "page_number": 86,
                "text_snippet": "For all subjects, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95% CI) using the Cox Proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, smoking history (current versus former smokers), and Investigator's choice of platinum therapy) as the covariates."
              }
            },
            {
              "id": "estimand-003",
              "instanceType": "Estimand",
              "name": "Secondary Estimand for PFS in LSP+ Subgroup",
              "text": "Treatment effect on Progression-Free Survival comparing Veliparib plus Carboplatin/Paclitaxel versus Investigator's Choice of standard chemotherapy in the LSP+ subgroup. Death without progression is a component of the endpoint.",
              "endpoint_id": "endpoint-003",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Veliparib plus Carboplatin and Paclitaxel"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98389",
                    "decode": "Active Comparator Arm"
                  },
                  "description": "Investigator's Choice of standard chemotherapy"
                },
                "provenance": {
                  "section_number": "5.1",
                  "page_number": 30,
                  "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy..."
                }
              },
              "population": {
                "analysis_population_id": "population-002",
                "description": "All randomized subjects who are positive for the Lung Subtyping Panel (LSP) signature.",
                "provenance": {
                  "section_number": "8.1.5.1",
                  "page_number": 85,
                  "text_snippet": "For the LSP+ subgroup, the distribution of PFS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups..."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-003",
                "description": "Progression-Free Survival (time from randomization to progression or death).",
                "provenance": {
                  "section_number": "8.1.2.2",
                  "page_number": 84,
                  "text_snippet": "PFS will be defined as the number of days from the date that the subject was randomized to the date the subject experiences an event of disease progression or to the date of death (all causes of mortality) if disease progression is not reached."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-003",
                  "name": "Death without progression",
                  "description": "Subject dies before experiencing disease progression.",
                  "strategy": {
                    "code": "C178900",
                    "decode": "Composite Strategy"
                  },
                  "strategy_rationale": "Death is considered an event of interest and is included in the composite endpoint definition of PFS.",
                  "provenance": {
                    "section_number": "8.1.2.2",
                    "page_number": 84,
                    "text_snippet": "PFS will be defined as the number of days from the date that the subject was randomized to the date the subject experiences an event of disease progression or to the date of death (all causes of mortality) if disease progression is not reached."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [],
              "provenance": {
                "section_number": "8.1.5.1",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the distribution of PFS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95% CI) using Cox proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, Investigator's choice of platinum therapy and smoking status) as covariates."
              }
            }
          ],
          "analysis_populations": [
            {
              "id": "population-001",
              "instanceType": "AnalysisPopulation",
              "name": "All Subjects Population",
              "label": "All Subjects",
              "text": "All randomized subjects, analyzed according to the treatment arm to which they were randomized.",
              "population_type": {
                "code": "C71105",
                "decode": "Full Analysis Set"
              },
              "inclusion_criteria": [
                "All subjects who are randomized"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.1.5.3",
                "page_number": 86,
                "text_snippet": "For all subjects, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups..."
              }
            },
            {
              "id": "population-002",
              "instanceType": "AnalysisPopulation",
              "name": "LSP+ Subgroup Population",
              "label": "LSP+",
              "text": "All randomized subjects who are positive for the Lung Subtyping Panel (LSP) signature.",
              "population_type": {
                "code": "C93001",
                "decode": "Modified Intent-to-Treat Population"
              },
              "inclusion_criteria": [
                "All randomized subjects",
                "Subject is positive for the Lung Subtyping Panel (LSP) signature"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-001"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.1.4",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups..."
              }
            },
            {
              "id": "population-003",
              "instanceType": "AnalysisPopulation",
              "name": "Safety Population",
              "label": "Safety",
              "text": "All randomized subjects who received at least one dose of study drug.",
              "population_type": {
                "code": "C115932",
                "decode": "Safety Population"
              },
              "inclusion_criteria": [
                "All randomized subjects who received at least one dose of study drug"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.1.8",
                "page_number": 89,
                "text_snippet": "Subjects who were randomized but did not receive study drug will not be included in the analyses of safety."
              }
            }
          ],
          "provenance": {
            "section_number": "4.0",
            "page_number": 29,
            "text_snippet": "Study Objectives"
          }
        },
        "sap_analyses": {
          "sensitivity_analyses": [
            {
              "id": "sens-001",
              "instanceType": "SensitivityAnalysis",
              "name": "Unstratified analysis of OS and PFS",
              "description": "Comparison of OS and PFS between the two treatment groups using unstratified log-rank test and unstratified and unadjusted Cox proportional hazards model.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the robustness of the primary analysis results without adjustment for covariates.",
              "analysis_population_id": "population-002",
              "missing_data_handling": "Same as primary analysis",
              "statistical_model": "Unstratified log-rank test and unadjusted Cox PH model",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "In addition to the covariate-adjusted Cox PH analyses for the primary and secondary efficacy endpoints, the unstratified log-rank test and unstratified and unadjusted Cox proportional hazards model may be used for the comparison of OS and PFS between the two treatment groups."
              }
            },
            {
              "id": "sens-002",
              "instanceType": "SensitivityAnalysis",
              "name": "Censoring at subsequent therapy for OS and PFS",
              "description": "Analysis of OS and PFS where data are censored at the date of initiation of other chemotherapies.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To estimate the treatment effect before the influence of subsequent anti-cancer therapies (Hypothetical strategy).",
              "analysis_population_id": "population-002",
              "missing_data_handling": "Censoring at initiation of subsequent therapy",
              "statistical_model": "Same as primary analysis",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "For those subjects who take other chemotherapies during the study or after they withdraw from the study, the primary efficacy OS and secondary efficacy endpoint of PFS will be censored at the date of subject's initiation of other chemotherapies."
              }
            },
            {
              "id": "sens-003",
              "instanceType": "SensitivityAnalysis",
              "name": "On-treatment analysis for OS and PFS",
              "description": "Analysis of OS and PFS including only data and events occurring on treatment or within 30 days of the last dose of study drug.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To estimate the direct effect of the study treatment, excluding events that occur long after treatment discontinuation (While on treatment strategy).",
              "analysis_population_id": "population-002",
              "missing_data_handling": "Censoring at 30 days post last dose of study drug",
              "statistical_model": "Same as primary analysis",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "For OS and PFS, additional analyses may also be performed, such as 1) including only data and events occurring on treatment or within 30 days of the last dose of study drug"
              }
            },
            {
              "id": "sens-004",
              "instanceType": "SensitivityAnalysis",
              "name": "Exploratory Cox model with additional baseline factors",
              "description": "A Cox proportional hazard model to explore the effect of additional baseline factors on OS and PFS.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173330",
                "decode": "Supplementary Analysis"
              },
              "purpose": "To explore the influence of various baseline factors on treatment effect.",
              "analysis_population_id": "population-002",
              "missing_data_handling": "Same as primary analysis",
              "statistical_model": "Cox Proportional Hazard Model",
              "covariates": [
                "LSP subgroup",
                "LSP status unknown",
                "tumor stage",
                "smoking history",
                "gender",
                "ECOG",
                "Investigator's preferred platinum doublet therapy"
              ],
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "2) using a Cox proportional hazard model to explore the effect of baseline factors including (but not limited to) the following: LSP subgroup, LSP status unknown, tumor stage (locally advanced versus metastatic), smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, and others"
              }
            }
          ],
          "statistical_methods": [
            {
              "id": "method-001",
              "instanceType": "StatisticalMethod",
              "name": "Primary Analysis of OS in LSP+ Subgroup",
              "description": "The distribution of OS will be estimated using Kaplan-Meier methodology and compared between treatment groups using a Cox proportional hazard model.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "model_type": "Cox Proportional Hazard Model",
              "stratification_factors": [],
              "covariates": [
                "ECOG",
                "Investigator's choice of platinum therapy",
                "smoking status"
              ],
              "alpha": 0.025,
              "multiplicity": {
                "method": "None",
                "description": "Primary endpoint tested at a one-sided alpha of 0.025."
              },
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.4",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95%CI) using Cox proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, Investigator's choice of platinum therapy, and smoking status) as the covariates."
              }
            },
            {
              "id": "method-002",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of PFS in LSP+ Subgroup",
              "description": "The distribution of PFS will be estimated using Kaplan-Meier methodology and compared between treatment groups using a Cox proportional hazard model.",
              "for_endpoint_ids": [
                "endpoint-003"
              ],
              "model_type": "Cox Proportional Hazard Model",
              "stratification_factors": [],
              "covariates": [
                "ECOG",
                "Investigator's choice of platinum therapy",
                "smoking status"
              ],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Fixed Sequence",
                "description": "Part of the fixed sequence testing procedure."
              },
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.1",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the distribution of PFS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95% CI) using Cox proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, Investigator's choice of platinum therapy and smoking status) as covariates."
              }
            },
            {
              "id": "method-003",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of ORR in LSP+ Subgroup",
              "description": "ORR will be estimated and compared between the two treatment groups using Fisher's exact test.",
              "for_endpoint_ids": [
                "endpoint-005"
              ],
              "model_type": "Fisher's Exact Test",
              "stratification_factors": [],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Fixed Sequence",
                "description": "Part of the fixed sequence testing procedure."
              },
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 85,
                "text_snippet": "For the LSP+ subgroup, the ORR (proportion of subjects with a complete or partial response based on RECIST (version 1.1) will be estimated and compared between the two treatment groups using Fisher's exact test."
              }
            },
            {
              "id": "method-004",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of OS in All Subjects",
              "description": "The distribution of OS will be estimated using Kaplan-Meier methodology and compared between treatment groups using a Cox proportional hazard model.",
              "for_endpoint_ids": [
                "endpoint-002"
              ],
              "model_type": "Cox Proportional Hazard Model",
              "stratification_factors": [],
              "covariates": [
                "ECOG",
                "smoking history",
                "Investigator's choice of platinum therapy"
              ],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Fixed Sequence",
                "description": "Part of the fixed sequence testing procedure."
              },
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.3",
                "page_number": 86,
                "text_snippet": "For all subjects, the distribution of OS will be estimated for each treatment group using Kaplan-Meier methodology and compared between the two treatment groups (HR and 95% CI) using the Cox Proportional hazard model with treatment group, important prognostic factors (e.g., ECOG, smoking history (current versus former smokers), and Investigator's choice of platinum therapy) as the covariates."
              }
            },
            {
              "id": "method-005",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of ORR in All Subjects",
              "description": "ORR will be estimated and compared between the two treatment groups using Cochran-Mantel-Haenszel (CMH) test.",
              "for_endpoint_ids": [
                "endpoint-006"
              ],
              "model_type": "Cochran-Mantel-Haenszel Test",
              "stratification_factors": [
                "ECOG",
                "smoking history",
                "Investigator's preferred platinum therapy"
              ],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Fixed Sequence",
                "description": "Part of the fixed sequence testing procedure."
              },
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.5",
                "page_number": 86,
                "text_snippet": "For all subjects, the ORR will be estimated and compared between the two treatment groups using Cochran-Mantel-Haenszel (CMH) test; stratified by ECOG, smoking history (current versus former smokers), and Investigator's preferred platinum therapy."
              }
            }
          ],
          "subgroup_analyses": [
            {
              "id": "subgroup-001",
              "instanceType": "SubgroupAnalysis",
              "name": "LSP Status Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by LSP status.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "LSP status",
              "categories": [
                {
                  "name": "LSP+",
                  "definition": "LSP positive"
                },
                {
                  "name": "LSP-",
                  "definition": "LSP negative"
                },
                {
                  "name": "LSP unknown",
                  "definition": "LSP status unknown"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-002",
              "instanceType": "SubgroupAnalysis",
              "name": "Smoking History Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by smoking history.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "Smoking history",
              "categories": [
                {
                  "name": "Current smoker",
                  "definition": "Current smoker"
                },
                {
                  "name": "Former smoker",
                  "definition": "Former smoker"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-003",
              "instanceType": "SubgroupAnalysis",
              "name": "Gender Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by gender.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "Gender",
              "categories": [
                {
                  "name": "Male",
                  "definition": "Male"
                },
                {
                  "name": "Female",
                  "definition": "Female"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-004",
              "instanceType": "SubgroupAnalysis",
              "name": "ECOG Performance Status Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by baseline ECOG performance status.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "ECOG performance status",
              "categories": [
                {
                  "name": "ECOG 0",
                  "definition": "ECOG PS = 0"
                },
                {
                  "name": "ECOG 1",
                  "definition": "ECOG PS = 1"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-005",
              "instanceType": "SubgroupAnalysis",
              "name": "Preferred Platinum Doublet Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by Investigator's preferred platinum doublet therapy.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "Investigator's preferred platinum doublet therapy",
              "categories": [
                {
                  "name": "Carboplatin/paclitaxel",
                  "definition": "Carboplatin/paclitaxel"
                },
                {
                  "name": "Cisplatin/pemetrexed",
                  "definition": "Cisplatin/pemetrexed"
                },
                {
                  "name": "Carboplatin/pemetrexed",
                  "definition": "Carboplatin/pemetrexed"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-006",
              "instanceType": "SubgroupAnalysis",
              "name": "Post-Study Therapy Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by receipt of post-study anti-cancer therapy.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "Post-study anti-cancer therapy",
              "categories": [
                {
                  "name": "Received post-study therapy",
                  "definition": "Received post-study anti-cancer therapy (e.g., anti-PD-1, IO etc.)"
                },
                {
                  "name": "Did not receive post-study therapy",
                  "definition": "Did not receive post-study anti-cancer therapy"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "3) subgroup analysis by LSP subgroup, LSP status unknown, smoking history (current smoker versus former smoker), gender, ECOG performance status (0 versus 1), Investigator's preferred platinum doublet therapy, post-study anti cancer therapy (e.g., anti-PD-1, IO etc.) and others."
              }
            },
            {
              "id": "subgroup-007",
              "instanceType": "SubgroupAnalysis",
              "name": "Tumor Stage Subgroup Analysis",
              "description": "Primary efficacy analysis repeated by baseline tumor stage.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004"
              ],
              "subgroup_variable": "Tumor stage",
              "categories": [
                {
                  "name": "Locally advanced",
                  "definition": "Locally advanced"
                },
                {
                  "name": "Metastatic",
                  "definition": "Metastatic"
                }
              ],
              "analysis_method": "Subgroup-specific point estimates and 95% CI for HR",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.1.7",
                "page_number": 88,
                "text_snippet": "2) using a Cox proportional hazard model to explore the effect of baseline factors including (but not limited to) the following: LSP subgroup, LSP status unknown, tumor stage (locally advanced versus metastatic)..."
              }
            },
            {
              "id": "subgroup-008",
              "instanceType": "SubgroupAnalysis",
              "name": "Safety Analysis by Population",
              "description": "Safety analyses will be performed separately for LSP+ subgroup, LSP- subgroup, and the entire study population.",
              "for_endpoint_ids": [],
              "subgroup_variable": "Analysis Population for Safety",
              "categories": [
                {
                  "name": "LSP+ subgroup",
                  "definition": "Safety population subjects who are LSP+"
                },
                {
                  "name": "LSP- subgroup",
                  "definition": "Safety population subjects who are LSP-"
                },
                {
                  "name": "Entire study population",
                  "definition": "All subjects in the safety population"
                }
              ],
              "analysis_method": "Descriptive statistics of safety data",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.8",
                "page_number": 88,
                "text_snippet": "Statistical analyses of safety data described below will be performed for three study population separately: LSP+ subgroup, LSP– subgroup, entire study population."
              }
            }
          ],
          "multiplicity_adjustment": {
            "method": "Fixed Sequence",
            "description": "Secondary endpoints are tested sequentially in a fixed order: PFS in LSP+, ORR in LSP+, OS in all subjects, PFS in all subjects, ORR in all subjects. Testing stops at the first non-significant result to control the family-wise error rate.",
            "alpha_allocation": "Overall alpha of 0.05 (two-sided) is controlled across the primary and secondary endpoints.",
            "gatekeeping_strategy": "Hierarchical testing with the primary endpoint (OS in LSP+ subgroup) as the gatekeeper. If the primary endpoint is not statistically significant, no formal statistical testing will be performed for secondary endpoints.",
            "provenance": {
              "section_number": "8.1.2.2",
              "page_number": 83,
              "text_snippet": "Fixed sequence testing procedure will be used for analyses of the primary and secondary efficacy endpoints to control for the family-wise error rate (FWER). If veliparib treatment group is not statistically significantly better than the Investigator's choice of platinum therapy group for the primary efficacy endpoint of OS in LSP + subgroup, then statistical significance will not be declared for any of the secondary efficacy endpoints, regardless of the observed P values."
            }
          },
          "missing_data_handling": {
            "primary_method": "Censoring",
            "method_description": "For time-to-event endpoints (OS, PFS), subjects without an event are censored at the date they were last known to be alive or progression-free. For PFS, if a subject misses two or more consecutive disease assessments, data are censored at the last valid assessment.",
            "assumptions": [
              "Censoring is non-informative."
            ],
            "provenance": {
              "section_number": "8.1.2.2",
              "page_number": 84,
              "text_snippet": "However, if a disease progression event occurs after a subject misses two or more consecutive disease assessments, then this subject's data will be censored at the last disease progression assessment prior to the missing disease assessments. All events of death will be included for subjects who had not experienced disease progression provided the death occurred within 18 weeks of the last tumor assessment."
            }
          },
          "provenance": {
            "section_number": "8.0",
            "page_number": 82,
            "text_snippet": "Statistical Methods and Determination of Sample Size"
          }
        },
        "extraction_statistics": {
          "objectives_count": 3,
          "endpoints_count": 9,
          "estimands_count": 3,
          "populations_count": 3,
          "sensitivity_analyses_count": 4,
          "statistical_methods_count": 5,
          "subgroup_analyses_count": 8,
          "has_multiplicity_adjustment": true,
          "has_missing_data_strategy": true
        },
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-359"
        }
      },
      "_agentDocumentation": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json"
      }
    },
    "adverseEvents": {
      "moduleId": "adverse_events",
      "instanceType": "AdverseEvents",
      "data": {
        "id": "M14-359-adverse-events",
        "instanceType": "AdverseEvents",
        "name": "M14-359 Adverse Events",
        "ae_definitions": {
          "ae_definition": "An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.",
          "teae_definition": "Treatment-emergent events are those that have an onset on or after the day of the first dose of study drug.",
          "collection_start": "time of study drug administration",
          "collection_end": "30 days following discontinuation of study drug administration",
          "collection_end_days": 30,
          "pre_existing_condition_handling": "Any worsening of a pre-existing condition or illness is considered an adverse event.",
          "provenance": {
            "section_number": "6.1.1",
            "page_number": 73,
            "text_snippet": "An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment."
          }
        },
        "sae_criteria": {
          "sae_definition": "If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a serious adverse event (SAE) within 24 hours of the site being made aware of the serious adverse event.",
          "criteria": [
            {
              "id": "sae-001",
              "criterion_type": {
                "code": "C48275",
                "decode": "Death",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in the death of a subject.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 74,
                "text_snippet": "Death of Subject An event that results in the death of a subject."
              }
            },
            {
              "id": "sae-002",
              "criterion_type": {
                "code": "C82569",
                "decode": "Life Threatening",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that, in the opinion of the Investigator, would have resulted in immediate fatality if medical intervention had not been taken.",
              "exclusions": [
                "This does not include an event that would have been fatal if it had occurred in a more severe form."
              ],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 74,
                "text_snippet": "Life-Threatening An event that, in the opinion of the Investigator, would have resulted in immediate fatality if medical intervention had not been taken. This does not include an event that would have been fatal if it had occurred in a more severe form."
              }
            },
            {
              "id": "sae-003",
              "criterion_type": {
                "code": "C83052",
                "decode": "Hospitalization Required",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in an admission to the hospital for any length of time.",
              "exclusions": [
                "This does not include an emergency room visit or admission to an outpatient facility."
              ],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 74,
                "text_snippet": "Hospitalization or Prolongation of Hospitalization An event that results in an admission to the hospital for any length of time or prolongs the subject's hospital stay. This does not include an emergency room visit or admission to an outpatient facility."
              }
            },
            {
              "id": "sae-004",
              "criterion_type": {
                "code": "C83053",
                "decode": "Prolonged Hospitalization",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that prolongs the subject's hospital stay.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 74,
                "text_snippet": "Hospitalization or Prolongation of Hospitalization An event that results in an admission to the hospital for any length of time or prolongs the subject's hospital stay."
              }
            },
            {
              "id": "sae-005",
              "criterion_type": {
                "code": "C82577",
                "decode": "Disability",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in a condition that substantially interferes with the activities of daily living of a study subject.",
              "exclusions": [
                "Disability is not intended to include experiences of relatively minor medical significance such as headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle)."
              ],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 75,
                "text_snippet": "Persistent or Significant Disability/Incapacity An event that results in a condition that substantially interferes with the activities of daily living of a study subject. Disability is not intended to include experiences of relatively minor medical significance such as headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle)."
              }
            },
            {
              "id": "sae-006",
              "criterion_type": {
                "code": "C82579",
                "decode": "Congenital Anomaly",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An anomaly detected at or after birth, or any anomaly that results in fetal loss.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 75,
                "text_snippet": "Congenital Anomaly An anomaly detected at or after birth, or any anomaly that results in fetal loss."
              }
            },
            {
              "id": "sae-007",
              "criterion_type": {
                "code": "C84265",
                "decode": "Medically Important",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above (i.e., death of subject, life-threatening, hospitalization, prolongation of hospitalization, congenital anomaly, or persistent or significant disability/incapacity). Additionally, any elective or spontaneous abortion or stillbirth is considered an important medical event.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.2",
                "page_number": 75,
                "text_snippet": "Important Medical Event Requiring Medical or Surgical Intervention to Prevent Serious Outcome An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above... Additionally, any elective or spontaneous abortion or stillbirth is considered an important medical event."
              }
            }
          ],
          "provenance": {
            "section_number": "6.1.2",
            "page_number": 74,
            "text_snippet": "If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a serious adverse event (SAE) within 24 hours of the site being made aware of the serious adverse event."
          }
        },
        "grading_system": {
          "system_name": "NCI CTCAE",
          "system_version": "4.0",
          "grade_definitions": [
            {
              "grade": 1,
              "label": "Mild",
              "definition": "The adverse event is transient and easily tolerated by the subject."
            },
            {
              "grade": 2,
              "label": "Moderate",
              "definition": "The adverse event causes the subject discomfort and interrupts the subject's usual activities."
            },
            {
              "grade": 3,
              "label": "Severe",
              "definition": "The adverse event causes considerable interference with the subject's usual activities and may be incapacitating or life-threatening."
            },
            {
              "grade": 4,
              "label": "Severe",
              "definition": "The adverse event causes considerable interference with the subject's usual activities and may be incapacitating or life-threatening."
            },
            {
              "grade": 5,
              "label": "Death",
              "definition": "Death."
            }
          ],
          "provenance": {
            "section_number": "6.3",
            "page_number": 76,
            "text_snippet": "The study Investigator will rate the severity of each adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events NCI CTCAE version 4.0.\nFor adverse events not captured by the NCI CTCAE version 4.0, the Investigator will use the following definitions to rate the severity of each adverse event:\nMild (Grade 1) The adverse event is transient and easily tolerated by the subject.\nModerate (Grade 2) The adverse event causes the subject discomfort and"
          }
        },
        "causality_assessment": {
          "assessed_by": [
            "Investigator"
          ],
          "assessed_for": [
            "veliparib",
            "carboplatin",
            "paclitaxel",
            "cisplatin",
            "pemetrexed",
            "NSCLC"
          ],
          "categories": [
            {
              "category_type": {
                "code": "C53258",
                "decode": "Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An adverse event where there is evidence to suggest a causal relationship between the study drug and the adverse event.",
              "protocol_term": "Reasonable Possibility"
            },
            {
              "category_type": {
                "code": "C53257",
                "decode": "Not Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An adverse event where there is no evidence to suggest a causal relationship between the study drug and the adverse event.",
              "protocol_term": "No Reasonable Possibility"
            }
          ],
          "provenance": {
            "section_number": "6.4",
            "page_number": 77,
            "text_snippet": "The Investigator will use the following definitions to assess the relationship of the adverse event to the use of study drug (for the purpose of this section, study drug is considered veliparib, carboplatin, paclitaxel, cisplatin or pemetrexed):\nReasonable Possibility An adverse event where there is evidence to suggest a causal relationship between the study drug and the adverse event.\nNo Reasonable Possibility An adverse event where there is no evidence to suggest a causal relationship between"
          }
        },
        "coding_dictionary": {
          "dictionary_name": "MedDRA",
          "dictionary_version": "most current",
          "provenance": {
            "section_number": "8.1.8.2",
            "page_number": 89,
            "text_snippet": "Treatment-emergent adverse events will be summarized by preferred terms within a System and Organ Class according to the most current MedDRA dictionary."
          }
        },
        "reporting_procedures": {
          "sae_reporting": {
            "initial_report_hours": 24,
            "recipients": [
              "sponsor"
            ],
            "method": "Serious adverse event data entered into the electronic data capture (EDC) system. If EDC is not operable, faxed or emailed to Clinical Pharmacovigilance.",
            "provenance": {
              "section_number": "6.6.1",
              "page_number": 79,
              "text_snippet": "In the event of a serious adverse event, whether associated with study drug or not, the Investigator will notify the Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse event by entering the serious adverse event data into the electronic data capture (EDC) system."
            }
          },
          "susar_reporting": {
            "fatal_timeline_days": 7,
            "non_fatal_timeline_days": 15,
            "provenance": {
              "section_number": null,
              "page_number": 80,
              "text_snippet": "The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with Directive 2001/20/EC."
            }
          },
          "pregnancy_reporting": {
            "timeline_hours": 24,
            "outcome_tracking": true,
            "partner_pregnancy": true,
            "provenance": {
              "section_number": "6.7",
              "page_number": 81,
              "text_snippet": "However, the medical outcome of an elective or spontaneous abortion, stillbirth or congenital anomaly is considered a serious adverse event and must be reported to AbbVie within 24 hours of the site becoming aware of the event."
            }
          },
          "expedited_reporting_criteria": [
            "Serious adverse events which are considered expected due to the underlying disease of NSCLC would not be expedited unless locally required.",
            "Deaths that are more likely related to disease progression will not be an expedited report."
          ],
          "provenance": {
            "section_number": "6.6.1",
            "page_number": 79,
            "text_snippet": "Serious adverse events which are considered expected due to the underlying disease of NSCLC as described in Section 6.2 or Appendix F would not be expedited as individual safety case reports to regulatory authorities unless locally required."
          }
        },
        "aesi_list": [],
        "dlt_criteria": {
          "has_dlt_criteria": false
        },
        "safety_committees": [],
        "extraction_statistics": {
          "aesi_count": 0,
          "dlt_criteria_count": 0,
          "sae_criteria_count": 7,
          "has_grading_system": true,
          "has_causality_assessment": true,
          "has_dlt_criteria": false
        },
        "provenance": {
          "section_number": "6.0",
          "page_number": 73,
          "text_snippet": "6.0 Adverse Events"
        }
      },
      "_agentDocumentation": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json"
      }
    },
    "safetyDecisionPoints": {
      "moduleId": "safety_decision_points",
      "instanceType": "SafetyDecisionPoints",
      "data": {
        "id": "M14-359-safety-decision-points",
        "instanceType": "SafetyDecisionPoints",
        "name": "M14-359 Safety Decision Points",
        "discovered_categories": [
          {
            "category_id": "cat-001",
            "category_name": "Hematologic Toxicity",
            "category_description": "Rules related to blood cell counts and febrile neutropenia.",
            "parameters_count": 3,
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "Hematologic Toxicity"
            }
          },
          {
            "category_id": "cat-002",
            "category_name": "Gastrointestinal Toxicity",
            "category_description": "Rules related to nausea, vomiting, and stomatitis.",
            "parameters_count": 2,
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "Gastrointestinal Toxicity"
            }
          },
          {
            "category_id": "cat-003",
            "category_name": "Hepatic Toxicity",
            "category_description": "Rules related to liver function tests (bilirubin, ALT).",
            "parameters_count": 2,
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "Hepatic Toxicity"
            }
          },
          {
            "category_id": "cat-004",
            "category_name": "Neurologic Toxicity",
            "category_description": "Rules related to peripheral neuropathy and seizures.",
            "parameters_count": 2,
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 73,
              "text_snippet": "Neurologic Toxicity"
            }
          },
          {
            "category_id": "cat-005",
            "category_name": "General Toxicity",
            "category_description": "General rules for severe toxicities not otherwise specified.",
            "parameters_count": 1,
            "provenance": {
              "section_number": "5.7.1",
              "page_number": 71,
              "text_snippet": "For any subject who experiences grade 3/4 toxicity which is not attributable to carboplatin/paclitaxel or the underlying disease, the veliparib dose is to be held until the toxicity resolves to grade 1 or lower or to baseline if grade 2 is present at the time of study entry."
            }
          }
        ],
        "decision_points": [
          {
            "id": "dp-001",
            "parameter_name": "Neutropenia without fever",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "ANC (cells/mm³)",
            "decision_rules": [
              {
                "rule_id": "dp-001-r1",
                "rule_type": "dose_hold",
                "rule_description": "Delay treatment for Grade 3/4 neutropenia on Day 1 of a cycle.",
                "conditions": {
                  "grade": "3-4",
                  "anc_threshold": "<1500",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay carboplatin and paclitaxel until ANC recovery."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": ">=1500",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "For absolute neutrophil count (ANC) < 1,500/mm³ or platelet count < 100,000/mm³ on Day 1 of each cycle, treatment is to be delayed until recovery of ANC and platelet count above these values."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Weekly if chemotherapy is withheld due to hematologic toxicity.",
              "method": "CBC",
              "provenance": {
                "section_number": "5.7.2",
                "page_number": 71,
                "text_snippet": "If chemotherapy must be withheld due to hematologic toxicity, CBC and platelet counts should be obtained weekly until the counts reach the lower limits for treatment as outlined."
              }
            },
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 3/4 Neutropenia without fever"
            }
          },
          {
            "id": "dp-002",
            "parameter_name": "Febrile Neutropenia",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-002-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce carboplatin and paclitaxel dose for Grade 3/4 febrile neutropenia.",
                "conditions": {
                  "grade": "3-4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce to Dose Level -1 for 1st episode."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce to Dose Level -2 for 2nd episode."
                  },
                  {
                    "action_type": "supportive_care",
                    "action_description": "Consider Prophylactic G-CSF after 1st episode."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "Grade 3/4 Febrile Neutropenia | Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode. Any further reduction after consultation with AbbVie medical monitor. Consider Prophylactic G-CSF after 1st episode"
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 3/4 Febrile Neutropenia"
            }
          },
          {
            "id": "dp-003",
            "parameter_name": "Thrombocytopenia",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "Platelet count (cells/mm³)",
            "decision_rules": [
              {
                "rule_id": "dp-003-r1",
                "rule_type": "dose_hold",
                "rule_description": "Delay treatment for platelet count < 100,000/mm³ on Day 1 of a cycle.",
                "conditions": {
                  "grade": null,
                  "platelet_threshold": "<100000",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay treatment until platelet count recovery."
                  }
                ],
                "recovery_criteria": {
                  "platelet_required": ">=100000",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "For absolute neutrophil count (ANC) < 1,500/mm³ or platelet count < 100,000/mm³ on Day 1 of each cycle, treatment is to be delayed until recovery of ANC and platelet count above these values."
                }
              },
              {
                "rule_id": "dp-003-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce carboplatin and paclitaxel dose for Grade 4 thrombocytopenia.",
                "conditions": {
                  "grade": "4",
                  "platelet_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce to Dose Level -1 for 1st episode."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce to Dose Level -2 for 2nd episode."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "Grade 4 Thrombocytopenia | Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode. Any further reduction after consultation with AbbVie medical monitor."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Weekly if chemotherapy is withheld due to hematologic toxicity.",
              "method": "CBC",
              "provenance": {
                "section_number": "5.7.2",
                "page_number": 71,
                "text_snippet": "If chemotherapy must be withheld due to hematologic toxicity, CBC and platelet counts should be obtained weekly until the counts reach the lower limits for treatment as outlined."
              }
            },
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 4 Thrombocytopenia"
            }
          },
          {
            "id": "dp-004",
            "parameter_name": "Nausea/Vomiting",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-004-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce carboplatin and paclitaxel dose for Grade 3/4 nausea/vomiting despite maximal anti-emetic therapy.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce dose of carboplatin and paclitaxel by 1 dose level."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=1",
                  "timeframe": "before initiation of a new cycle"
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "For grade 3 or 4 nausea/vomiting despite maximal anti-emetic therapy or for grade 3 or 4 stomatitis, the dose of carboplatin and paclitaxel are to be reduced by 1 dose level. Nausea, vomiting, and stomatitis are to have resolved to grade 1 before initiation of a new cycle of therapy."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 3/4 nausea, vomiting despite standard supportive care, or grade 3/4 Stomatitis"
            }
          },
          {
            "id": "dp-005",
            "parameter_name": "Stomatitis",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-005-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce carboplatin and paclitaxel dose for Grade 3/4 stomatitis.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce dose of carboplatin and paclitaxel by 1 dose level."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=1",
                  "timeframe": "before initiation of a new cycle"
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "For grade 3 or 4 nausea/vomiting despite maximal anti-emetic therapy or for grade 3 or 4 stomatitis, the dose of carboplatin and paclitaxel are to be reduced by 1 dose level. Nausea, vomiting, and stomatitis are to have resolved to grade 1 before initiation of a new cycle of therapy."
                }
              },
              {
                "rule_id": "dp-005-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue treatment if stomatitis does not resolve.",
                "conditions": {
                  "grade": ">1",
                  "value_threshold": null,
                  "duration": "3 weeks"
                },
                "actions": [
                  {
                    "action_type": "discontinue_treatment",
                    "action_description": "Discontinue subject's study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "If the stomatitis has not resolved to grade 1 or less within 3 weeks, the subject's study treatment is to be discontinued."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 3/4 nausea, vomiting despite standard supportive care, or grade 3/4 Stomatitis"
            }
          },
          {
            "id": "dp-006",
            "parameter_name": "Bilirubin Elevation",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "Value (x ULN)",
            "decision_rules": [
              {
                "rule_id": "dp-006-r1",
                "rule_type": "dose_hold",
                "rule_description": "Hold paclitaxel for bilirubin > 1.5 x ULN with increased ALT.",
                "conditions": {
                  "grade": null,
                  "bilirubin_threshold": ">1.5",
                  "alt_condition": "increased above ULN"
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Hold paclitaxel until bilirubin recovery."
                  }
                ],
                "recovery_criteria": {
                  "bilirubin_required": "<=1.5",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 72,
                  "text_snippet": "For bilirubin > 1.5 × ULN with increased ALT above ULN that is attributed to protocol therapy, paclitaxel is to be held until bilirubin is ≤ 1.5 × ULN, and the dose is to be reduced by one level when treatment is resumed."
                }
              },
              {
                "rule_id": "dp-006-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce paclitaxel dose after recovery from bilirubin elevation.",
                "conditions": {
                  "grade": null,
                  "bilirubin_threshold": ">1.5",
                  "alt_condition": "increased above ULN"
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -1 for 1st episode."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -2 for 2nd episode."
                  }
                ],
                "recovery_criteria": {
                  "bilirubin_required": "<=1.5",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "Bilirubin > 1.5 × ULN with increased ALT above ULN | Paclitaxel Dose: Hold until recovery, then reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Bilirubin > 1.5 × ULN with increased ALT above ULN"
            }
          },
          {
            "id": "dp-007",
            "parameter_name": "ALT Elevation",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "Value (x ULN)",
            "decision_rules": [
              {
                "rule_id": "dp-007-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce paclitaxel dose for ALT > 5 x ULN with bilirubin < 1.5 x ULN.",
                "conditions": {
                  "grade": null,
                  "alt_threshold": ">5",
                  "bilirubin_condition": "<1.5"
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -1 for 1st episode."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -2 for 2nd episode."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "ALT > 5 × ULN with Bilirubin < 1.5 × ULN | Paclitaxel Dose: Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: ALT > 5 × ULN with Bilirubin < 1.5 × ULN"
            }
          },
          {
            "id": "dp-008",
            "parameter_name": "Peripheral Neuropathy",
            "parameter_category": "Neurologic Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-008-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce paclitaxel dose for Grade 2 neuropathy.",
                "conditions": {
                  "grade": "2",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -1."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "Grade 2 Neuropathy | Paclitaxel Dose: Reduce to Dose Level –1."
                }
              },
              {
                "rule_id": "dp-008-r2",
                "rule_type": "dose_hold",
                "rule_description": "Hold paclitaxel for Grade 3/4 neuropathy.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Hold paclitaxel until recovery."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.2.1",
                  "page_number": 73,
                  "text_snippet": "For grade 3/4 neuropathy, paclitaxel dose is to be held until neuropathy is grade 2, and the dose is to be reduced to Dose Level –2 when treatment is resumed."
                }
              },
              {
                "rule_id": "dp-008-r3",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce paclitaxel dose upon resuming treatment after Grade 3/4 neuropathy.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce paclitaxel to Dose Level -2 when treatment is resumed."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 113,
                  "text_snippet": "Grade 3/4 Neuropathy | Paclitaxel Dose: Hold until recovery to Grade 2. Reduce to Dose Level –2."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Adverse Event: Grade 2 Neuropathy / Grade 3/4 Neuropathy"
            }
          },
          {
            "id": "dp-009",
            "parameter_name": "Seizure",
            "parameter_category": "Neurologic Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-009-r1",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue veliparib for seizure attributed to veliparib.",
                "conditions": {
                  "grade": ">=2",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue veliparib."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "5.7.1",
                  "page_number": 71,
                  "text_snippet": "For any ≥ grade 2 event of seizure attributed to veliparib, veliparib is to be discontinued and the event should be discussed with the AbbVie medical monitor."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": "5.7.1",
              "page_number": 71,
              "text_snippet": "For any ≥ grade 2 event of seizure attributed to veliparib, veliparib is to be discontinued and the event should be discussed with the AbbVie medical monitor."
            }
          },
          {
            "id": "dp-010",
            "parameter_name": "General Toxicity (Veliparib-related)",
            "parameter_category": "General Toxicity",
            "measurement_type": "Grade (NCI CTCAE)",
            "decision_rules": [
              {
                "rule_id": "dp-010-r1",
                "rule_type": "dose_hold",
                "rule_description": "Hold veliparib for Grade 3/4 toxicity not attributable to carboplatin/paclitaxel.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Hold veliparib until toxicity resolves."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.1",
                  "page_number": 71,
                  "text_snippet": "For any subject who experiences grade 3/4 toxicity which is not attributable to carboplatin/paclitaxel or the underlying disease, the veliparib dose is to be held until the toxicity resolves to grade 1 or lower or to baseline if grade 2 is present at the time of study entry."
                }
              },
              {
                "rule_id": "dp-010-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce veliparib dose upon resuming treatment after Grade 3/4 toxicity.",
                "conditions": {
                  "grade": "3-4",
                  "value_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce veliparib dose by one dose level."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "5.7.1",
                  "page_number": 71,
                  "text_snippet": "Upon resuming veliparib treatment, the dose is to be reduced one dose level."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": "5.7.1",
              "page_number": 71,
              "text_snippet": "The following are guidelines for dose reduction, delay and discontinuation of veliparib:"
            }
          }
        ],
        "stopping_rules_summary": {
          "total_permanent_stopping_conditions": 8,
          "stopping_conditions": [
            {
              "condition_id": "stop-001",
              "condition_type": "individual_subject",
              "description": "Radiographic progression according to RECIST version 1.1.",
              "trigger_threshold": "RECIST 1.1 defined progression",
              "action": "Withdrawal from study treatment",
              "provenance": {
                "section_number": "5.4",
                "page_number": 56,
                "text_snippet": "The subject has radiographic progression according to RECIST version 1.1."
              }
            },
            {
              "condition_id": "stop-002",
              "condition_type": "individual_subject",
              "description": "Requirement for cancer-directed radiotherapy or surgery related to clinical disease progression.",
              "trigger_threshold": "Need for alternative anti-cancer therapy",
              "action": "Withdrawal from study treatment",
              "provenance": {
                "section_number": "5.4",
                "page_number": 56,
                "text_snippet": "The subject requires cancer-directed radiotherapy or surgery related to clinical disease progression, or alternate anti-cancer agents during the study period."
              }
            },
            {
              "condition_id": "stop-003",
              "condition_type": "individual_subject",
              "description": "Treatment toxicity which, in the Investigator's opinion, prohibits further therapy.",
              "trigger_threshold": "Investigator's clinical judgment of unacceptable toxicity",
              "action": "Withdrawal from study treatment",
              "provenance": {
                "section_number": "5.4",
                "page_number": 56,
                "text_snippet": "The subject experiences treatment toxicity which, in the Investigator's opinion, prohibits further therapy or the Investigator believes it is otherwise in the best interest of the subject."
              }
            },
            {
              "condition_id": "stop-004",
              "condition_type": "individual_subject",
              "description": "Pregnancy is confirmed or subject begins breastfeeding.",
              "trigger_threshold": "Confirmed pregnancy or start of breastfeeding",
              "action": "Withdrawal from study treatment",
              "provenance": {
                "section_number": "5.4",
                "page_number": 56,
                "text_snippet": "Subject is suspected to be pregnant; pregnancy is confirmed or begins breastfeeding during the treatment portion of the study."
              }
            },
            {
              "condition_id": "stop-005",
              "condition_type": "individual_subject",
              "description": "Subject decides to withdraw consent.",
              "trigger_threshold": "Patient decision",
              "action": "Withdrawal from study",
              "provenance": {
                "section_number": "5.4",
                "page_number": 56,
                "text_snippet": "The subject decides to withdraw consent for any reason."
              }
            },
            {
              "condition_id": "stop-006",
              "condition_type": "individual_subject",
              "description": "Veliparib dose reduction beyond 40 mg BID is required.",
              "trigger_threshold": "Required dose is < 40 mg BID",
              "action": "Permanent discontinuation of veliparib",
              "provenance": {
                "section_number": "5.7.1",
                "page_number": 71,
                "text_snippet": "Any dose reduction beyond 40 mg BID is to result in veliparib discontinuation."
              }
            },
            {
              "condition_id": "stop-007",
              "condition_type": "individual_subject",
              "description": "Grade 2 or higher seizure attributed to veliparib.",
              "trigger_threshold": "Grade >= 2 seizure",
              "action": "Permanent discontinuation of veliparib",
              "provenance": {
                "section_number": "5.7.1",
                "page_number": 71,
                "text_snippet": "For any ≥ grade 2 event of seizure attributed to veliparib, veliparib is to be discontinued and the event should be discussed with the AbbVie medical monitor."
              }
            },
            {
              "condition_id": "stop-008",
              "condition_type": "individual_subject",
              "description": "Stomatitis has not resolved to grade 1 or less within 3 weeks.",
              "trigger_threshold": "Stomatitis > Grade 1 for 3 weeks",
              "action": "Permanent discontinuation of study treatment",
              "provenance": {
                "section_number": "5.7.2.1",
                "page_number": 72,
                "text_snippet": "If the stomatitis has not resolved to grade 1 or less within 3 weeks, the subject's study treatment is to be discontinued."
              }
            }
          ],
          "provenance": {
            "section_number": "5.4",
            "page_number": 56,
            "text_snippet": "Each subject will be withdrawn from the study or study treatment (as applicable) per Section 5.4.1 if any of the following occur:"
          }
        },
        "dose_modification_levels": {
          "has_defined_levels": true,
          "levels": [
            {
              "level_id": "dose-0",
              "level_name": "Starting Dose Level",
              "veliparib_dose": "120 mg BID",
              "carboplatin_dose": "AUC 6",
              "paclitaxel_dose": "200 mg/m²",
              "provenance": {
                "section_number": null,
                "page_number": 70,
                "text_snippet": "Starting Dose Level | AUC 6 | 200 mg/m² | 120 mg BID"
              }
            },
            {
              "level_id": "dose-1",
              "level_name": "Dose Level -1",
              "veliparib_dose": "80 mg BID",
              "carboplatin_dose": "AUC 5",
              "paclitaxel_dose": "175 mg/m²",
              "provenance": {
                "section_number": null,
                "page_number": 70,
                "text_snippet": "Dose Level –1 | AUC 5 | 175 mg/m² | 80 mg BID"
              }
            },
            {
              "level_id": "dose-2",
              "level_name": "Dose Level -2",
              "veliparib_dose": "40 mg BID",
              "carboplatin_dose": "AUC 4",
              "paclitaxel_dose": "150 mg/m²",
              "provenance": {
                "section_number": null,
                "page_number": 70,
                "text_snippet": "Dose Level –2 | AUC 4 | 150 mg/m² | 40 mg BID"
              }
            }
          ],
          "minimum_dose": "Veliparib: 40 mg BID; Carboplatin: AUC 4; Paclitaxel: 150 mg/m²",
          "re_escalation_allowed": false,
          "re_escalation_criteria": "Re-escalation of chemotherapy treatments or veliparib doses is not allowed.",
          "provenance": {
            "section_number": null,
            "page_number": 70,
            "text_snippet": "Table 9. Suggested Guidelines for Veliparib + Carboplatin/Paclitaxel Independent Dose Reductions"
          }
        },
        "organ_specific_adjustments": [
          {
            "id": "organ-001",
            "organ_system": "Hepatic",
            "organ_system_detail": "Liver function impairment",
            "adjustment_trigger": "Bilirubin > 1.5 x ULN with increased ALT above ULN",
            "adjustment_action": "Hold paclitaxel until recovery, then reduce to Dose Level -1 (1st episode) or -2 (2nd episode). No change for carboplatin.",
            "monitoring_requirements": "As per standard of care.",
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Bilirubin > 1.5 × ULN with increased ALT above ULN | Paclitaxel Dose: Hold until recovery, then reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode. Any further reduction requires consultation with AbbVie medical monitor."
            }
          },
          {
            "id": "organ-002",
            "organ_system": "Hepatic",
            "organ_system_detail": "Liver function impairment",
            "adjustment_trigger": "ALT > 5 x ULN with Bilirubin < 1.5 x ULN",
            "adjustment_action": "Reduce paclitaxel to Dose Level -1 (1st episode) or -2 (2nd episode). No change for carboplatin.",
            "monitoring_requirements": "As per standard of care.",
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "ALT > 5 × ULN with Bilirubin < 1.5 × ULN | Paclitaxel Dose: Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode. Any further reduction requires consultation with AbbVie medical monitor."
            }
          },
          {
            "id": "organ-003",
            "organ_system": "Neurologic",
            "organ_system_detail": "Peripheral neuropathy",
            "adjustment_trigger": "Grade 2 neuropathy",
            "adjustment_action": "Reduce paclitaxel to Dose Level -1. No change for carboplatin.",
            "monitoring_requirements": "As per standard of care.",
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Grade 2 Neuropathy | Paclitaxel Dose: Reduce to Dose Level –1."
            }
          },
          {
            "id": "organ-004",
            "organ_system": "Neurologic",
            "organ_system_detail": "Peripheral neuropathy",
            "adjustment_trigger": "Grade 3/4 neuropathy",
            "adjustment_action": "Hold paclitaxel until recovery to Grade 2, then reduce to Dose Level -2. No change for carboplatin.",
            "monitoring_requirements": "As per standard of care.",
            "provenance": {
              "section_number": null,
              "page_number": 113,
              "text_snippet": "Grade 3/4 Neuropathy | Paclitaxel Dose: Hold until recovery to Grade 2. Reduce to Dose Level –2."
            }
          }
        ],
        "extraction_statistics": {
          "decision_points_count": 10,
          "stopping_rules_count": 8,
          "organ_adjustments_count": 4,
          "dose_levels_count": 3,
          "categories_count": 5
        },
        "provenance": {
          "section_number": "5.7",
          "page_number": 70,
          "text_snippet": "All dose reductions are considered permanent. Re-escalation of chemotherapy treatments or veliparib doses is not allowed."
        }
      },
      "_agentDocumentation": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json"
      }
    },
    "concomitantMedications": {
      "moduleId": "concomitant_medications",
      "instanceType": "ConcomitantMedications",
      "data": {
        "id": "M14-359-concomitant-medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "name": "M14-359 Concomitant Medication Restrictions",
        "description": "Medication restrictions and requirements for M14-359",
        "prohibited_medications": [
          {
            "id": "proh-001",
            "instanceType": "ProhibitedMedication",
            "medication_class": "PARP inhibitors",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "contraindicated"
            },
            "prohibition_reason_detail": "Prior treatment with a PARP inhibitor is an exclusion criterion.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Subjects must not have been previously treated with a PARP inhibitor.",
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 37,
              "text_snippet": "11. Subject has previously been treated with a PARP inhibitor."
            }
          },
          {
            "id": "proh-002",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Anti-cancer agents",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "efficacy_interference"
            },
            "prohibition_reason_detail": "Concurrent anti-cancer agents or investigational agents are not permitted during the study.",
            "prohibition_period": {
              "decode": "treatment_plus_followup"
            },
            "prohibition_period_detail": "Prohibited throughout the study until after the Final Visit.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Anti-cancer agents: No anti-cancer agents or investigational agents may be taken throughout the study until after the Final Visit."
            }
          },
          {
            "id": "proh-003",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Investigational agents",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "study_design"
            },
            "prohibition_reason_detail": "Concurrent investigational agents are not permitted during the study.",
            "prohibition_period": {
              "decode": "treatment_plus_followup"
            },
            "prohibition_period_detail": "Prohibited throughout the study until after the Final Visit.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Anti-cancer agents: No anti-cancer agents or investigational agents may be taken throughout the study until after the Final Visit."
            }
          }
        ],
        "restricted_medications": [
          {
            "id": "rest-001",
            "instanceType": "RestrictedMedication",
            "medication_class": "Radiation Therapy",
            "specific_drugs": [],
            "restriction_type": {
              "decode": "conditional_use"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "medical_monitor",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Allowed only for palliative radiation to a non-target lesion. The AbbVie medical monitor must be contacted if the subject requires radiotherapy during the study."
            },
            "rationale": "To avoid confounding efficacy assessments and manage potential overlapping toxicities.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "Radiation: Radiation therapy is not allowed during the study, except for palliative radiation to a non-target lesion. Sites to be radiated should be assessed for radiographic progression, prior to beginning radiotherapy. If the subject requires radiotherapy during the study, the AbbVie medical monitor must be contacted."
            }
          },
          {
            "id": "rest-002",
            "instanceType": "RestrictedMedication",
            "medication_class": "Surgery",
            "specific_drugs": [],
            "restriction_type": {
              "decode": "approval_required"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "medical_monitor",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "If the subject requires surgery during the study, the AbbVie medical monitor must be contacted."
            },
            "rationale": "To assess potential impact on study participation and safety.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Surgery: If the subject requires surgery during the study, the AbbVie medical monitor must be contacted."
            }
          },
          {
            "id": "rest-003",
            "instanceType": "RestrictedMedication",
            "medication_class": "NK-1 receptor antagonists",
            "specific_drugs": [
              "aprepitant"
            ],
            "restriction_type": {
              "decode": "avoid_if_possible"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "investigator_discretion",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Aprepitant is not recommended for anti-emetic therapy, though clinicians may consider its use."
            },
            "rationale": "Protocol preferred anti-emetic regimen is palonosetron and dexamethasone.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "Aprepitant is not recommended, though clinicians may consider its use. If clinicians opt to use aprepitant, dosing guidelines are as follows:\nAprepitant: 125 mg Day 1, 80 mg Days 2 and 3"
            }
          },
          {
            "id": "rest-004",
            "instanceType": "RestrictedMedication",
            "medication_class": "Bone-modifying agents",
            "specific_drugs": [
              "bisphosphonates",
              "denosumab"
            ],
            "restriction_type": {
              "decode": "timing_restriction"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": "First time administration should be delayed until after cycle 1.",
              "clinical_scenario": "Permitted for bone metastases."
            },
            "rationale": "To not introduce both veliparib and a new bone-modifying agent together for the first time, to better assess causality of any new adverse events.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "The use of bisphosphonates or denosumab for bone metastases is permitted, but it is strongly encouraged that first time administration of a bisphosphonate or denosumab should be delayed until after cycle 1 so as to not introduce both the veliparib and bisphosphonate/denosumab together for the first time."
            }
          },
          {
            "id": "rest-005",
            "instanceType": "RestrictedMedication",
            "medication_class": "Ototoxic and Nephrotoxic Drugs",
            "specific_drugs": [
              "aminoglycosides",
              "vancomycin",
              "capreomycin",
              "diuretics"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Use with caution when administered with carboplatin."
            },
            "rationale": "May increase or exacerbate toxicity due to carboplatin-induced changes in renal function.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Carboplatin: Ototoxic and nephrotoxic drugs such as aminoglycosides, vancomycin, capreomycin and diuretics, may increase or exacerbate toxicity due to carboplatin induced changes in renal function."
            }
          }
        ],
        "required_medications": [
          {
            "id": "req-001",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "Corticosteroids",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": null
            },
            "timing": {
              "relative_to": "paclitaxel infusion",
              "time_before_minutes": null,
              "timing_description": "Administered prior to paclitaxel infusion, per institutional guidelines."
            },
            "purpose": "To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel.",
            "alternatives": [],
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Premedication: To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel, manage according to institutional guidelines, the locally approved product label, local practice, or applicable SmPC (i.e., premedication with corticosteroids, diphenhydramine, and H2 antagonists)."
            }
          },
          {
            "id": "req-002",
            "instanceType": "RequiredMedication",
            "medication_name": "diphenhydramine",
            "medication_class": "H1 antagonist",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": null
            },
            "timing": {
              "relative_to": "paclitaxel infusion",
              "time_before_minutes": null,
              "timing_description": "Administered prior to paclitaxel infusion, per institutional guidelines."
            },
            "purpose": "To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel.",
            "alternatives": [],
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Premedication: To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel, manage according to institutional guidelines, the locally approved product label, local practice, or applicable SmPC (i.e., premedication with corticosteroids, diphenhydramine, and H2 antagonists)."
            }
          },
          {
            "id": "req-003",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "H2 antagonists",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": null
            },
            "timing": {
              "relative_to": "paclitaxel infusion",
              "time_before_minutes": null,
              "timing_description": "Administered prior to paclitaxel infusion, per institutional guidelines."
            },
            "purpose": "To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel.",
            "alternatives": [],
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Premedication: To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel, manage according to institutional guidelines, the locally approved product label, local practice, or applicable SmPC (i.e., premedication with corticosteroids, diphenhydramine, and H2 antagonists)."
            }
          },
          {
            "id": "req-004",
            "instanceType": "RequiredMedication",
            "medication_name": "palonosetron",
            "medication_class": "5-HT3 receptor antagonist",
            "requirement_type": {
              "decode": "supportive_care"
            },
            "dosing": {
              "dose": "0.25 mg IV or 0.50 mg oral",
              "route": {
                "decode": "other"
              },
              "frequency": "Day 1 only"
            },
            "timing": {
              "relative_to": "chemotherapy",
              "time_before_minutes": null,
              "timing_description": "Administered on Day 1 of each cycle."
            },
            "purpose": "Anti-emetic therapy",
            "alternatives": [
              "ondansetron",
              "granisetron"
            ],
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "For anti-emetic therapy, ASCO guidelines recommend a two drug combination of palonosetron and dexamethasone. If palonosetron is not available, any of the first generation 5-HT3 receptor antagonists may be used, preferably ondansetron or granisetron. ASCO dosing guidelines are as follows: Palonosetron: 0.25 mg IV OR 0.50 mg oral, Day 1 only"
            }
          },
          {
            "id": "req-005",
            "instanceType": "RequiredMedication",
            "medication_name": "dexamethasone",
            "medication_class": "Corticosteroid",
            "requirement_type": {
              "decode": "supportive_care"
            },
            "dosing": {
              "dose": "8 mg",
              "route": {
                "decode": "other"
              },
              "frequency": "Days 1 to 3"
            },
            "timing": {
              "relative_to": "chemotherapy",
              "time_before_minutes": null,
              "timing_description": "Administered on Days 1 to 3 of each cycle."
            },
            "purpose": "Anti-emetic therapy",
            "alternatives": [],
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "Dexamethasone: 8 mg (IV or oral), Days 1 to 3"
            }
          }
        ],
        "rescue_medications": [],
        "washout_requirements": [
          {
            "id": "wash-001",
            "instanceType": "WashoutRequirement",
            "medication_class": "Cytotoxic chemotherapy or chemoradiotherapy for NSCLC",
            "specific_drugs": [],
            "washout_duration_days": 365,
            "washout_description": "Must be completed greater than 12 months prior to C1D-2, except for adjuvant or neoadjuvant therapy.",
            "rationale": "To ensure subjects are receiving first-line therapy for advanced/metastatic disease and to allow for resolution of prior treatment toxicities.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "6. Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC, except adjuvant or neoadjuvant therapy > 12 months prior to C1D-2..."
            }
          },
          {
            "id": "wash-002",
            "instanceType": "WashoutRequirement",
            "medication_class": "Targeted small molecule monotherapy",
            "specific_drugs": [
              "EGFR inhibitors",
              "ALK inhibitors"
            ],
            "washout_duration_days": 14,
            "washout_description": "Must be received more than 14 days prior to C1D-2.",
            "rationale": "To allow for clearance of prior therapy and resolution of toxicities.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "6. ...subject has received targeted small molecule monotherapy for EGFR and/or ALK-positive disease ≤ 14 days prior to C1D-2..."
            }
          },
          {
            "id": "wash-003",
            "instanceType": "WashoutRequirement",
            "medication_class": "Biologic therapy",
            "specific_drugs": [],
            "washout_duration_days": 21,
            "washout_description": "Must be received more than 21 days prior to C1D-2.",
            "rationale": "To allow for clearance of prior therapy and resolution of toxicities.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "6. ...or biologic therapy ≤ 21 days prior to C1D-2."
            }
          },
          {
            "id": "wash-004",
            "instanceType": "WashoutRequirement",
            "medication_class": "Anti-cancer Chinese medicine or herbal remedies",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "Must be discontinued more than 14 days prior to C1D-2.",
            "rationale": "To avoid potential drug interactions and confounding effects.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "7. Subject has received anti-cancer Chinese medicine or anti-cancer herbal remedies within 14 days prior to C1D-2."
            }
          },
          {
            "id": "wash-005",
            "instanceType": "WashoutRequirement",
            "medication_class": "External Beam Radiation Therapy (EBRT) to bone",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "Focal EBRT to bone must be completed more than 2 weeks prior to C1D-2.",
            "rationale": "To allow for recovery from radiation effects.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "8. Subject has undergone focal External Beam Radiation Therapy (EBRT) to bone ≤ 2 weeks prior to C1D-2..."
            }
          },
          {
            "id": "wash-006",
            "instanceType": "WashoutRequirement",
            "medication_class": "External Beam Radiation Therapy (EBRT) to larger fields",
            "specific_drugs": [],
            "washout_duration_days": 28,
            "washout_description": "EBRT to larger fields (i.e., 100 cm2 to thorax) must be completed more than 4 weeks prior to C1D-2.",
            "rationale": "To allow for recovery from radiation effects.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 36,
              "text_snippet": "8. ...or subject has undergone EBRT to larger fields (i.e., 100 cm2 to thorax) ≤ 4 weeks prior to C1D-2."
            }
          },
          {
            "id": "wash-007",
            "instanceType": "WashoutRequirement",
            "medication_class": "Non-prescription anti-cancer supplements",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "A 14-day washout period from C1D-2 must be documented.",
            "rationale": "To avoid potential drug interactions and confounding effects.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Alternate therapy: No herbal remedies or non-prescription anti-cancer supplements may be taken for cancer treatment concurrently with veliparib (a 14-day washout period from C1D-2 must be documented)."
            }
          }
        ],
        "drug_interactions": [
          {
            "id": "int-001",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "other"
            },
            "severity": {
              "decode": "weak"
            },
            "affected_drugs": [
              "midazolam",
              "buspirone",
              "felodipine",
              "lovastatin",
              "eletriptan",
              "repaglinide",
              "rosiglitazone",
              "sildenafil",
              "simvastatin",
              "triazolam"
            ],
            "clinical_effect": "Paclitaxel is a substrate of CYP3A4 and CYP2C8; concomitant use with other substrates requires caution.",
            "management": {
              "decode": "allowed_with_caution"
            },
            "management_detail": "Caution should be taken when administering paclitaxel concomitantly with known substrates of CYP3A4 or CYP2C8. Recommendations per local label should be observed.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Paclitaxel: Caution should also be taken when administering paclitaxel concomitantly with known substrates (e.g., midazolam, buspirone, felodipine, lovastatin, eletriptan, repaglinide, rosiglitazone, sildenafil, simvastatin, and triazolam)... of CYP3A4 or CYP2C8."
            }
          },
          {
            "id": "int-002",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "other"
            },
            "severity": {
              "decode": "weak"
            },
            "affected_drugs": [
              "atazanavir",
              "clarithromycin",
              "erythromycin",
              "fluoxetine",
              "gemfibrozil",
              "indinavir",
              "itraconazole",
              "ketoconazole",
              "nefazodone",
              "nelfinavir",
              "ritonavir",
              "saquinavir",
              "telithromycin"
            ],
            "clinical_effect": "Paclitaxel exposure may be altered by inhibitors of CYP3A4 or CYP2C8.",
            "management": {
              "decode": "allowed_with_caution"
            },
            "management_detail": "Caution should be taken when administering paclitaxel concomitantly with known inhibitors of CYP3A4 or CYP2C8. Recommendations per local label should be observed.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Paclitaxel: Caution should also be taken when administering paclitaxel concomitantly with known... inhibitors (e.g., atazanavir, clarithromycin, erythromycin, fluoxetine, gemfibrozil, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin)... of CYP3A4 or CYP2C8."
            }
          },
          {
            "id": "int-003",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "other"
            },
            "severity": {
              "decode": "weak"
            },
            "affected_drugs": [
              "rifampin",
              "carbamazepine",
              "phenytoin",
              "phenobarbital",
              "efavirenz",
              "nevirapine"
            ],
            "clinical_effect": "Paclitaxel exposure may be altered by inducers of CYP3A4 or CYP2C8.",
            "management": {
              "decode": "allowed_with_caution"
            },
            "management_detail": "Caution should be taken when administering paclitaxel concomitantly with known inducers of CYP3A4 or CYP2C8. Recommendations per local label should be observed.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 40,
              "text_snippet": "Paclitaxel: Caution should also be taken when administering paclitaxel concomitantly with known... inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, efavirenz, and nevirapine) of CYP3A4 or CYP2C8."
            }
          }
        ],
        "allowed_medications": [
          {
            "id": "allow-001",
            "instanceType": "AllowedMedication",
            "medication_class": "Hormonal contraceptives",
            "specific_drugs": [],
            "notes": "Hormonal contraceptives are allowed.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Hormonal contraceptives, hormonal replacement therapy, etc. are allowed."
            }
          },
          {
            "id": "allow-002",
            "instanceType": "AllowedMedication",
            "medication_class": "Hormonal replacement therapy",
            "specific_drugs": [],
            "notes": "Hormonal replacement therapy is allowed.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 38,
              "text_snippet": "Hormonal contraceptives, hormonal replacement therapy, etc. are allowed."
            }
          },
          {
            "id": "allow-003",
            "instanceType": "AllowedMedication",
            "medication_class": "Erythropoiesis-stimulating agents",
            "specific_drugs": [
              "erythropoietin",
              "darbepoetin alpha"
            ],
            "notes": "May be administered during dosing of veliparib and carboplatin/paclitaxel.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "Growth factors: Biologic response modifiers administered for erythropoiesis (e.g., erythropoietin, darbepoetin alpha) may be administered during dosing of veliparib and carboplatin/paclitaxel."
            }
          },
          {
            "id": "allow-004",
            "instanceType": "AllowedMedication",
            "medication_class": "Granulocyte growth factors",
            "specific_drugs": [
              "G-CSF",
              "GM-CSF"
            ],
            "notes": "To be administered according to the Investigator's standard practice and/or ASCO guidelines. After C1D1, may be given to prevent dose reductions or delays.",
            "provenance": {
              "section_number": "5.2.3.2",
              "page_number": 39,
              "text_snippet": "Granulocyte growth factors (e.g., G CSF, GM-CSF, etc.) are to be administered according to the Investigator's standard practice and/or ASCO guidelines. After C1D1, growth factors may be given with the intent to prevent dose reductions or delays after C1D1."
            }
          }
        ],
        "vaccine_policy": {
          "instanceType": "VaccinePolicy",
          "live_vaccines_prohibited": null,
          "live_vaccine_washout_days": null,
          "inactivated_vaccines_allowed": null,
          "covid_vaccine_policy": null,
          "specific_restrictions": [
            "The protocol does not state a general vaccine policy, but notes that local product labels for carboplatin and paclitaxel should be referenced for contraindications, giving yellow fever vaccine (a live vaccine) as an example."
          ],
          "provenance": {
            "section_number": "5.2.3.2",
            "page_number": 38,
            "text_snippet": "The locally approved carboplatin and paclitaxel product labels or SmPCs should be referenced to determine if there are any contraindications associated with concomitant medications (e.g., yellow fever vaccine, phenytoin, etc.)."
          }
        },
        "herbal_supplements_policy": {
          "instanceType": "HerbalSupplementsPolicy",
          "prohibited_supplements": [
            "Anti-cancer Chinese medicine",
            "Anti-cancer herbal remedies",
            "Non-prescription anti-cancer supplements"
          ],
          "rationale": "To avoid potential drug interactions and confounding effects on efficacy and safety. A 14-day washout is required before C1D-2.",
          "provenance": {
            "section_number": "5.2.3.2",
            "page_number": 40,
            "text_snippet": "Alternate therapy: No herbal remedies or non-prescription anti-cancer supplements may be taken for cancer treatment concurrently with veliparib (a 14-day washout period from C1D-2 must be documented)."
          }
        },
        "provenance": {
          "section_number": "5.2.3",
          "page_number": 37,
          "text_snippet": "5.2.3 Prior and Concomitant Therapy"
        }
      },
      "_agentDocumentation": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json"
      }
    },
    "biospecimenHandling": {
      "moduleId": "biospecimen_handling",
      "instanceType": "BiospecimenHandling",
      "data": {
        "discovered_specimen_types": [
          {
            "specimen_id": "SPEC-001",
            "specimen_name": "Whole Blood for Genetic (DNA) Analysis",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "pharmacogenomics",
            "purpose_description": "Optional with Consent PG Blood Sampling Genetic (DNA)",
            "provenance": {
              "section_number": "5.3.1.2",
              "page_number": 51,
              "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis."
            }
          },
          {
            "specimen_id": "SPEC-002",
            "specimen_name": "Blood for Plasma Markers",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "pharmacodynamics",
            "purpose_description": "PD Blood Sampling Plasma Markers",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 52,
              "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL (Baseline and Final Visit) or 6 mL (all other timepoints) of blood will be collected pre-dose by venipuncture at timepoints outlined in Table 3 in conjunction with PK samples, if possible."
            }
          },
          {
            "specimen_id": "SPEC-003",
            "specimen_name": "Blood for Serum Markers",
            "specimen_category": "blood",
            "specimen_subtype": "serum",
            "purpose": "pharmacodynamics",
            "purpose_description": "Serum Markers",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 52,
              "text_snippet": "Blood Collection for Serum Markers\nApproximately 5 mL of blood will be collected pre-dose by venipuncture as outlined in Table 3."
            }
          },
          {
            "specimen_id": "SPEC-004",
            "specimen_name": "Archived FFPE tissue blocks",
            "specimen_category": "tissue",
            "specimen_subtype": "ffpe_tissue",
            "purpose": "biomarker_analysis",
            "purpose_description": "To determine the subjects' tumor LSP status",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 52,
              "text_snippet": "Tissue Collection\nSubjects must consent to provide available archival tumor (biopsy preferred, or cytology) for analysis. It is recognized that samples suitable for analysis will not be available from all consenting subjects."
            }
          },
          {
            "specimen_id": "SPEC-005",
            "specimen_name": "Blood for PK analysis",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "pharmacokinetics",
            "provenance": {
              "section_number": "5.3.2.1",
              "page_number": 53,
              "text_snippet": "Veliparib Pharmacokinetic Specimen Collection\nApproximately 3 mL of blood will be collected by venipuncture for veliparib concentrations at 0 hours (just before morning dose of veliparib) and other timepoints as specified per Table 4."
            }
          }
        ],
        "collection_schedule": [
          {
            "schedule_id": "SCHED-001",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "C1D-2",
            "timepoint_type": "treatment_period",
            "relative_time": "C1D-2",
            "collection_window": {
              "description": "If sample is not collected at C1D-2, it may be collected at any time throughout the study."
            },
            "provenance": {
              "section_number": "5.3.1.2",
              "page_number": 51,
              "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis... If the sample is not collected on C1D-2, it may be collected at any time throughout the study."
            }
          },
          {
            "schedule_id": "SCHED-002",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "C1D-2, C3D1",
            "timepoint_type": "treatment_period",
            "relative_time": "Pre-dose",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "PD Blood Sampling Plasma Markersa | C1D-2, C3D1 | Pre-dose"
            }
          },
          {
            "schedule_id": "SCHED-003",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Final Visit",
            "timepoint_type": "end_of_study",
            "relative_time": "At the time of the clinic visit",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "PD Blood Sampling Plasma Markersa | Final Visit | At the time of the clinic visit"
            }
          },
          {
            "schedule_id": "SCHED-004",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "C1D-2, C3D1",
            "timepoint_type": "treatment_period",
            "relative_time": "Pre-dose",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "Serum Markers | C1D-2, C3D1 | Pre-dose"
            }
          },
          {
            "schedule_id": "SCHED-005",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "Final Visit",
            "timepoint_type": "end_of_study",
            "relative_time": "At the time of the clinic visit",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "Serum Markers | Final Visit | At the time of the clinic visit"
            }
          },
          {
            "schedule_id": "SCHED-006",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "Screening or C1D-2",
            "timepoint_type": "screening",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "Tissue Sample Collection | Screening or C1D-2"
            }
          },
          {
            "schedule_id": "SCHED-007",
            "specimen_ref": "SPEC-005",
            "timepoint_name": "C1D-2",
            "timepoint_type": "treatment_period",
            "relative_time": "1, 2, 3 h after Veliparib AM Dose",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 43,
              "text_snippet": "Veliparib PK Sampling | C1D-2 | -- | 1, 2, 3 h"
            }
          },
          {
            "schedule_id": "SCHED-008",
            "specimen_ref": "SPEC-005",
            "timepoint_name": "C2D1, C3D1, C4D1",
            "timepoint_type": "treatment_period",
            "relative_time": "0 h (Before the administration of the morning dose of veliparib)",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 43,
              "text_snippet": "Veliparib PK Samplinga | C2D1, C3D1, C4D1 | 0 ha | --"
            }
          }
        ],
        "processing_requirements": [
          {
            "specimen_ref": "SPEC-001",
            "processing_id": "PROC-001",
            "processing_step": "Freezing",
            "description": "Frozen (as per the study specific laboratory manual)",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 43,
              "text_snippet": "Whole Blood Frozen (as per the study specific laboratory manual)"
            }
          },
          {
            "specimen_ref": "SPEC-002",
            "processing_id": "PROC-002",
            "processing_step": "Centrifugation and Freezing",
            "description": "The complete process of centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw.",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 52,
              "text_snippet": "The complete process of centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw."
            }
          },
          {
            "specimen_ref": "SPEC-003",
            "processing_id": "PROC-003",
            "processing_step": "Clot formation, Centrifugation and Freezing",
            "description": "The complete process of clot formation, centrifugation, transfer to cryovials and freezing should be accomplished in less than 90 minutes from the time of blood draw.",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 52,
              "text_snippet": "The complete process of clot formation, centrifugation, transfer to cryovials and freezing should be accomplished in less than 90 minutes from the time of blood draw."
            }
          },
          {
            "specimen_ref": "SPEC-005",
            "processing_id": "PROC-004",
            "processing_step": "Conversion to Plasma and Freezing",
            "description": "Blood -> Plasma Frozen (as per the study specific laboratory manual)",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 43,
              "text_snippet": "Blood → Plasma Frozen (as per the study specific laboratory manual)"
            }
          }
        ],
        "storage_requirements": [
          {
            "storage_id": "STOR-001",
            "specimen_ref": "SPEC-001",
            "storage_condition": "frozen",
            "duration": "up to 20 years",
            "provenance": {
              "section_number": "5.3.1.2",
              "page_number": 51,
              "text_snippet": "AbbVie will store the DNA samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on ABT-888 (or drugs of this class) continues but no longer than 20 years."
            }
          }
        ],
        "shipping_requirements": [
          {
            "shipping_id": "SHIP-001",
            "specimen_ref": "SPEC-001",
            "shipping_condition": "frozen",
            "destination": "AbbVie or a designated laboratory",
            "provenance": {
              "section_number": "5.3.1.2",
              "page_number": 51,
              "text_snippet": "Samples will be shipped frozen to AbbVie or a designated laboratory for DNA extraction and long-term storage."
            }
          }
        ],
        "central_laboratory": {
          "performs_analysis": true,
          "lab_name": "Certified central laboratory",
          "lab_vendor_name": "Not specified",
          "provenance": {
            "section_number": "Clinical Laboratory Tests",
            "page_number": 47,
            "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis. The central laboratory will provide instructions regarding the collection, processing and shipping of samples. All laboratory samples will be shipped to the central laboratory."
          }
        },
        "volume_summary": {
          "specimen_ref": "SPEC-001",
          "volume": 4,
          "unit": "mL",
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 51,
            "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis."
          }
        },
        "id": "biospecimen-handling-001",
        "instanceType": "BiospecimenHandling",
        "name": "M14-359 Biospecimen Handling"
      },
      "_agentDocumentation": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements.\n    Essential for central lab setup, biobank configuration, and site laboratory\n    manual generation.",
        "scope": "- Specimen types and collection requirements\n    - Tube types, volumes, and handling\n    - Processing instructions (centrifugation, aliquoting)\n    - Storage conditions (temperature, duration)\n    - Shipping requirements (courier, temperature monitoring)\n    - Central lab vs local lab procedures\n    - Biobanking/future research samples",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual",
          "Appendix: Sample Handling Instructions"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical"
          },
          {
            "name": "Processing Instructions",
            "description": "Centrifugation, aliquoting, timing requirements",
            "dataPath": "processing_instructions[]",
            "downstreamUses": [
              "Site training materials",
              "Lab manual generation",
              "Quality checks"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          },
          {
            "name": "Shipping Requirements",
            "description": "Temperature, courier, documentation for specimen transport",
            "dataPath": "shipping_requirements",
            "downstreamUses": [
              "Logistics planning",
              "Courier configuration",
              "Chain of custody"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals",
          "Set up shipping logistics and temperature monitoring",
          "Design sample collection CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json"
      }
    },
    "laboratorySpecifications": {
      "moduleId": "laboratory_specifications",
      "instanceType": "LaboratorySpecifications",
      "data": {
        "id": "LS-001",
        "instanceType": "LaboratorySpecifications",
        "name": "Laboratory Specifications",
        "description": "Protocol-discovered laboratory testing requirements",
        "central_laboratory": {
          "vendor_name": "A certified central laboratory will be used.",
          "accreditations": null,
          "data_transfer_method": null,
          "provenance": {
            "section_number": "4.7",
            "page_number": 47,
            "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis."
          }
        },
        "discovered_panels": [
          {
            "panel_id": "PNL-001",
            "panel_name": "Hematology",
            "panel_code": null,
            "panel_description": "Assessment of blood cells and related parameters.",
            "panel_category": "hematology",
            "test_count": 14,
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Table 5. Clinical Laboratory Tests\nHematology"
            }
          },
          {
            "panel_id": "PNL-002",
            "panel_name": "Clinical Chemistry",
            "panel_code": null,
            "panel_description": "Assessment of chemical components in the blood.",
            "panel_category": "chemistry",
            "test_count": 18,
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Table 5. Clinical Laboratory Tests\nClinical Chemistry"
            }
          },
          {
            "panel_id": "PNL-003",
            "panel_name": "Urinalysis",
            "panel_code": null,
            "panel_description": "Assessment of urine properties and components.",
            "panel_category": "urinalysis",
            "test_count": 8,
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Table 5. Clinical Laboratory Tests\nUrinalysis"
            }
          },
          {
            "panel_id": "PNL-004",
            "panel_name": "Coagulation",
            "panel_code": null,
            "panel_description": "Assessment of blood clotting function.",
            "panel_category": "coagulation",
            "test_count": 2,
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Table 5. Clinical Laboratory Tests\nCoagulation"
            }
          },
          {
            "panel_id": "PNL-005",
            "panel_name": "Serum Pregnancy Test",
            "panel_code": null,
            "panel_description": "Detection of Human Chorionic Gonadotropin (hCG) in serum.",
            "panel_category": "chemistry",
            "test_count": 1,
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Table 5. Clinical Laboratory Tests\nSerum Pregnancy Test"
            }
          }
        ],
        "laboratory_tests": [
          {
            "test_id": "LAB-001",
            "test_name": "Hematocrit",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures the proportion of red blood cells in blood.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nHematocrit"
            }
          },
          {
            "test_id": "LAB-002",
            "test_name": "Hemoglobin",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "g/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for anemia, a potential side effect of chemotherapy.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nHemoglobin"
            }
          },
          {
            "test_id": "LAB-003",
            "test_name": "Red blood cell (RBC) count",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Quantifies red blood cells, important for oxygen transport.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nRed blood cell (RBC) count"
            }
          },
          {
            "test_id": "LAB-004",
            "test_name": "White blood cell (WBC) count",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for leukopenia, a sign of myelosuppression.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nWhite blood cell (WBC) count"
            }
          },
          {
            "test_id": "LAB-005",
            "test_name": "Neutrophils",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "/mm3",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Absolute Neutrophil Count (ANC) is critical for assessing infection risk and eligibility for treatment.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nNeutrophils"
            }
          },
          {
            "test_id": "LAB-006",
            "test_name": "Bands (if indicated)",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Immature neutrophils, may indicate infection.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nBands (if indicated)"
            }
          },
          {
            "test_id": "LAB-007",
            "test_name": "Lymphocytes",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of the immune system.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nLymphocytes"
            }
          },
          {
            "test_id": "LAB-008",
            "test_name": "Monocytes",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of the immune system.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nMonocytes"
            }
          },
          {
            "test_id": "LAB-009",
            "test_name": "Basophils (if indicated)",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of the immune system.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nBasophils (if indicated)"
            }
          },
          {
            "test_id": "LAB-010",
            "test_name": "Eosinophils (if indicated)",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of the immune system.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nEosinophils (if indicated)"
            }
          },
          {
            "test_id": "LAB-011",
            "test_name": "Platelet count",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "/mm3",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for thrombocytopenia, a risk for bleeding.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nPlatelet count (estimate not acceptable)"
            }
          },
          {
            "test_id": "LAB-012",
            "test_name": "Mean corpuscular volume",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures the average size of red blood cells.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nMean corpuscular volume"
            }
          },
          {
            "test_id": "LAB-013",
            "test_name": "Mean corpuscular hemoglobin concentration",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures the concentration of hemoglobin in a given volume of packed red blood cells.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nMean corpuscular hemoglobin concentration"
            }
          },
          {
            "test_id": "LAB-014",
            "test_name": "RBC distribution width",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures the variation in red blood cell size or volume.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Hematology\nRBC distribution width"
            }
          },
          {
            "test_id": "LAB-015",
            "test_name": "Blood urea nitrogen (BUN)",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nBlood urea nitrogen (BUN)"
            }
          },
          {
            "test_id": "LAB-016",
            "test_name": "Serum creatinine",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function, used to calculate creatinine clearance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nSerum creatinine**"
            }
          },
          {
            "test_id": "LAB-017",
            "test_name": "Total bilirubin",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses hepatic function.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nTotal bilirubin"
            }
          },
          {
            "test_id": "LAB-018",
            "test_name": "Serum glutamic-pyruvic transaminase (SGPT/ALT)",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses hepatic function.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nSerum glutamic-pyruvic transaminase (SGPT/ALT)"
            }
          },
          {
            "test_id": "LAB-019",
            "test_name": "Serum glutamic-oxaloacetic transaminase (SGOT/AST)",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses hepatic function.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nSerum glutamic-oxaloacetic transaminase (SGOT/AST)"
            }
          },
          {
            "test_id": "LAB-020",
            "test_name": "Alkaline phosphatase",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses hepatic and bone function.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nAlkaline phosphatase"
            }
          },
          {
            "test_id": "LAB-021",
            "test_name": "Sodium",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nSodium"
            }
          },
          {
            "test_id": "LAB-022",
            "test_name": "Potassium",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nPotassium"
            }
          },
          {
            "test_id": "LAB-023",
            "test_name": "Calcium",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nCalcium"
            }
          },
          {
            "test_id": "LAB-024",
            "test_name": "Inorganic phosphorus",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nInorganic phosphorus"
            }
          },
          {
            "test_id": "LAB-025",
            "test_name": "Uric acid",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function and metabolic status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nUric acid"
            }
          },
          {
            "test_id": "LAB-026",
            "test_name": "Total protein",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses nutritional status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nTotal protein"
            }
          },
          {
            "test_id": "LAB-027",
            "test_name": "Glucose",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses glucose metabolism.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nGlucose"
            }
          },
          {
            "test_id": "LAB-028",
            "test_name": "Albumin",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses nutritional and hepatic status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nAlbumin"
            }
          },
          {
            "test_id": "LAB-029",
            "test_name": "Lactate dehydrogenase (LDH)",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "General marker of tissue damage.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nLactate dehydrogenase (LDH)"
            }
          },
          {
            "test_id": "LAB-030",
            "test_name": "Magnesium",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nMagnesium"
            }
          },
          {
            "test_id": "LAB-031",
            "test_name": "Chloride",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses electrolyte balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nChloride"
            }
          },
          {
            "test_id": "LAB-032",
            "test_name": "Bicarbonate",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses acid-base balance.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Clinical Chemistry\nBicarbonate"
            }
          },
          {
            "test_id": "LAB-033",
            "test_name": "Specific gravity",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures urine concentration.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nSpecific gravity"
            }
          },
          {
            "test_id": "LAB-034",
            "test_name": "Ketones",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for ketones in urine.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nKetones"
            }
          },
          {
            "test_id": "LAB-035",
            "test_name": "pH",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures acidity of urine.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\npH"
            }
          },
          {
            "test_id": "LAB-036",
            "test_name": "Protein",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for protein in urine, a sign of kidney problems.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nProtein"
            }
          },
          {
            "test_id": "LAB-037",
            "test_name": "Blood",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for blood in urine.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nBlood"
            }
          },
          {
            "test_id": "LAB-038",
            "test_name": "Glucose",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for sugar in urine.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nGlucose"
            }
          },
          {
            "test_id": "LAB-039",
            "test_name": "Urobilinogen",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for liver disease.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nUrobilinogen"
            }
          },
          {
            "test_id": "LAB-040",
            "test_name": "Bilirubin",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Checks for liver disease.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Urinalysis\nBilirubin"
            }
          },
          {
            "test_id": "LAB-041",
            "test_name": "Activated Partial Thromboplastin Time (aPTT)",
            "test_code": null,
            "panel_ref": "PNL-004",
            "specimen_type": "plasma",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses coagulation status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Coagulation\nActivated Partial Thromboplastin Time (aPTT)*"
            }
          },
          {
            "test_id": "LAB-042",
            "test_name": "International Normalized Ratio (INR)",
            "test_code": null,
            "panel_ref": "PNL-004",
            "specimen_type": "plasma",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses coagulation status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Coagulation\nInternational Normalized Ratio (INR)*"
            }
          },
          {
            "test_id": "LAB-043",
            "test_name": "Human Chorionic Gonadotropin (hCG)",
            "test_code": null,
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Confirms pregnancy status.",
            "provenance": {
              "section_number": "Table 5",
              "page_number": 48,
              "text_snippet": "Serum Pregnancy Test\nHuman Chorionic Gonadotropin (hCG)***"
            }
          },
          {
            "test_id": "LAB-044",
            "test_name": "Urine Pregnancy Test",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screens for pregnancy prior to dosing.",
            "provenance": {
              "section_number": "4.6",
              "page_number": 46,
              "text_snippet": "A urine pregnancy test should also be performed prior to dosing on C1D-2 if > 7 days since obtaining Screening serum test results. Local urine pregnancy testing should also be performed at each subsequent Cycle Day 1 visit."
            }
          },
          {
            "test_id": "LAB-045",
            "test_name": "Creatinine Clearance",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Calculated using the Cockcroft-Gault formula. Confirmation may be done by a local direct measurement method (e.g., 24 hour urine collection or radioisotope).",
            "unit": "mL/min",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function for eligibility and carboplatin dosing.",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "Renal function: Serum calculated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula; confirmation of creatinine clearance/GFR may be done by a local direct measurement method..."
            }
          }
        ],
        "testing_schedule": [
          {
            "schedule_id": "SCH-001",
            "test_or_panel_ref": "PNL-001",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Within 28 days of randomization",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 1 Day -2",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 1 Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 2-6 Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Final Visit",
                "timepoint_type": "follow_up",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Maintenance Therapy",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "For subjects receiving maintenance therapy"
              }
            ],
            "frequency": "At screening, C1D-2, and Day 1 of each cycle",
            "provenance": {
              "section_number": "Table 2",
              "page_number": 41,
              "text_snippet": "Table 2. Study Activities\nChemistry/Hematologyi X X X X X X"
            }
          },
          {
            "schedule_id": "SCH-002",
            "test_or_panel_ref": "PNL-002",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Within 28 days of randomization",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 1 Day -2",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 1 Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 2-6 Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              },
              {
                "timepoint_name": "Final Visit",
                "timepoint_type": "follow_up",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Maintenance Therapy",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "For subjects receiving maintenance therapy"
              }
            ],
            "frequency": "At screening, C1D-2, and Day 1 of each cycle",
            "provenance": {
              "section_number": "Table 2",
              "page_number": 41,
              "text_snippet": "Table 2. Study Activities\nChemistry/Hematologyi X X X X X X"
            }
          },
          {
            "schedule_id": "SCH-003",
            "test_or_panel_ref": "PNL-003",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Within 28 days of randomization",
                "conditions": null
              },
              {
                "timepoint_name": "Cycle 1 Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72 hours of scheduled day",
                "conditions": null
              }
            ],
            "frequency": "At screening and C1D1",
            "provenance": {
              "section_number": "Table 2",
              "page_number": 41,
              "text_snippet": "Table 2. Study Activities\nUrinalysisi X X"
            }
          },
          {
            "schedule_id": "SCH-004",
            "test_or_panel_ref": "PNL-004",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Within 28 days of randomization",
                "conditions": null
              }
            ],
            "frequency": "At Screening only",
            "provenance": {
              "section_number": "Table 2",
              "page_number": 41,
              "text_snippet": "Table 2. Study Activities\naPTT, INRi X"
            }
          },
          {
            "schedule_id": "SCH-005",
            "test_or_panel_ref": "PNL-005",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Within 28 days of randomization",
                "conditions": "For female subjects of childbearing potential."
              },
              {
                "timepoint_name": "Unscheduled",
                "timepoint_type": "unscheduled",
                "window": null,
                "conditions": "To confirm a positive urine pregnancy test or if pregnancy is suspected."
              }
            ],
            "frequency": "At screening and as needed.",
            "provenance": {
              "section_number": "4.6",
              "page_number": 46,
              "text_snippet": "For subjects of childbearing potential, a serum pregnancy test will be performed at Screening... A positive urine pregnancy test will be confirmed with a serum pregnancy test."
            }
          },
          {
            "schedule_id": "SCH-006",
            "test_or_panel_ref": "LAB-044",
            "timepoints": [
              {
                "timepoint_name": "Cycle 1 Day -2",
                "timepoint_type": "treatment",
                "window": "Prior to dosing",
                "conditions": "For female subjects of childbearing potential, unless serum test was collected within 7 days."
              },
              {
                "timepoint_name": "Each subsequent Cycle Day 1 visit",
                "timepoint_type": "treatment",
                "window": "Prior to dosing",
                "conditions": "For female subjects of childbearing potential."
              }
            ],
            "frequency": "Prior to dosing at C1D-2 and each subsequent Cycle Day 1.",
            "provenance": {
              "section_number": "4.6",
              "page_number": 46,
              "text_snippet": "A urine pregnancy test should also be performed prior to dosing on C1D-2 if > 7 days since obtaining Screening serum test results. Local urine pregnancy testing should also be performed at each subsequent Cycle Day 1 visit."
            }
          }
        ],
        "sample_collection_requirements": {
          "fasting_requirements": "Not specified.",
          "timing_requirements": "Clinical laboratory tests can be performed up to 72 hours prior to dosing.",
          "processing_requirements": "Plasma markers: Centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw. Serum markers: Clot formation, centrifugation, transfer to cryovials and freezing should be accomplished in less than 90 minutes from the time of blood draw.",
          "storage_requirements": "PGx, PD, and PK samples to be shipped frozen.",
          "shipping_requirements": "Samples will be shipped to AbbVie or a designated laboratory.",
          "provenance": {
            "section_number": "5.3.1.3",
            "page_number": 52,
            "text_snippet": "Blood Collection for Plasma Markers...The complete process of centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw.\nBlood Collection for Serum Markers...The complete process of clot formation, centrifugation, transfer to cryovials and freezing should be accomplished in less than 90 minutes from the time of blood draw."
          }
        },
        "lab_based_dose_modifications": [
          {
            "modification_id": "MOD-001",
            "parameter_name": "Absolute neutrophil count (ANC)",
            "trigger_condition": "ANC < 1,500/mm³ on Day 1 of each cycle",
            "operator": "lt",
            "threshold_value": 1500,
            "threshold_unit": "/mm3",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay treatment until recovery of ANC ≥ 1,500/mm³.",
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "For absolute neutrophil count (ANC) < 1,500/mm3 or platelet count < 100,000/mm3 on Day 1 of each cycle, treatment is to be delayed until recovery of ANC and platelet count above these values."
            }
          },
          {
            "modification_id": "MOD-002",
            "parameter_name": "Platelet count",
            "trigger_condition": "Platelet count < 100,000/mm³ on Day 1 of each cycle",
            "operator": "lt",
            "threshold_value": 100000,
            "threshold_unit": "/mm3",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay treatment until recovery of platelet count ≥ 100,000/mm³.",
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "For absolute neutrophil count (ANC) < 1,500/mm3 or platelet count < 100,000/mm3 on Day 1 of each cycle, treatment is to be delayed until recovery of ANC and platelet count above these values."
            }
          },
          {
            "modification_id": "MOD-003",
            "parameter_name": "Febrile Neutropenia",
            "trigger_condition": "Grade 3/4 Febrile Neutropenia",
            "operator": "eq",
            "threshold_value": 3,
            "threshold_unit": "Grade",
            "reference_type": "CTCAE",
            "required_action": "dose_reduce",
            "recovery_criteria": "Reduce carboplatin and paclitaxel to Dose Level -1 for 1st episode and Dose Level -2 for 2nd episode.",
            "provenance": {
              "section_number": "Appendix G",
              "page_number": 113,
              "text_snippet": "Grade 3/4 Febrile Neutropenia\nCarboplatin Dose: Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode.\nPaclitaxel Dose: Reduce to Dose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
            }
          },
          {
            "modification_id": "MOD-004",
            "parameter_name": "Thrombocytopenia",
            "trigger_condition": "Grade 4 Thrombocytopenia",
            "operator": "eq",
            "threshold_value": 4,
            "threshold_unit": "Grade",
            "reference_type": "CTCAE",
            "required_action": "dose_reduce",
            "recovery_criteria": "Reduce carboplatin and paclitaxel to Dose Level -1 for 1st episode and Dose Level -2 for 2nd episode.",
            "provenance": {
              "section_number": "Appendix G",
              "page_number": 113,
              "text_snippet": "Grade 4 Thrombocytopenia\nDose Level –1 for 1st episode and Dose Level –2 for 2nd episode."
            }
          },
          {
            "modification_id": "MOD-005",
            "parameter_name": "Bilirubin and ALT",
            "trigger_condition": "Bilirubin > 1.5 × ULN with increased ALT above ULN",
            "operator": "gt",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "reference_type": "ULN",
            "required_action": "dose_hold",
            "recovery_criteria": "Paclitaxel is to be held until bilirubin is ≤ 1.5 × ULN, and the dose is to be reduced by one level when treatment is resumed.",
            "provenance": {
              "section_number": "5.7.2.1",
              "page_number": 72,
              "text_snippet": "For bilirubin > 1.5 × ULN with increased ALT above ULN that is attributed to protocol therapy, paclitaxel is to be held until bilirubin is ≤ 1.5 × ULN, and the dose is to be reduced by one level when treatment is resumed."
            }
          },
          {
            "modification_id": "MOD-006",
            "parameter_name": "ALT and Bilirubin",
            "trigger_condition": "ALT > 5 × ULN with bilirubin < 1.5 × ULN",
            "operator": "gt",
            "threshold_value": 5,
            "threshold_unit": "xULN",
            "reference_type": "ULN",
            "required_action": "dose_reduce",
            "recovery_criteria": "Paclitaxel dose is to be reduced by one level.",
            "provenance": {
              "section_number": "6.0",
              "page_number": 73,
              "text_snippet": "For ALT > 5 × ULN with bilirubin < 1.5 × ULN that is attributed to protocol therapy, paclitaxel dose is to be reduced by one level."
            }
          }
        ],
        "eligibility_lab_criteria": [
          {
            "criteria_id": "ELIG-001",
            "criteria_type": "inclusion",
            "parameter_name": "Absolute neutrophil count (ANC)",
            "condition": "Absolute neutrophil count (ANC) ≥ 1,500/mm³ (1.5 × 10⁹/L)",
            "operator": "gte",
            "threshold_value": 1500,
            "threshold_unit": "/mm3",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "Bone Marrow: Absolute neutrophil count (ANC) ≥ 1,500/mm3 (1.5 × 109/L);"
            }
          },
          {
            "criteria_id": "ELIG-002",
            "criteria_type": "inclusion",
            "parameter_name": "Platelets",
            "condition": "Platelets ≥ 100,000/mm³ (100 × 10⁹/L)",
            "operator": "gte",
            "threshold_value": 100000,
            "threshold_unit": "/mm3",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "Platelets ≥ 100,000/mm3 (100 × 109/L);"
            }
          },
          {
            "criteria_id": "ELIG-003",
            "criteria_type": "inclusion",
            "parameter_name": "Hemoglobin",
            "condition": "Hemoglobin ≥ 9.0 g/dL",
            "operator": "gte",
            "threshold_value": 9.0,
            "threshold_unit": "g/dL",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "Hemoglobin ≥ 9.0 g/dL;"
            }
          },
          {
            "criteria_id": "ELIG-004",
            "criteria_type": "inclusion",
            "parameter_name": "Creatinine clearance",
            "condition": "serum calculated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula",
            "operator": "gt",
            "threshold_value": 50,
            "threshold_unit": "mL/min",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "Renal function: Serum calculated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula;"
            }
          },
          {
            "criteria_id": "ELIG-005",
            "criteria_type": "inclusion",
            "parameter_name": "AST and ALT",
            "condition": "AST and ALT ≤ 2.5 × ULN unless liver metastases are present, then AST and ALT < 5.0 × ULN",
            "operator": "lte",
            "threshold_value": 2.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 35,
              "text_snippet": "Hepatic function: AST and ALT ≤ 2.5 × ULN unless liver metastases are present, then AST and ALT < 5.0 × ULN;"
            }
          },
          {
            "criteria_id": "ELIG-006",
            "criteria_type": "inclusion",
            "parameter_name": "Bilirubin",
            "condition": "bilirubin ≤ 1.5 × ULN; unless Gilbert's Syndrome is present, then bilirubin ≥ 1.5 × ULN",
            "operator": "lte",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 35,
              "text_snippet": "bilirubin ≤ 1.5 × ULN unless Gilbert's Syndrome is present, then bilirubin ≥ 1.5 × ULN."
            }
          }
        ],
        "critical_value_reporting": {
          "notification_timeline": "Not explicitly defined. Clinically significant laboratory values will be recorded as adverse events.",
          "notification_recipients": null,
          "documentation_requirements": "Record as adverse event if criteria are met.",
          "critical_value_list": [],
          "provenance": {
            "section_number": "4.7",
            "page_number": 47,
            "text_snippet": "Any laboratory value outside the reference range that is considered clinically significant by the Investigator will be followed as appropriate. Clinically significant laboratory values will be recorded as adverse events if they meet the criteria as specified in Section 6.1.1."
          }
        },
        "abnormal_result_grading": {
          "grading_system": "NCI CTCAE",
          "grading_version": "4.0",
          "clinically_significant_threshold": null,
          "ae_reporting_threshold": null,
          "provenance": {
            "section_number": "5.3.4",
            "page_number": 54,
            "text_snippet": "Adverse events intensity and laboratory evaluation changes will be assessed by utilizing NCI CTCAE version 4.0."
          }
        },
        "pregnancy_testing": {
          "required": true,
          "applicable_population": "Female subjects of childbearing potential (i.e., those who are not postmenopausal for at least 1 year or surgically sterile).",
          "test_type": "serum, urine",
          "timing": "Serum test at Screening. Urine test prior to dosing at C1D-2 (if serum test > 7 days old) and at each subsequent Cycle Day 1 visit. A positive urine test will be confirmed with a serum test.",
          "sensitivity": null,
          "action_if_positive": "Administration of study drug must be discontinued immediately. The site must report the positive pregnancy test result by telephone within 24 hours.",
          "provenance": {
            "section_number": "4.6",
            "page_number": 46,
            "text_snippet": "For subjects of childbearing potential, a serum pregnancy test will be performed at Screening... A urine pregnancy test should also be performed prior to dosing on C1D-2 if > 7 days since obtaining Screening serum test results. Local urine pregnancy testing should also be performed at each subsequent Cycle Day 1 visit."
          }
        },
        "pharmacokinetic_samples": {
          "pk_sampling_required": true,
          "analytes": [
            "veliparib"
          ],
          "sample_type": "plasma",
          "timepoints_description": "C1D-2: 1, 2, and 3 hours after AM dose. C2D1, C3D1, C4D1: 0 hours (pre-dose).",
          "volume_per_sample": "Approximately 3 mL of blood",
          "processing_requirements": "Blood to be processed to plasma and frozen as per the study specific laboratory manual.",
          "provenance": {
            "section_number": "5.3.2.1",
            "page_number": 53,
            "text_snippet": "Approximately 3 mL of blood will be collected by venipuncture for veliparib concentrations at 0 hours (just before morning dose of veliparib) and other timepoints as specified per Table 4."
          }
        },
        "biomarker_samples": {
          "biomarker_sampling_required": true,
          "biomarkers": [
            {
              "name": "LSP status",
              "purpose": "To determine subject's tumor LSP status for primary endpoint analysis.",
              "sample_type": "archived_tumor_tissue",
              "timing": "Screening or C1D-2",
              "provenance": {
                "section_number": "10",
                "page_number": 10,
                "text_snippet": "LSP status: Available archived tumor tissue will be used to determine the subjects' tumor LSP status with a commercially developed RNA seq based LSP classifier developed in partnership with Qiagen."
              }
            },
            {
              "name": "Genetic (DNA) analysis",
              "purpose": "Pharmacogenetic analysis for factors contributing to disease or response to veliparib.",
              "sample_type": "whole_blood",
              "timing": "C1D-2 (or any time throughout the study)",
              "provenance": {
                "section_number": "5.3.1.2",
                "page_number": 51,
                "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis."
              }
            },
            {
              "name": "Plasma Markers",
              "purpose": "Pharmacodynamic correlative studies to evaluate known and novel markers of disease status.",
              "sample_type": "plasma",
              "timing": "C1D-2, C3D1, Final Visit (pre-dose)",
              "provenance": {
                "section_number": "Table 3",
                "page_number": 43,
                "text_snippet": "PD Blood Sampling Plasma Markersa C1D-2, C3D1 Pre-dose\nFinal Visit At the time of the clinic visit"
              }
            },
            {
              "name": "Serum Markers",
              "purpose": "Pharmacodynamic correlative studies to evaluate known and novel markers of disease status.",
              "sample_type": "serum",
              "timing": "C1D-2, C3D1, Final Visit (pre-dose)",
              "provenance": {
                "section_number": "Table 3",
                "page_number": 43,
                "text_snippet": "Serum Markers C1D-2, C3D1 Pre-dose\nFinal Visit At the time of the clinic visit"
              }
            }
          ],
          "optional_consent_required": true,
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 51,
            "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis. The procedure for obtaining and documenting informed consent is discussed in Section 9.3."
          }
        },
        "local_lab_requirements": {
          "local_lab_allowed": true,
          "allowed_tests": [
            "All tests for treatment decisions"
          ],
          "certification_requirements": "A qualified (e.g., certification or accreditation) local laboratory may be used.",
          "provenance": {
            "section_number": "4.7",
            "page_number": 47,
            "text_snippet": "A qualified (e.g., certification or accreditation) local laboratory may be used to perform laboratory analyses for treatment decisions as per standard of care."
          }
        },
        "extraction_statistics": {
          "total_panels_discovered": 5,
          "total_tests_discovered": 45,
          "total_schedule_entries": 6,
          "dose_modification_rules": 6,
          "eligibility_criteria_count": 6,
          "critical_values_defined": 0
        },
        "provenance": {
          "section_number": "4.7",
          "page_number": 47,
          "text_snippet": "Clinical Laboratory Tests\nSamples for chemistry, hematology and urinalysis will be collected per Table 2. Specific laboratory assessments are outlined in Table 5."
        }
      },
      "_agentDocumentation": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, normal ranges, eligibility-related lab\n    criteria, and lab-triggered dose modifications. Critical for central lab setup\n    and EDC lab data entry configuration.",
        "scope": "- Laboratory panels (hematology, chemistry, urinalysis, etc.)\n    - Individual tests with units and methods\n    - Eligibility-related lab criteria\n    - Lab-triggered dose modifications\n    - Hepatotoxicity monitoring (Hy's Law)\n    - Central vs local lab requirements\n    - Special lab tests (biomarkers, pharmacogenomics)",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications",
          "Appendix: Laboratory Reference Ranges"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical"
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Lab-Triggered Actions",
            "description": "Lab thresholds triggering dose holds/modifications",
            "dataPath": "lab_triggered_actions[]",
            "downstreamUses": [
              "EDC lab alerts",
              "Medical monitor dashboards",
              "Site guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry with units and ranges",
          "Create eligibility screening lab checklists",
          "Configure lab alert thresholds in EDC",
          "Generate hepatotoxicity monitoring workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json"
      }
    },
    "informedConsent": {
      "moduleId": "informed_consent",
      "instanceType": "InformedConsentElements",
      "data": {
        "id": "M14-359-informed-consent",
        "instanceType": "InformedConsentElements",
        "name": "M14-359 Informed Consent Elements",
        "description": "ICF content elements for M14-359",
        "study_overview": {
          "study_purpose": "To assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in subjects with metastatic or advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) who are positive for the Lung Subtype Panel (LSP) signature. The study will also evaluate survival in the entire study population, progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and quality of life (QoL).",
          "study_duration_for_participant": "Participants will receive treatment for a maximum of 6 cycles (each cycle is 21 days). After treatment, physician visits and tumor assessments will occur every 9 weeks for the first year, and then every 12 weeks until disease progression or death. Survival information will be collected every 2 months until the study ends.",
          "number_of_visits": null,
          "total_time_commitment": null,
          "number_of_participants": "Approximately 595 subjects will be enrolled in the study.",
          "study_locations": "This is a multicenter study with approximately 150 study sites.",
          "provenance": {
            "section_number": "1.2",
            "page_number": 4,
            "text_snippet": "Synopsis\n...\nObjectives: \nThe primary objective of the study is to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival compared to Investigator's choice of standard chemotherapy in Lung Subtype Panel (LSP) positive subjects with metastatic or advanced NSCLC.\n...\nStudy Sites: 150\n...\nNumber of Subjects to be Enrolled: 595"
          }
        },
        "study_procedures": {
          "screening_procedures": [
            {
              "procedure_id": "PROC-001",
              "procedure_name": "Informed Consent",
              "description": "Reviewing the study details and signing the consent form.",
              "frequency": "Once, before any study procedures",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "9.3",
                "page_number": 93,
                "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject, the person who administered the informed consent, and any other signatories according to local requirements."
              }
            },
            {
              "procedure_id": "PROC-002",
              "procedure_name": "Medical and Cancer History Review",
              "description": "Review of your past and current health, including your cancer diagnosis.",
              "frequency": "At screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "Medical and Cancer History X"
              }
            },
            {
              "procedure_id": "PROC-003",
              "procedure_name": "Physical Examination",
              "description": "A full physical exam, including measurement of height and weight.",
              "frequency": "At screening and at the start of each treatment cycle.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "Physical Exam (including weight) Xf Xf X X X X X"
              }
            },
            {
              "procedure_id": "PROC-004",
              "procedure_name": "Vital Signs",
              "description": "Measurement of blood pressure, heart rate, and temperature.",
              "frequency": "At screening and at various points during treatment and follow-up.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "Vital Signs X X X X X X X X"
              }
            },
            {
              "procedure_id": "PROC-005",
              "procedure_name": "12-Lead Electrocardiogram (ECG)",
              "description": "To check the electrical activity of your heart.",
              "frequency": "At screening and at the start of treatment.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "12-Lead ECG X X"
              }
            },
            {
              "procedure_id": "PROC-006",
              "procedure_name": "Performance Status (ECOG)",
              "description": "Assessment of your ability to perform daily activities.",
              "frequency": "At screening and at various points during treatment and follow-up.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "Performance Status (ECOG) Xq Xg X X X X X"
              }
            },
            {
              "procedure_id": "PROC-007",
              "procedure_name": "Blood and Urine Tests",
              "description": "Collection of blood and urine samples to check blood counts, kidney function, and liver function.",
              "frequency": "At screening and at the start of each treatment cycle.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 41,
                "text_snippet": "Chemistry/Hematologyi X X X X X X X\nUrinalysisi X X"
              }
            },
            {
              "procedure_id": "PROC-008",
              "procedure_name": "Pregnancy Test",
              "description": "A serum or urine pregnancy test for female participants of childbearing potential.",
              "frequency": "At screening and prior to dosing in each cycle.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 42,
                "text_snippet": "h. Serum pregnancy test will be done at Screening. Urine pregnancy test will be done prior to dosing at C1D-2 unless the serum pregnancy test was collected within 7 days of C1D-2. Local urine pregnancy testing should also be performed at each subsequent Cycle Day 1 visit."
              }
            },
            {
              "procedure_id": "PROC-009",
              "procedure_name": "Tumor Assessments",
              "description": "CT scan of the chest and abdomen to measure tumor lesions.",
              "frequency": "At screening (baseline).",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 42,
                "text_snippet": "j. Baseline tumor assessments must be conducted within 28 days (inclusive) of randomization."
              }
            },
            {
              "procedure_id": "PROC-010",
              "procedure_name": "MRI of the Brain",
              "description": "An MRI or CT scan of the brain if there are signs or symptoms of central nervous system involvement.",
              "frequency": "At screening, if required.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 42,
                "text_snippet": "l. Baseline MRI of the brain only for subjects with suspected metastases due to neurologic signs or symptoms. A CT scan may be performed if an MRI is contraindicated."
              }
            },
            {
              "procedure_id": "PROC-011",
              "procedure_name": "Archival Tumor Tissue Sample",
              "description": "Consent to provide an existing (archived) tumor tissue or cytology sample for analysis of LSP status.",
              "frequency": "Once",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Main Inclusion",
                "page_number": 7,
                "text_snippet": "7. Subject must consent to provide archived tissue or cytology sample of NSCLC lesion (primary or metastatic) for analysis if available."
              }
            }
          ],
          "treatment_procedures": [
            {
              "procedure_id": "PROC-012",
              "procedure_name": "Study Drug Administration",
              "description": "Participants will be randomized to one of two arms: 1) Oral veliparib twice daily for 7 days, plus intravenous (IV) carboplatin and paclitaxel on Day 1 of each 21-day cycle. 2) Investigator's choice of standard platinum doublet chemotherapy (carboplatin/paclitaxel, cisplatin/pemetrexed, or carboplatin/pemetrexed) on Day 1 of each 21-day cycle.",
              "frequency": "For a maximum of 6 cycles.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 30,
                "text_snippet": "This is a Phase 3, randomized, open-label, multi-center study evaluating the efficacy, safety, and tolerability of veliparib plus carboplatin and paclitaxel versus Investigator's choice of standard chemotherapy... Subjects will be randomized in a 1:1 ratio to a maximum of 6 cycles of carboplatin/paclitaxel plus 120 mg BID of veliparib or a maximum of 6 cycles of Investigator's choice of platinum doublet chemotherapy..."
              }
            },
            {
              "procedure_id": "PROC-013",
              "procedure_name": "Maintenance Therapy",
              "description": "After completion of platinum doublet therapy, suitable subjects are strongly encouraged to receive maintenance pemetrexed.",
              "frequency": "On Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 31,
                "text_snippet": "Suitable subjects in either arm will receive pemetrexed maintenance therapy after completion of platinum doublet chemotherapy regimen. Maintenance pemetrexed will be administered on Day 1 of each 21-day cycle... Subjects will continue to receive maintenance therapy until toxicity requires cessation of therapy, or radiographic progression occurs."
              }
            },
            {
              "procedure_id": "PROC-014",
              "procedure_name": "Quality of Life Questionnaires",
              "description": "Completion of the NFLSI-17 and EQ-5D-5L questionnaires.",
              "frequency": "Prior to dosing on C1D-2, C3D1, C5D1, and at follow-up visits.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 2",
                "page_number": 42,
                "text_snippet": "m. Questionnaires for the assessment of quality of life will be collected prior to dosing on C1D-2, C3D1, C5D1 and at the Final Visit, every 9 weeks until 1 year after beginning therapy (C1D-2) ± 7 days (or beyond 1 year until maintenance therapy is discontinued), then every 12 weeks ± 7 days and at the Final Visit."
              }
            },
            {
              "procedure_id": "PROC-015",
              "procedure_name": "Pharmacokinetic (PK) Blood Sampling",
              "description": "Blood samples will be collected to measure the levels of veliparib in the body.",
              "frequency": "At specified timepoints during the first few cycles.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 4",
                "page_number": 43,
                "text_snippet": "Table 4. Schedule of Pharmacokinetic Assessments"
              }
            },
            {
              "procedure_id": "PROC-016",
              "procedure_name": "Pharmacodynamic (PD) Blood Sampling",
              "description": "Blood samples will be collected to look for biomarkers that may predict response to treatment.",
              "frequency": "At specified timepoints during the study.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 3",
                "page_number": 43,
                "text_snippet": "Table 3. Schedule of Pharmacogenetic and Pharmacodynamic Assessments"
              }
            },
            {
              "procedure_id": "PROC-017",
              "procedure_name": "Follow-up Tumor Assessments",
              "description": "CT scans to monitor tumor response.",
              "frequency": "On Cycle 3 Day 1 and Cycle 5 Day 1.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 31,
                "text_snippet": "Tumor assessments will be performed at baseline, prior to treatment on Cycle 3 Day 1 and Cycle 5 Day 1."
              }
            }
          ],
          "follow_up_procedures": [
            {
              "procedure_id": "PROC-018",
              "procedure_name": "Post-Treatment Follow-up Visits",
              "description": "Physician visits, quality of life assessments, and tumor assessments.",
              "frequency": "Every 9 weeks until 1 year after starting treatment, then every 12 weeks until radiographic progression or death.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 31,
                "text_snippet": "After cessation of therapy, physician visits and quality of life measures will be performed q9 weeks until one year after randomization (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death."
              }
            },
            {
              "procedure_id": "PROC-019",
              "procedure_name": "30-Day Safety Follow-Up",
              "description": "A follow-up visit approximately 30 days after the last dose of study drug to monitor for any ongoing adverse events.",
              "frequency": "Once, if the final visit is within 30 days of the last dose.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 31,
                "text_snippet": "All subjects who have a Final Visit ≤ 30 days after the last dose of study drug will have a Follow-Up Visit approximately 30 days after the last dose of study drug."
              }
            },
            {
              "procedure_id": "PROC-020",
              "procedure_name": "Survival Follow-up",
              "description": "The study site will contact you or check public records to see how you are doing.",
              "frequency": "Every 2 months after clinical assessments stop, until death or the end of the study.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1",
                "page_number": 51,
                "text_snippet": "Subjects no longer undergoing clinical assessments will have survival information reported at 2-month intervals (or as requested by sponsor to support data analysis) beginning at the last clinical assessment and continuing until the endpoint of death, the subject has become lost to follow-up, or AbbVie terminates the study."
              }
            }
          ],
          "optional_procedures": [
            {
              "procedure_id": "PROC-021",
              "procedure_name": "Pharmacogenetic (PG) Blood Sampling",
              "description": "A 4 mL whole blood sample will be collected for DNA isolation to study genetic factors that may contribute to disease or response to treatment. A separate informed consent is required for this procedure.",
              "frequency": "Once, can be collected at any time during the study.",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "5.3.1.2",
                "page_number": 51,
                "text_snippet": "One 4 mL whole blood sample for DNA isolation will be collected on C1D-2 from each subject who consents to provide a sample for pharmacogenetic analysis. The procedure for obtaining and documenting informed consent is discussed in Section 9.3. If the sample is not collected on C1D-2, it may be collected at any time throughout the study."
              }
            }
          ],
          "provenance": {
            "section_number": "Table 2",
            "page_number": 41,
            "text_snippet": "Table 2. Study Activities"
          }
        },
        "risks": {
          "known_risks": [
            {
              "risk_id": "RISK-001",
              "risk_description": "Neutropenia (low white blood cell count)",
              "severity": "severe",
              "frequency": "very_common",
              "management": "May require dose delay, dose reduction, or treatment with growth factors.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "The most common AEs reported in this study were neutropenia and fatigue (reported in > 50% of subjects)..."
              }
            },
            {
              "risk_id": "RISK-002",
              "risk_description": "Fatigue (tiredness)",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "Rest and supportive care.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "The most common AEs reported in this study were neutropenia and fatigue (reported in > 50% of subjects)..."
              }
            },
            {
              "risk_id": "RISK-003",
              "risk_description": "Nausea",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "Anti-nausea medications will be provided.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "...nausea, thrombocytopenia, and peripheral sensory neuropathy (> 40% of subjects)..."
              }
            },
            {
              "risk_id": "RISK-004",
              "risk_description": "Thrombocytopenia (low platelet count)",
              "severity": "severe",
              "frequency": "very_common",
              "management": "May require dose delay or dose reduction.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "...nausea, thrombocytopenia, and peripheral sensory neuropathy (> 40% of subjects)..."
              }
            },
            {
              "risk_id": "RISK-005",
              "risk_description": "Peripheral sensory neuropathy (numbness or tingling in hands and feet)",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "May require dose reduction or discontinuation of paclitaxel.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "...nausea, thrombocytopenia, and peripheral sensory neuropathy (> 40% of subjects)..."
              }
            },
            {
              "risk_id": "RISK-006",
              "risk_description": "Anemia (low red blood cell count)",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "May require blood transfusion or other supportive care.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "...and anemia, constipation, alopecia, diarrhea, decreased appetite, lymphopenia, and myalgia (> 20% of subjects)."
              }
            },
            {
              "risk_id": "RISK-007",
              "risk_description": "Constipation, diarrhea, decreased appetite, hair loss (alopecia), muscle pain (myalgia)",
              "severity": "mild",
              "frequency": "common",
              "management": "Supportive care and medications as needed.",
              "provenance": {
                "section_number": "3.4.3",
                "page_number": 27,
                "text_snippet": "...and anemia, constipation, alopecia, diarrhea, decreased appetite, lymphopenia, and myalgia (> 20% of subjects)."
              }
            },
            {
              "risk_id": "RISK-008",
              "risk_description": "Hypersensitivity (allergic) reactions to chemotherapy",
              "severity": "life-threatening",
              "frequency": "uncommon",
              "management": "Premedication is given to reduce the risk. Immediate medical attention is required if it occurs.",
              "provenance": {
                "section_number": "5.2.3.2",
                "page_number": 38,
                "text_snippet": "Premedication: To reduce the severity of hypersensitivity reactions due to treatment with paclitaxel, manage according to institutional guidelines, the locally approved product label, local practice, or applicable SmPC (i.e., premedication with corticosteroids, diphenhydramine, and H2 antagonists)."
              }
            }
          ],
          "potential_risks": [
            "Seizures",
            "Changes in testes or ovaries (effects on fertility)",
            "Development of secondary malignancies (other cancers)"
          ],
          "reproductive_risks": "The study drugs can cause harm to a developing fetus. Participants must not be pregnant or breastfeeding and must use effective contraception during the study and for a period after the last dose.",
          "unknown_risks_statement": "Other potential risks of veliparib administration, identified in preclinical studies or based on pharmacological mechanism, but not confirmed in clinical studies must also be considered.",
          "risk_mitigation_measures": "Regular monitoring of blood tests, physical exams, and side effects will be performed. Doses of study drugs may be delayed, reduced, or stopped to manage side effects. Supportive care, such as anti-nausea medication and growth factors, may be provided.",
          "provenance": {
            "section_number": "3.7",
            "page_number": 29,
            "text_snippet": "Risks in this study include toxicity from the addition of veliparib to standard therapy. Safety data from a blinded, randomized Phase 2 study of the proposed combination therapy in subjects with advanced NSCLC suggest low rates of additional toxicities and no compromise to the delivery of carboplatin and paclitaxel. Standard clinical practices to manage the toxicity of carboplatin + paclitaxel are well established."
          }
        },
        "benefits": {
          "potential_benefits": [
            "The addition of veliparib to standard chemotherapy may improve clinical outcomes for subjects with advanced NSCLC."
          ],
          "no_benefit_statement": "Participation in this study may not provide any direct benefit to you. Your condition may not improve or may worsen.",
          "societal_benefits": "The information learned from this study may help to improve the treatment of advanced NSCLC for future patients.",
          "provenance": {
            "section_number": "3.7",
            "page_number": 28,
            "text_snippet": "Benefits and Risks\nThis study proposes to establish improved clinical outcomes for subjects with advanced NSCLC through the addition of veliparib to standard therapy with carboplatin and paclitaxel."
          }
        },
        "alternatives": {
          "alternative_treatments": [
            {
              "treatment_name": "Standard Chemotherapy",
              "description": "Receiving standard first-line platinum-based chemotherapy combinations for NSCLC outside of this study.",
              "provenance": {
                "section_number": "5.6.1",
                "page_number": 68,
                "text_snippet": "ESMO and National Comprehensive Cancer Network (NCCN) guidelines recommend first-line cytotoxic chemotherapy treatment for metastatic non-small cell lung cancer with a platinum doublet combination."
              }
            },
            {
              "treatment_name": "Other Clinical Trials",
              "description": "Participating in a different research study.",
              "provenance": {
                "section_number": null,
                "page_number": 93,
                "text_snippet": "The Investigator or his/her representative will explain the nature of the study to the subject, and answer all questions regarding this study."
              }
            }
          ],
          "no_treatment_option": true,
          "standard_of_care_description": "First-line treatment for metastatic non-small cell lung cancer typically includes a platinum-based chemotherapy combination. For non-squamous NSCLC, this may be followed by maintenance therapy with pemetrexed.",
          "provenance": {
            "section_number": "5.6.1",
            "page_number": 68,
            "text_snippet": "ESMO and National Comprehensive Cancer Network (NCCN) guidelines recommend first-line cytotoxic chemotherapy treatment for metastatic non-small cell lung cancer with a platinum doublet combination. Commonly used platinum doublets for advanced NSCLC are cisplatin-gemcitabine, cisplatin-paclitaxel, cisplatin-docetaxel, carboplatin-paclitaxel, and cisplatin-pemetrexed (non-squamous NSCLC only)..."
          }
        },
        "compensation_costs": {
          "participant_compensation": null,
          "payment_schedule": null,
          "travel_reimbursement": "For participants in Japan, transportation expenses will be paid.",
          "participant_costs": [],
          "covered_costs": [
            "The study drug (veliparib) and other study-related chemotherapies will be provided.",
            "Costs for study-related procedures and tests will be covered by the sponsor."
          ],
          "injury_compensation": "For participants in Japan, if a health impairment occurs due to the study, the sponsor will cover treatment costs not covered by health insurance.",
          "provenance": {
            "section_number": "Appendix C",
            "page_number": 106,
            "text_snippet": "1.1 Expenditure of the Clinical Expense\nThe sponsor will pay the expenses related to this study to the investigative site... To lighten the burden imposed on the subject with participation to the study, transportation expenses, etc. will be paid to the subjects...\n1.2 Compensation for Health Impairment and Insurance\n1. If a subject suffers some sort of health impairment due to this study, the investigative site will provide treatment..."
          }
        },
        "confidentiality": {
          "data_protection_statement": "Information collected during the study will be kept confidential as required by law. Your identity will not be revealed in any publications or presentations resulting from this study.",
          "who_has_access": [
            "The study team at the site",
            "The sponsor (AbbVie) and its representatives",
            "Institutional Review Boards (IRBs) or Independent Ethics Committees (IECs)",
            "Regulatory authorities (such as the FDA)"
          ],
          "hipaa_authorization": null,
          "data_retention_period": "Study records will be retained according to local requirements. Optional genetic samples may be stored for up to 20 years.",
          "international_data_transfer": null,
          "data_sharing": "De-identified data may be used in scientific publications or presentations. De-identified genetic data may be analyzed as part of a multi-study assessment.",
          "provenance": {
            "section_number": "12.0",
            "page_number": 96,
            "text_snippet": "Any pharmacogenetic research that may be done using DNA samples from this study will be experimental in nature and the results will not be suitable for clinical decision making or subject management. Hence, neither the Investigator, the subject, nor the subject's physician (if different from the Investigator) will be informed of individual subject pharmacogenetic results..."
          }
        },
        "voluntary_participation": {
          "voluntary_statement": "Participation in this study is voluntary. You may choose not to participate or to withdraw at any time.",
          "withdrawal_rights": "You can withdraw your consent and stop participating in the study at any time for any reason, without penalty or loss of benefits to which you are otherwise entitled.",
          "withdrawal_consequences": null,
          "data_after_withdrawal": "Data collected up to the point of your withdrawal may still be used in the study analysis to maintain the integrity of the research.",
          "provenance": {
            "section_number": "5.4",
            "page_number": 55,
            "text_snippet": "Removal of Subjects from Therapy or Assessment\nEach subject has the right to withdraw from study treatment at any time. In addition, the Investigator may discontinue a subject from the study treatment at any time for any reason..."
          }
        },
        "special_consents": {
          "genetic_testing": {
            "required": false,
            "description": "An optional blood sample may be collected for DNA analysis to research genetic factors related to NSCLC or the response to treatment. A separate consent form is required.",
            "opt_out_allowed": true,
            "future_use": true,
            "results_disclosure": "Individual results from this research will not be shared with you or your doctor.",
            "provenance": {
              "section_number": "9.3",
              "page_number": 93,
              "text_snippet": "Pharmacogenetic analysis will only be performed if the subject has voluntarily signed and dated a separate pharmacogenetic informed consent, approved by an IRB/IEC, after the nature of the testing has been explained and the subject has had an opportunity to ask questions. The separate pharmacogenetic informed consent must be signed before the pharmacogenetic testing is performed."
            }
          },
          "biobanking": {
            "required": false,
            "storage_duration": "Up to 20 years",
            "future_research_use": true,
            "commercialization_statement": null,
            "destruction_option": null,
            "provenance": {
              "section_number": "5.3.1.2",
              "page_number": 51,
              "text_snippet": "AbbVie will store the DNA samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on ABT-888 (or drugs of this class) continues but no longer than 20 years."
            }
          },
          "photography_recording": null,
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 51,
            "text_snippet": "Blood Samples for Pharmacogenetic Analysis (Optional)"
          }
        },
        "contacts": {
          "study_questions_contact": "You can ask questions about the study to the Investigator or their representative.",
          "rights_questions_contact": "For questions about your rights as a research participant, you can contact the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).",
          "emergency_contact": "For safety-related concerns, the protocol lists contact information for the AbbVie Oncology Safety Management Team.",
          "twenty_four_hour_contact": "A phone number is provided to reach a physician through an operator for safety concerns.",
          "provenance": {
            "section_number": "6.6.1",
            "page_number": 79,
            "text_snippet": "For safety related concerns, contact the Oncology Safety Management Team at:\nOncology Group Safety Management\nAbbVie\n1 North Waukegan Road, IL 60064\nOr the physician through the operator at:\nPhone: [REDACTED]"
          }
        },
        "reproductive_requirements": {
          "pregnancy_testing_required": true,
          "contraception_requirements": "Female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use at least one of the specified methods of birth control.",
          "contraception_duration": "During the study and for at least 6 months after the last dose of chemotherapy.",
          "pregnancy_reporting": "If you or your partner becomes pregnant during the study or in the follow-up period, you must notify the study investigator immediately.",
          "breastfeeding_restrictions": "Participants must not be breastfeeding to be eligible for the study, and must not breastfeed during the treatment period.",
          "male_requirements": "Male participants must use a specified method of contraception with their female partners of childbearing potential during the study and for at least 6 months after treatment.",
          "provenance": {
            "section_number": "5.2.1",
            "page_number": 7,
            "text_snippet": "12. Female subjects of childbearing potential... and their male partners should practice at least one of the methods of birth control listed below during study and for at least 6 months after treatment with paclitaxel chemotherapy. Male subjects and their female partners of childbearing potential should practice at least one of the methods of birth control listed below during study and for at least 6 months after treatment with chemotherapy:\n10. Subject is pregnant or lactating."
          }
        },
        "extraction_statistics": {
          "has_risks": true,
          "has_benefits": true,
          "has_alternatives": true,
          "has_compensation": true,
          "has_genetic_consent": true,
          "has_biobanking": true,
          "risk_count": 8,
          "procedure_count": 21
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-359\nA Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator’s Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers"
        }
      },
      "_agentDocumentation": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements including study risks, benefits,\n    alternatives, and special consent requirements. Supports ICF template generation\n    and IRB submission preparation.",
        "scope": "- Key risks (common, serious, unknown)\n    - Potential benefits\n    - Treatment alternatives\n    - Compensation and costs\n    - Confidentiality provisions\n    - Genetic/biobanking consent elements\n    - Optional sub-study consents\n    - Witness requirements",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form",
          "Protocol Synopsis (Risks/Benefits)"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical"
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs in EDC",
          "Prepare IRB submission packages",
          "Configure biobank consent tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json"
      }
    },
    "proSpecifications": {
      "moduleId": "pro_specifications",
      "instanceType": "PROSpecifications",
      "data": {
        "id": "M14-359-pro-specifications",
        "instanceType": "PROSpecifications",
        "name": "M14-359 PRO Specifications",
        "description": "PRO/COA specifications for M14-359",
        "pro_instruments": [
          {
            "instrument_id": "PRO-001",
            "instrument_name": "NCCN-Functional Assessment of Cancer Therapy (FACT) Lung Symptom Index-17",
            "instrument_abbreviation": "NFLSI-17",
            "instrument_type": "disease_specific",
            "instrument_version": null,
            "copyright_holder": null,
            "license_required": null,
            "administration": {
              "mode": "paper",
              "device_type": "paper",
              "completion_location": "clinic",
              "language_versions": null,
              "estimated_completion_time": null,
              "provenance": {
                "section_number": null,
                "page_number": 50,
                "text_snippet": "Subjects in both arms must complete this questionnaire on paper forms, which is then entered into EDC by the Investigator or designee."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Baseline",
                  "visit_reference": "C1D-2",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycle 3 Day 1",
                  "visit_reference": "C3D1",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycle 5 Day 1",
                  "visit_reference": "C5D1",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Post-Treatment Follow-up (Year 1)",
                  "visit_reference": "Every 9 weeks until 1 year after beginning therapy",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "Post-Treatment Follow-up (After Year 1)",
                  "visit_reference": "Every 12 weeks after 1 year of therapy",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-006",
                  "timepoint_name": "Final Visit",
                  "visit_reference": "Final Visit",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                }
              ],
              "recall_period": "past 7 days",
              "completion_window_hours": null,
              "provenance": {
                "section_number": null,
                "page_number": 108,
                "text_snippet": "Please circle or mark one number per line to indicate your response as it applies to the past 7 days."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Disease-related symptoms-physical subscale (DRS-P)",
                  "domain_description": "10-item subscale",
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": null,
                    "page_number": 50,
                    "text_snippet": "The NFLSI-17 is a validated scale which has 17 items broken into the following: a 10-item disease-related symptoms-physical subscale (DRS-P)..."
                  }
                },
                {
                  "domain_name": "Treatment side effect subscale",
                  "domain_description": "3-item subscale",
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": null,
                    "page_number": 50,
                    "text_snippet": "The NFLSI-17 is a validated scale which has 17 items broken into the following: a 10-item disease-related symptoms-physical subscale (DRS-P), and a 3-item treatment side effect subscale..."
                  }
                },
                {
                  "domain_name": "Emotional health and quality of life",
                  "domain_description": "4 additional items",
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": null,
                    "page_number": 50,
                    "text_snippet": "...plus 4 additional items of importance to subjects regarding emotional health and quality of life."
                  }
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": null,
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": null,
                "page_number": 50,
                "text_snippet": "The NFLSI-17 is a validated scale which has 17 items broken into the following: a 10-item disease-related symptoms-physical subscale (DRS-P), and a 3-item treatment side effect subscale, plus 4 additional items of importance to subjects regarding emotional health and quality of life."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 50,
              "text_snippet": "To assess the subject's health-related quality of life and symptoms, two questionnaires will be administered: the NCCN-Functional Assessment of Cancer Therapy (FACT) Lung Symptom Index-17 (NFLSI-17) questionnaire and the European Quality of Life-5 Dimensions (EQ-5D-5L)."
            }
          },
          {
            "instrument_id": "PRO-002",
            "instrument_name": "European Quality of Life-5 Dimensions 5 Level",
            "instrument_abbreviation": "EQ-5D-5L",
            "instrument_type": "utility",
            "instrument_version": null,
            "copyright_holder": "EuroQoL Group",
            "license_required": true,
            "administration": {
              "mode": "paper",
              "device_type": "paper",
              "completion_location": "clinic",
              "language_versions": [
                "English version for the US"
              ],
              "estimated_completion_time": null,
              "provenance": {
                "section_number": null,
                "page_number": 50,
                "text_snippet": "Subjects in both arms must complete this questionnaire on paper forms, which is then entered into EDC by the Investigator or designee."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Baseline",
                  "visit_reference": "C1D-2",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycle 3 Day 1",
                  "visit_reference": "C3D1",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycle 5 Day 1",
                  "visit_reference": "C5D1",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Post-Treatment Follow-up (Year 1)",
                  "visit_reference": "Every 9 weeks until 1 year after beginning therapy",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "Post-Treatment Follow-up (After Year 1)",
                  "visit_reference": "Every 12 weeks after 1 year of therapy",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-006",
                  "timepoint_name": "Final Visit",
                  "visit_reference": "Final Visit",
                  "window_before_days": null,
                  "window_after_days": null,
                  "is_required": true
                }
              ],
              "recall_period": "TODAY",
              "completion_window_hours": null,
              "provenance": {
                "section_number": null,
                "page_number": 110,
                "text_snippet": "Under each heading, please check the ONE box that best describes your health TODAY"
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Mobility",
                  "domain_description": null,
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": "E",
                    "page_number": 110,
                    "text_snippet": "Mobility"
                  }
                },
                {
                  "domain_name": "Self-Care",
                  "domain_description": null,
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": "E",
                    "page_number": 110,
                    "text_snippet": "Self-Care"
                  }
                },
                {
                  "domain_name": "Usual Activities",
                  "domain_description": null,
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": "E",
                    "page_number": 110,
                    "text_snippet": "Usual Activities (e.g., work, study, housework, family or leisure activities)"
                  }
                },
                {
                  "domain_name": "Pain/Discomfort",
                  "domain_description": null,
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": "E",
                    "page_number": 110,
                    "text_snippet": "Pain/Discomfort"
                  }
                },
                {
                  "domain_name": "Anxiety/Depression",
                  "domain_description": null,
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": null,
                  "provenance": {
                    "section_number": "E",
                    "page_number": 110,
                    "text_snippet": "Anxiety/Depression"
                  }
                },
                {
                  "domain_name": "Visual Analog Scale (VAS)",
                  "domain_description": "Overall health assessment",
                  "items_included": null,
                  "score_range": "0-100",
                  "higher_is_better": true,
                  "provenance": {
                    "section_number": null,
                    "page_number": 51,
                    "text_snippet": "The EQ-5D-5L also contains a visual analog scale (VAS) to assess the subject's overall health."
                  }
                }
              ],
              "total_score_available": true,
              "scoring_algorithm": "Conversion of the 5 dimensions to a utility score.",
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": null,
                "page_number": 51,
                "text_snippet": "The EuroQol 5 Dimensions 5 Level (EQ-5D-5L) is a generic preference instrument that has been validated in numerous populations. The EQ-5D-5L is composed of 5 questions that can be converted into a utility score for use in an economic evaluation to adjust life- years gained by the subject's health-related quality of life."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 50,
              "text_snippet": "To assess the subject's health-related quality of life and symptoms, two questionnaires will be administered: the NCCN-Functional Assessment of Cancer Therapy (FACT) Lung Symptom Index-17 (NFLSI-17) questionnaire and the European Quality of Life-5 Dimensions (EQ-5D-5L)."
            }
          }
        ],
        "epro_system": {},
        "clinro_instruments": [
          {
            "instrument_id": "CLINRO-001",
            "instrument_name": "ECOG Performance Status",
            "assessor": "investigator",
            "training_certification_required": null,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Screening",
              "C1D-2",
              "Day 1 of Cycles 2-6",
              "Final Visit",
              "Maintenance Therapy Visits (every 9 weeks for 1 year, then every 12 weeks)"
            ],
            "provenance": {
              "section_number": null,
              "page_number": 41,
              "text_snippet": "Performance Status (ECOG)"
            }
          },
          {
            "instrument_id": "CLINRO-002",
            "instrument_name": "Response Evaluation Criteria In Solid Tumors",
            "instrument_version": "1.1",
            "assessor": "investigator",
            "training_certification_required": null,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Baseline (within 28 days of randomization)",
              "Cycle 3 Day 1",
              "Cycle 5 Day 1",
              "Post-treatment every 9 weeks for 1 year",
              "Post-treatment every 12 weeks thereafter until progression or death",
              "Final Visit"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 6,
              "text_snippet": "Radiographic information will be collected to determine response according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1."
            }
          },
          {
            "instrument_id": "CLINRO-003",
            "instrument_name": "Common Terminology Criteria for Adverse Events",
            "instrument_version": "4.0",
            "assessor": "investigator",
            "training_certification_required": null,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Each study visit"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 6,
              "text_snippet": "Toxicities will be graded at each study visit according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."
            }
          }
        ],
        "obsro_instruments": [],
        "perfo_instruments": [],
        "daily_diary": null,
        "analysis_specifications": {
          "primary_pro_endpoint": null,
          "secondary_pro_endpoints": [],
          "exploratory_pro_endpoints": [
            "Comparison of Duration of Overall Response (DOR), ECOG performance status, and Quality of Life (QoL) between treatment arms in LSP+ subjects and the entire study population."
          ],
          "analysis_population": "LSP+ subgroup and entire study population",
          "statistical_methods": [
            "For NFLSI-17: Multivariate repeated measures models to compare changes from baseline.",
            "For EQ-5D-5L: Descriptive statistics for individual items, utility score, and VAS score, including mean change from baseline.",
            "For ECOG Performance Status: Analysis of covariance (ANCOVA) to compare changes from baseline."
          ],
          "sensitivity_analyses": [],
          "responder_analysis_planned": false,
          "time_to_event_analysis_planned": false,
          "provenance": {
            "section_number": "8.1.2.3",
            "page_number": 84,
            "text_snippet": "In addition to the primary and secondary efficacy analyses, the tertiary objectives are to compare DOR, ECOG performance status and Quality of Life (QoL) via the NCCN-Functional Assessment of Cancer Therapy (FACT) Lung Symptom Index-17 (NFLSI-17) questionnaire and the European Quality of Life-5 Dimensions (EQ-5D-5L) in LSP+ subjects and in the entire study population between the two treatment groups."
          }
        },
        "extraction_statistics": {
          "pro_instrument_count": 2,
          "clinro_count": 3,
          "obsro_count": 0,
          "perfo_count": 0,
          "has_epro": false,
          "has_daily_diary": false,
          "total_assessment_timepoints": 10
        },
        "provenance": {
          "section_number": "1.2",
          "page_number": 9,
          "text_snippet": "Criteria for Evaluation"
        }
      },
      "_agentDocumentation": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome (PRO) and clinical outcome assessment (COA)\n    specifications including instruments, ePRO system configuration, and compliance\n    requirements. Essential for ePRO/eCOA vendor configuration.",
        "scope": "- PRO instruments (questionnaires, scales)\n    - ePRO/eCOA system configuration\n    - ClinRO instruments (clinician-rated)\n    - ObsRO instruments (observer-rated)\n    - PerfO instruments (performance outcomes)\n    - Daily diaries\n    - Administration timing and windows\n    - Compliance thresholds\n    - Scoring and MCID definitions",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments",
          "Appendix: PRO Administration Guide"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "ePRO System Configuration",
            "description": "Vendor, platform, alerts, reminders, compliance thresholds",
            "dataPath": "epro_system",
            "downstreamUses": [
              "ePRO vendor requirements",
              "Device configuration",
              "Integration specs"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "Assessment Schedule",
            "description": "Timepoints, windows, recall periods for each instrument",
            "dataPath": "pro_instruments[].schedule",
            "downstreamUses": [
              "ePRO scheduling",
              "Compliance alerts",
              "Site calendars"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts",
          "Generate site PRO administration training",
          "Create PRO endpoint analysis specifications",
          "Configure reminder schedules"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json"
      }
    },
    "dataManagement": {
      "moduleId": "data_management",
      "instanceType": "DataManagement",
      "data": {
        "id": "M14-359-data-management",
        "instanceType": "DataManagementPlan",
        "name": "M14-359 Data Management Plan",
        "edc_specifications": {
          "instanceType": "EDCSpecifications",
          "vendor_name": "Medidata Solutions Incorporated",
          "system_capabilities": [
            "randomization",
            "audit_trail",
            "electronic_signature",
            "IWRS_integration",
            "central_lab_integration"
          ],
          "integration_systems": [
            {
              "id": "integration-001",
              "system_type": "IWRS",
              "vendor_name": null,
              "transfer_frequency": null,
              "transfer_method": null,
              "provenance": {
                "section_number": "5.5.4",
                "page_number": 65,
                "text_snippet": "All subjects in the study will be randomized using an IRT system. Before the study is initiated, directions for the IRT will be provided to each site. The site will contact the IRT system to obtain a Screening (subject) number once the subject has signed the informed consent and a study-specific procedure has been performed (i.e., central laboratory samples drawn)."
              }
            },
            {
              "id": "integration-002",
              "system_type": "central_lab",
              "vendor_name": null,
              "transfer_frequency": null,
              "transfer_method": null,
              "provenance": {
                "section_number": null,
                "page_number": 47,
                "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis. The central laboratory will provide instructions regarding the collection, processing and shipping of samples. All laboratory samples will be shipped to the central laboratory."
              }
            }
          ],
          "language_requirements": [
            "English"
          ],
          "crf_modules": [
            {
              "id": "crf-001",
              "module_name": "Informed Consent",
              "forms": [
                "Informed Consent"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Informed Consent"
              }
            },
            {
              "id": "crf-002",
              "module_name": "Medical and Cancer History",
              "forms": [
                "Medical History",
                "Cancer History"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Medical and Cancer History"
              }
            },
            {
              "id": "crf-003",
              "module_name": "Physical Exam",
              "forms": [
                "Physical Exam"
              ],
              "visit_schedule": [
                "Screening",
                "Cycle 1 Day -2"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Physical Exam (including weight)"
              }
            },
            {
              "id": "crf-004",
              "module_name": "Vital Signs",
              "forms": [
                "Vital Signs"
              ],
              "visit_schedule": [
                "Screening",
                "Cycle 1 Day 1",
                "Cycle 1 Day 15",
                "Cycle 2-6 Day 1"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Vital Signs"
              }
            },
            {
              "id": "crf-005",
              "module_name": "12-Lead ECG",
              "forms": [
                "ECG"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "12-Lead ECG"
              }
            },
            {
              "id": "crf-006",
              "module_name": "Performance Status (ECOG)",
              "forms": [
                "ECOG"
              ],
              "visit_schedule": [
                "Screening",
                "Cycle 1 Day -2"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Performance Status (ECOG)"
              }
            },
            {
              "id": "crf-007",
              "module_name": "Pregnancy Status",
              "forms": [
                "Pregnancy Test"
              ],
              "visit_schedule": [
                "Screening",
                "Cycle 1 Day -2"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Documentation of Non-Childbearing Status or Pregnancy Test"
              }
            },
            {
              "id": "crf-008",
              "module_name": "Laboratory Assessments",
              "forms": [
                "Chemistry",
                "Hematology",
                "Urinalysis",
                "Coagulation"
              ],
              "visit_schedule": [
                "Screening",
                "Cycle 1 Day -2"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Chemistry/Hematology, Urinalysis, aPTT, INR"
              }
            },
            {
              "id": "crf-009",
              "module_name": "Tumor Assessments",
              "forms": [
                "Tumor Assessment",
                "MRI of the Brain"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Tumor Assessments, MRI of the Brain"
              }
            },
            {
              "id": "crf-010",
              "module_name": "Quality of Life Questionnaires",
              "forms": [
                "NFLSI-17",
                "EQ-5D-5L"
              ],
              "visit_schedule": [
                "Cycle 1 Day -2"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "QoL Questionnaires"
              }
            },
            {
              "id": "crf-011",
              "module_name": "Adverse Event and Concomitant Medication",
              "forms": [
                "Adverse Event",
                "Concomitant Medication"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Adverse Event and Concomitant Medication Assessment"
              }
            },
            {
              "id": "crf-012",
              "module_name": "Survival",
              "forms": [
                "Survival Follow-up"
              ],
              "visit_schedule": [
                "Survival Period"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 2.",
                "page_number": 41,
                "text_snippet": "Survival"
              }
            }
          ],
          "provenance": {
            "section_number": "10.2",
            "page_number": 95,
            "text_snippet": "Case report forms (CRF) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable. The CRF data for this study are being collected with an electronic data capture (EDC) system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
          }
        },
        "data_standards": {
          "instanceType": "DataStandards",
          "sdtm_version": null,
          "sdtm_ig_version": null,
          "adam_version": null,
          "controlled_terminology": {
            "cdisc_ct_version": null,
            "meddra_version": null,
            "whodrug_version": null,
            "snomed_version": null
          },
          "define_xml_required": false,
          "define_xml_version": null,
          "adrg_required": false,
          "sdrg_required": false,
          "provenance": {
            "section_number": "8.1.8.2",
            "page_number": 89,
            "text_snippet": "Treatment-emergent adverse events will be summarized by preferred terms within a System and Organ Class according to the most current MedDRA dictionary."
          }
        },
        "data_quality": {
          "instanceType": "DataQuality",
          "edit_checks": {
            "standard_checks": [
              "date_logic"
            ],
            "protocol_specific_checks": [],
            "auto_query_enabled": null
          },
          "sdv_strategy": {
            "approach": null,
            "sdv_percentage": null,
            "critical_data_points": [],
            "sdv_timing": null
          },
          "query_management": {
            "resolution_target_days": null,
            "escalation_threshold_days": null,
            "auto_query_triggers": []
          },
          "data_review": {
            "medical_review_frequency": null,
            "statistical_review_frequency": null,
            "data_review_committee": null
          },
          "provenance": {
            "section_number": "11.0",
            "page_number": 96,
            "text_snippet": "Computer logic and manual checks will be created to identify items such as inconsistent study dates. Any necessary corrections will be made to the eCRF."
          }
        },
        "database_management": {
          "instanceType": "DatabaseManagement",
          "database_design": {
            "external_data_sources": [
              "central_lab",
              "IWRS"
            ],
            "calculated_fields": [],
            "derived_variables": []
          },
          "interim_locks": [],
          "final_database_lock": {
            "trigger_event": "When LSP status is determined by the Qiagen assay for all submitted tissue samples, there will be a final review of the eCRF data.",
            "timeline_days_from_lplv": null,
            "prerequisites": [
              "All data collection completed",
              "Data reviewed for completeness",
              "All data management QA and QC procedures performed"
            ],
            "signoff_required": [],
            "provenance": {
              "section_number": "8.1.3",
              "page_number": 85,
              "text_snippet": "When LSP status is determined by the Qiagen assay for all submitted tissue samples, there will be a final review of the eCRF data. When the data collection is completed and reviewed for completeness and all data management quality assurance (QA) and quality control (QC) procedures are performed, the clinical database data will be extracted for documentation and statistical analyses of the efficacy and safety data."
            }
          },
          "provenance": {
            "section_number": "10.2",
            "page_number": 95,
            "text_snippet": "Case report forms (CRF) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable. The CRF data for this study are being collected with an electronic data capture (EDC) system..."
          }
        },
        "data_transfers": {
          "instanceType": "DataTransfers",
          "central_lab": {
            "vendor_name": null,
            "transfer_frequency": null,
            "transfer_method": null,
            "data_reconciliation": true
          },
          "imaging": null,
          "epro": null,
          "external_adjudication": null,
          "dsmb_exports": null,
          "provenance": {
            "section_number": null,
            "page_number": 47,
            "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis. The central laboratory will provide instructions regarding the collection, processing and shipping of samples. All laboratory samples will be shipped to the central laboratory."
          }
        },
        "data_archival": {
          "instanceType": "DataArchival",
          "retention_period_years": 20,
          "retention_basis": "Local requirements",
          "archival_format": [
            "electronic"
          ],
          "archival_location": "sponsor",
          "destruction_policy": null,
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 51,
            "text_snippet": "AbbVie will store the DNA samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on ABT-888 (or drugs of this class) continues but no longer than 20 years."
          }
        },
        "extraction_statistics": {
          "has_edc_specifications": true,
          "has_data_standards": true,
          "has_sdv_strategy": true,
          "has_database_lock_plan": true,
          "integration_count": 2,
          "crf_module_count": 12
        },
        "provenance": {
          "section_number": "10.2",
          "page_number": 95,
          "text_snippet": "Case Report Forms\nCase report forms (CRF) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable. The CRF data for this study are being collected with an electronic data capture (EDC) system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
        }
      },
      "_agentDocumentation": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications including EDC configuration, CDISC standards,\n    data quality requirements, and database lock procedures. Guides EDC setup and\n    data management planning.",
        "scope": "- EDC system requirements\n    - CDISC standards (CDASH, SDTM, ADaM versions)\n    - Data entry timelines\n    - Query management\n    - Database lock procedures\n    - Source data verification requirements\n    - Data transfer specifications",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "EDC Requirements",
            "description": "EDC system specifications, vendor requirements",
            "dataPath": "edc_system",
            "downstreamUses": [
              "EDC vendor selection",
              "System configuration",
              "User setup"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          },
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          },
          {
            "name": "Data Entry Timelines",
            "description": "Expected data entry windows after visit",
            "dataPath": "data_entry_timelines",
            "downstreamUses": [
              "KRI configuration",
              "Site metrics",
              "Query aging rules"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines and alerts",
          "Set up CDISC standards compliance checks",
          "Generate data management plan templates",
          "Configure query management workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json"
      }
    },
    "siteOperationsLogistics": {
      "moduleId": "site_operations_logistics",
      "instanceType": "SiteOperationsLogistics",
      "data": {
        "id": "NCT02264990-site-operations-logistics",
        "instanceType": "SiteOperationsLogistics",
        "name": "NCT02264990 Site Operations & Logistics",
        "site_selection": {
          "instanceType": "SiteSelectionCriteria",
          "required_criteria": [
            {
              "id": "REQ-001",
              "criterion": "Access to Patient Population",
              "description": "Site must have access to adult subjects with metastatic or advanced non-squamous NSCLC who are current or former smokers.",
              "assessment_method": "Feasibility assessment",
              "minimum_requirement": "Sufficient patient volume to meet enrollment goals.",
              "provenance": {
                "section_number": "5.2",
                "page_number": 33,
                "text_snippet": "The study population will consist of adult subjects who are current or former smokers with cytologically or histologically confirmed locally advanced or metastatic non-squamous NSCLC that is not amenable to surgical resection or radiation with curative intent, and who have not received prior cytotoxic chemotherapy or chemoradiotherapy for their NSCLC."
              }
            },
            {
              "id": "REQ-002",
              "criterion": "Clinical Expertise",
              "description": "Site personnel must be experienced in the preparation and handling of parenteral cancer chemotherapeutic agents.",
              "assessment_method": "Review of site and personnel experience.",
              "minimum_requirement": "Demonstrated experience in oncology trials and chemotherapy administration.",
              "provenance": {
                "section_number": "5.5.3",
                "page_number": 64,
                "text_snippet": "All chemotherapy agents administered as part of this protocol should be prepared for administration by clinicians experienced in the preparation and handling of parenteral cancer chemotherapeutic agents."
              }
            },
            {
              "id": "REQ-003",
              "criterion": "Facility and Equipment",
              "description": "Site must have the necessary facilities and equipment to conduct the trial, including for IV infusions, imaging, and sample handling.",
              "assessment_method": "Site qualification visit/questionnaire.",
              "minimum_requirement": "Access to CT scanner (or MRI), ECG, and certified laboratory services.",
              "provenance": {
                "section_number": "4.8",
                "page_number": 48,
                "text_snippet": "A CT scan of the full chest and abdomen (with image of liver and adrenal glands) will be used in the evaluation of tumor responses, as per Table 2... Magnetic resonance imaging (MRI) can be conducted in cases where local laws/requirements mandate, but should have Sponsor approval prior to performing the MRI."
              }
            }
          ],
          "preferred_criteria": [],
          "exclusionary_criteria": [],
          "geographic_requirements": {
            "countries": [
              "USA",
              "JPN"
            ],
            "regions": [
              "North America",
              "Asia-Pacific",
              "Europe"
            ],
            "site_count_target": 150,
            "language_requirements": [],
            "provenance": {
              "section_number": "1.2",
              "page_number": 4,
              "text_snippet": "Study Sites: 150"
            }
          },
          "facility_requirements": {
            "equipment_required": [
              "CT scanner",
              "MRI scanner (if CT contraindicated)",
              "12-lead ECG machine",
              "IV infusion equipment"
            ],
            "laboratory_capabilities": [
              "On-site phlebotomy",
              "Sample processing (centrifugation, freezing)",
              "Ability to ship samples to central lab"
            ],
            "pharmacy_capabilities": "Secure, temperature-controlled storage for investigational products.",
            "storage_capabilities": "Ambient temperature storage (15-30°C), refrigerated and frozen storage for samples.",
            "provenance": {
              "section_number": "5.5.2.3",
              "page_number": 63,
              "text_snippet": "All clinical supplies must be stored in a secure place until they are dispensed for subject use, are destroyed at the site or are returned to AbbVie."
            }
          },
          "experience_requirements": {
            "therapeutic_area_experience": "Experience in conducting clinical trials for Non-Small Cell Lung Cancer (NSCLC).",
            "phase_experience": "Experience with Phase 3 oncology trials.",
            "gcp_compliance_record": "Must be able to conduct the study in accordance with ICH GCP and local regulations.",
            "provenance": {
              "section_number": "9.2",
              "page_number": 93,
              "text_snippet": "The study will be conducted in accordance with the protocol, International Conference on Harmonization (ICH) guidelines, applicable regulations and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki."
            }
          },
          "provenance": {
            "section_number": "5.2",
            "page_number": 33,
            "text_snippet": "Selection of Study Population"
          }
        },
        "regulatory_ethics": {
          "instanceType": "RegulatoryEthics",
          "regulatory_authorities": [
            {
              "id": "AUTH-001",
              "authority_name": "European Medicines Agency",
              "country_region": "European Union",
              "submission_type": "Clinical Trial Application",
              "submission_number": "EudraCT 2014-002565-30",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "EudraCT 2014-002565-30"
              }
            },
            {
              "id": "AUTH-002",
              "authority_name": "U.S. Food and Drug Administration",
              "country_region": "USA",
              "submission_type": "Investigational New Drug (IND) Application",
              "submission_number": "NCT02264990",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "NCT02264990"
              }
            }
          ],
          "ethics_committees": [
            {
              "id": "EC-001",
              "committee_type": "IEC/IRB",
              "centralized_or_local": "local",
              "approval_requirements": "Approval of the protocol, any amendments, the Investigator's Brochure, the informed consent, and all other forms of subject information is required prior to implementation or use.",
              "approval_timeline": null,
              "continuing_review_frequency": "As required by local regulations.",
              "provenance": {
                "section_number": "9.1",
                "page_number": 92,
                "text_snippet": "Good Clinical Practice (GCP) requires that the clinical protocol, any protocol amendments, the Investigator's Brochure, the informed consent and all other forms of subject information related to the study (e.g., advertisements used to recruit subjects) and any other necessary documents be reviewed by an IEC/IRB."
              }
            }
          ],
          "informed_consent": {
            "consent_type": "written",
            "languages_required": [],
            "reconsent_triggers": [
              "protocol_amendment",
              "important_new_information"
            ],
            "assent_required": false,
            "electronic_consent_allowed": false,
            "provenance": {
              "section_number": "9.3",
              "page_number": 93,
              "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject, the person who administered the informed consent, and any other signatories according to local requirements."
            }
          },
          "data_privacy": {
            "applicable_regulations": [],
            "data_transfer_requirements": null,
            "anonymization_requirements": "Confidentiality of all information received or developed in connection with the protocol must be maintained.",
            "provenance": {
              "section_number": "14.0",
              "page_number": 98,
              "text_snippet": "4. I agree to maintain the confidentiality of all information received or developed in connection with this protocol."
            }
          },
          "provenance": {
            "section_number": "9.0",
            "page_number": 92,
            "text_snippet": "Ethics"
          }
        },
        "site_personnel": {
          "instanceType": "SitePersonnel",
          "principal_investigator": {
            "qualifications_required": [
              "Qualified physician"
            ],
            "responsibilities": [
              "Conducting the study in accordance with the protocol and applicable regulations",
              "Personally conducting or supervising the investigation",
              "Informing subjects and obtaining informed consent",
              "Reporting adverse experiences",
              "Maintaining adequate and accurate records",
              "Ensuring IEC/IRB review and approval"
            ],
            "delegation_restrictions": [],
            "time_commitment": null,
            "provenance": {
              "section_number": "Appendix A",
              "page_number": 103,
              "text_snippet": "Responsibilities of the Clinical Investigator\nClinical research studies sponsored by AbbVie are subject to the Good Clinical Practices (GCP) and local regulations and guidelines governing the study at the site location. In signing the Investigator Agreement in Section 14.0 of this protocol, the Investigator is agreeing to the following:\n1. Conducting the study in accordance with the relevant, current protocol... \n2. Personally conducting or supervising the described investigation(s).\n3."
            }
          },
          "sub_investigators": {
            "provenance": {
              "section_number": "Appendix A",
              "page_number": 103,
              "text_snippet": "Responsibilities of the Clinical Investigator"
            }
          },
          "coordinators": {
            "provenance": {
              "section_number": "Appendix A",
              "page_number": 103,
              "text_snippet": "Responsibilities of the Clinical Investigator"
            }
          },
          "provenance": {
            "section_number": "Appendix A",
            "page_number": 103,
            "text_snippet": "Responsibilities of the Clinical Investigator"
          }
        },
        "training_requirements": {
          "instanceType": "TrainingRequirements",
          "protocol_training": {
            "required_for": [
              "PI",
              "All site staff involved in the study"
            ],
            "format": "in_person",
            "duration": null,
            "assessment_required": false,
            "completion_deadline": "before_study_start",
            "provenance": {
              "section_number": "6.2",
              "page_number": 62,
              "text_snippet": "Instructions for the handling of study supplies to the study site are available in the veliparib IB, study Dosing Cards and from participants at the Site Initiation Visit."
            }
          },
          "gcp_training": {
            "required": true,
            "frequency": null,
            "certification_required": false,
            "accepted_providers": [],
            "provenance": {
              "section_number": "9.2",
              "page_number": 93,
              "text_snippet": "The study will be conducted in accordance with the protocol, International Conference on Harmonization (ICH) guidelines, applicable regulations and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki."
            }
          },
          "specialized_training": [
            {
              "id": "TRAIN-001",
              "training_name": "Parenteral Chemotherapy Preparation and Handling",
              "required_for": [
                "Clinicians administering chemotherapy"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "5.5.3",
                "page_number": 64,
                "text_snippet": "All chemotherapy agents administered as part of this protocol should be prepared for administration by clinicians experienced in the preparation and handling of parenteral cancer chemotherapeutic agents."
              }
            }
          ],
          "training_documentation": {},
          "provenance": {
            "section_number": "5.5.3",
            "page_number": 64,
            "text_snippet": "All chemotherapy agents administered as part of this protocol should be prepared for administration by clinicians experienced in the preparation and handling of parenteral cancer chemotherapeutic agents."
          }
        },
        "monitoring_plan": {
          "instanceType": "MonitoringPlan",
          "monitoring_approach": "traditional",
          "site_initiation_visit": {
            "required": true,
            "timing": "before_first_patient",
            "format": "on_site",
            "activities": [
              "Instructions for handling of study supplies"
            ],
            "provenance": {
              "section_number": "6.2",
              "page_number": 62,
              "text_snippet": "Instructions for the handling of study supplies to the study site are available in the veliparib IB, study Dosing Cards and from participants at the Site Initiation Visit."
            }
          },
          "routine_monitoring": {
            "frequency": null,
            "visit_type": "on_site",
            "sdv_percentage": 100,
            "sdv_scope": [
              "eCRF entries will be verified against source documents"
            ],
            "remote_monitoring_activities": [],
            "provenance": {
              "section_number": "10.2",
              "page_number": 95,
              "text_snippet": "AbbVie (or their representatives) will also be allowed access to all source documents pertinent to the study in order to verify eCRF entries."
            }
          },
          "triggered_monitoring": {
            "provenance": {
              "section_number": "9.2",
              "page_number": 93,
              "text_snippet": "On-site monitoring will be performed before, during and after the trial to assure appropriate conduct of the trial in accordance with ICH GCP."
            }
          },
          "close_out_visit": {
            "required": true,
            "timing": "after_study_completion_or_termination",
            "format": "on_site",
            "activities": [
              "Overall accountability of the study drug"
            ],
            "provenance": {
              "section_number": "6.7",
              "page_number": 67,
              "text_snippet": "An overall accountability of the study drug supplied by AbbVie will be performed and verified by the site monitor throughout the study and at the study site closeout visit."
            }
          },
          "provenance": {
            "section_number": "9.2",
            "page_number": 93,
            "text_snippet": "On-site monitoring will be performed before, during and after the trial to assure appropriate conduct of the trial in accordance with ICH GCP."
          }
        },
        "site_activation_timeline": {
          "instanceType": "SiteActivationTimeline",
          "site_selection_phase": null,
          "feasibility_assessment": null,
          "contract_negotiation": null,
          "regulatory_submission": null,
          "ethics_approval": null,
          "site_training": null,
          "site_initiation_visit": null,
          "first_patient_ready": null,
          "critical_path_items": [
            "IEC/IRB approval",
            "Drug shipment authorization"
          ],
          "provenance": {
            "section_number": "9.1",
            "page_number": 92,
            "text_snippet": "IEC/IRB approval of the protocol, informed consent and subject information and/or advertising, as relevant, will be obtained prior to the authorization of drug shipment to a study site."
          }
        },
        "drug_supply_logistics": {
          "instanceType": "DrugSupplyLogistics",
          "packaging_labeling": {
            "blinding_requirements": "open_label",
            "label_languages": [
              "English",
              "Local language"
            ],
            "temperature_indicators": false,
            "tamper_evident": false,
            "kit_design": null,
            "provenance": {
              "section_number": "5.5.2.2",
              "page_number": 62,
              "text_snippet": "Each bottle label will include all information as required by local regulations and must remain affixed to the bottle."
            }
          },
          "storage_distribution": {
            "storage_temperature": "15-25°C",
            "distribution_model": "central",
            "cold_chain_required": false,
            "shelf_life_months": null,
            "shipping_conditions": "Ambient",
            "provenance": {
              "section_number": "5.5.2.3",
              "page_number": 63,
              "text_snippet": "Study Drug Storage Conditions\nStudy Drug Country Storage Conditions\nVeliparib All countries, except Australia/New Zealand/Japan Store at 15° to 25°C (59° to 77°F)"
            }
          },
          "inventory_management": {
            "iwrs_rtsm_system": "IRT system",
            "kit_design": "pooled",
            "resupply_triggers": "site_request",
            "resupply_threshold_days": null,
            "expiry_management": null,
            "provenance": {
              "section_number": "4.9",
              "page_number": 49,
              "text_snippet": "An Interactive Response Technology system (IRT) will be utilized to register subjects."
            }
          },
          "dispensing_schedule": [
            {
              "id": "DISP-001",
              "visit_name": "C1D-2",
              "cycle_day": "Day -2",
              "kits_dispensed": [
                "Veliparib"
              ],
              "quantity_dispensed": "Sufficient quantities for Cycle 1 Days -2 and -1.",
              "titration_rules": null,
              "provenance": {
                "section_number": "4.9",
                "page_number": 49,
                "text_snippet": "Randomized subjects will receive sufficient quantities of veliparib for Cycle 1 Days –2 and –1."
              }
            },
            {
              "id": "DISP-002",
              "visit_name": "C1D1",
              "cycle_day": "Day 1",
              "kits_dispensed": [
                "Veliparib"
              ],
              "quantity_dispensed": "Sufficient for Days 1-5 of current cycle and Days -2, -1 of the following cycle.",
              "titration_rules": null,
              "provenance": {
                "section_number": "4.9",
                "page_number": 49,
                "text_snippet": "Beginning with C1D1, subjects will receive veliparib for Days 1 – 5 of the current cycle and a separate bottle for Days –2, –1 of the following cycle."
              }
            }
          ],
          "drug_accountability": {
            "accountability_frequency": "Each study visit",
            "accountability_method": "kit_count",
            "documentation_requirements": "Site will record dose of all study drugs in source documents and eCRF. Subjects return all veliparib bottles.",
            "discrepancy_handling": null,
            "provenance": {
              "section_number": "5.5.7",
              "page_number": 66,
              "text_snippet": "The site will record the dose of carboplatin, paclitaxel, cisplatin and pemetrexed given to each subject in the source documents and on the eCRF... Subjects will be instructed to return all veliparib bottles (empty, partially filled or full) to the study site personnel prior to each cycle, their first post-treatment visit and/or at the Final Visit."
            }
          },
          "drug_return_destruction": {
            "return_required": true,
            "return_timing": "Upon completion or termination of the study.",
            "destruction_method": "return_to_sponsor",
            "destruction_documentation": null,
            "environmental_requirements": null,
            "provenance": {
              "section_number": "6.7",
              "page_number": 67,
              "text_snippet": "Upon completion or termination of the study, all original bottles/cartons containing unused veliparib and if applicable carboplatin, paclitaxel, cisplatin and pemetrexed (empty containers will be defaced and discarded on site) will be returned to AbbVie according to AbbVie's instructions..."
            }
          },
          "dosing_error_handling": {
            "overdose_procedures": null,
            "underdose_procedures": null,
            "missed_dose_procedures": "If a subject misses a scheduled dose of veliparib and less than 6 hours have passed, the dose should be immediately taken. If more than 6 hours have passed, the subject should not take the missed dose but wait for the next regularly scheduled dose.",
            "dose_timing_windows": null,
            "provenance": {
              "section_number": "5.5.1.1",
              "page_number": 59,
              "text_snippet": "It is recommended that if a subject misses a scheduled dose of veliparib and less than 6 hours have passed since the scheduled dosing time, the dose should be immediately taken. It is recommended that if more than 6 hours have passed since the scheduled dosing time, the subject should not take the missed dose but should wait for the next regularly scheduled dose."
            }
          },
          "comparator_medications": [
            {
              "id": "COMP-001",
              "medication_name": "Carboplatin",
              "source": "commercially_obtained",
              "provenance": {
                "section_number": "5.5.2.1",
                "page_number": 61,
                "text_snippet": "The non-investigational medicinal products available for use within the Investigator's choice of standard chemotherapy treatment arm are listed in Table 7."
              }
            },
            {
              "id": "COMP-002",
              "medication_name": "Paclitaxel",
              "source": "commercially_obtained",
              "provenance": {
                "section_number": "5.5.2.1",
                "page_number": 61,
                "text_snippet": "The non-investigational medicinal products available for use within the Investigator's choice of standard chemotherapy treatment arm are listed in Table 7."
              }
            },
            {
              "id": "COMP-003",
              "medication_name": "Cisplatin",
              "source": "commercially_obtained",
              "provenance": {
                "section_number": "5.5.2.1",
                "page_number": 61,
                "text_snippet": "The non-investigational medicinal products available for use within the Investigator's choice of standard chemotherapy treatment arm are listed in Table 7."
              }
            },
            {
              "id": "COMP-004",
              "medication_name": "Pemetrexed",
              "source": "commercially_obtained",
              "provenance": {
                "section_number": "5.5.2.1",
                "page_number": 61,
                "text_snippet": "The non-investigational medicinal products available for use within the Investigator's choice of standard chemotherapy treatment arm are listed in Table 7."
              }
            }
          ],
          "emergency_unblinding": {
            "unblinding_allowed": false,
            "unblinding_triggers": [],
            "unblinding_procedure": "Study is open-label.",
            "who_can_unblind": [],
            "documentation_required": null,
            "provenance": {
              "section_number": "1.0",
              "page_number": 1,
              "text_snippet": "A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy..."
            }
          },
          "provenance": {
            "section_number": "5.5",
            "page_number": 59,
            "text_snippet": "Treatments"
          }
        },
        "technology_systems": {
          "instanceType": "TechnologySystems",
          "edc_system": {
            "vendor_name": "Medidata Solutions Incorporated",
            "system_capabilities": [
              "electronic_case_report_forms",
              "audit_trail",
              "electronic_signature"
            ],
            "integration_requirements": [],
            "language_requirements": [],
            "provenance": {
              "section_number": "10.2",
              "page_number": 95,
              "text_snippet": "The CRF data for this study are being collected with an electronic data capture (EDC) system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
            }
          },
          "iwrs_rtsm": {
            "vendor_name": null,
            "functions": [
              "randomization",
              "drug_dispensing"
            ],
            "integration_with_edc": false,
            "provenance": {
              "section_number": "4.9",
              "page_number": 49,
              "text_snippet": "An Interactive Response Technology system (IRT) will be utilized to register subjects."
            }
          },
          "epro_devices": {
            "required": false,
            "device_type": "paper",
            "instruments_collected": [
              "NFLSI-17",
              "EQ-5D-5L"
            ],
            "training_required": false,
            "provenance": {
              "section_number": "5.0",
              "page_number": 50,
              "text_snippet": "Subjects in both arms must complete this questionnaire on paper forms, which is then entered into EDC by the Investigator or designee."
            }
          },
          "central_services": [
            {
              "id": "SVC-001",
              "service_type": "central_lab",
              "vendor_name": null,
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": "4.7",
                "page_number": 47,
                "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis."
              }
            },
            {
              "id": "SVC-002",
              "service_type": "other",
              "vendor_name": "Qiagen",
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": "1.2",
                "page_number": 5,
                "text_snippet": "Subjects LSP status (positive or negative) will be determined from tissue samples obtained to confirm diagnosis of NSCLC with a commercially developed RNA seq based LSP classifier developed in partnership with Qiagen."
              }
            }
          ],
          "provenance": {
            "section_number": "10.2",
            "page_number": 95,
            "text_snippet": "Case Report Forms"
          }
        },
        "equipment_facilities": {
          "instanceType": "EquipmentFacilities",
          "specialized_equipment": [
            {
              "id": "EQUIP-001",
              "equipment": "CT scanner",
              "required_or_preferred": "required",
              "specifications": "Full chest and abdomen scans. Slice thickness of 5 mm or less.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "4.8",
                "page_number": 48,
                "text_snippet": "A CT scan of the full chest and abdomen (with image of liver and adrenal glands) will be used in the evaluation of tumor responses, as per Table 2"
              }
            },
            {
              "id": "EQUIP-002",
              "equipment": "MRI scanner",
              "required_or_preferred": "required",
              "specifications": "For brain imaging if CNS involvement is suspected or if CT is contraindicated.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "4.9",
                "page_number": 49,
                "text_snippet": "A baseline MRI (or CT if MRI is contraindicated) of the brain is to be performed on any subject with signs or symptoms suggesting CNS involvement by tumor."
              }
            },
            {
              "id": "EQUIP-003",
              "equipment": "12-lead ECG machine",
              "required_or_preferred": "required",
              "specifications": null,
              "calibration_frequency": null,
              "provenance": {
                "section_number": "4.5",
                "page_number": 45,
                "text_snippet": "A resting 12-lead ECG will be performed per Table 2."
              }
            }
          ],
          "facility_requirements": {
            "patient_space": "Area for intravenous infusion of chemotherapy.",
            "storage_space": "Secure place for clinical supplies.",
            "safety_equipment": [],
            "provenance": {
              "section_number": "5.5.2.3",
              "page_number": 63,
              "text_snippet": "All clinical supplies must be stored in a secure place until they are dispensed for subject use, are destroyed at the site or are returned to AbbVie."
            }
          },
          "provenance": {
            "section_number": "4.8",
            "page_number": 48,
            "text_snippet": "Tumor Assessments (Radiologic)"
          }
        },
        "vendor_coordination": [
          {
            "id": "VENDOR-001",
            "vendor_type": "other",
            "vendor_name": "Medidata Solutions Incorporated",
            "services_provided": [
              "Electronic data capture (Rave®)"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "10.2",
              "page_number": 95,
              "text_snippet": "The CRF data for this study are being collected with an electronic data capture (EDC) system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
            }
          },
          {
            "id": "VENDOR-002",
            "vendor_type": "iwrs_rtsm",
            "vendor_name": "IRT vendor",
            "services_provided": [
              "Randomization",
              "Drug supply management"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "4.9",
              "page_number": 49,
              "text_snippet": "An Interactive Response Technology system (IRT) will be utilized to register subjects... A copy of all randomization schedules will be kept by the Clinical Statistics Department at AbbVie and a copy will be forwarded to the IRT vendor."
            }
          },
          {
            "id": "VENDOR-003",
            "vendor_type": "central_lab",
            "vendor_name": "Qiagen",
            "services_provided": [
              "LSP status determination from tumor tissue"
            ],
            "site_interface_required": false,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "1.2",
              "page_number": 5,
              "text_snippet": "Subjects LSP status (positive or negative) will be determined from tissue samples obtained to confirm diagnosis of NSCLC with a commercially developed RNA seq based LSP classifier developed in partnership with Qiagen."
            }
          },
          {
            "id": "VENDOR-004",
            "vendor_type": "central_lab",
            "vendor_name": "Certified central laboratory",
            "services_provided": [
              "Chemistry, hematology, and urinalysis assessments"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "4.7",
              "page_number": 47,
              "text_snippet": "All laboratory samples will be assessed using a certified central laboratory and these data will be used for all data analysis."
            }
          }
        ],
        "extraction_statistics": {
          "has_site_selection_criteria": true,
          "has_regulatory_info": true,
          "has_personnel_requirements": true,
          "has_training_requirements": true,
          "has_monitoring_plan": true,
          "has_activation_timeline": true,
          "has_drug_supply_info": true,
          "has_technology_systems": true,
          "has_dispensing_schedule": true,
          "has_drug_accountability": true,
          "has_emergency_unblinding": true,
          "site_count_target": 150,
          "country_count": 2,
          "vendor_count": 4,
          "comparator_medication_count": 4
        },
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-359\n\nA Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers"
        }
      },
      "_agentDocumentation": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements including equipment, training, drug supply,\n    and vendor coordination. Supports site initiation planning and CTMS configuration.",
        "scope": "- Site equipment requirements\n    - Training requirements\n    - Drug storage and handling\n    - IP accountability procedures\n    - Vendor coordination\n    - Site qualification criteria\n    - Document requirements",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements",
          "Appendix: Training Guide"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium"
          },
          {
            "name": "Training Requirements",
            "description": "Required site training modules",
            "dataPath": "training_requirements[]",
            "downstreamUses": [
              "LMS configuration",
              "Site initiation tracking",
              "Delegation logs"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments",
          "Create equipment requirement lists",
          "Set up IP accountability workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json"
      }
    },
    "qualityManagement": {
      "moduleId": "quality_management",
      "instanceType": "QualityManagement",
      "data": {
        "id": "M14-359-quality-management",
        "instanceType": "QualityManagement",
        "name": "M14-359 Quality Management",
        "ich_m11_section": "6.3",
        "monitoring": {
          "monitoring_approach": {
            "instanceType": "MonitoringApproach",
            "strategy": "hybrid",
            "rationale": "A combination of on-site monitoring, as specified in the protocol, and centralized data review is employed to ensure subject safety, data integrity, and trial quality in accordance with ICH E6(R2) principles.",
            "regulatory_framework": [
              "ICH_E6_R2"
            ],
            "adaptive_monitoring": true,
            "centralized_monitoring_enabled": true,
            "centralized_monitoring_tools": [
              "EDC_data_review",
              "statistical_monitoring",
              "KRI_dashboard"
            ],
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol specifies both on-site monitoring and centralized data quality checks, which constitutes a hybrid monitoring strategy. The adaptive and risk-based nature is inferred from modern trial conduct standards (ICH E6 R2) which are referenced by implication through GCP compliance statements.",
                "supporting_context": [
                  "Section 9.2, Page 93: 'On-site monitoring will be performed before, during and after the trial to assure appropriate conduct of the trial in accordance with ICH GCP.'",
                  "Section 11.0, Page 96: 'Computer logic and manual checks will be created to identify items such as inconsistent study dates. Any necessary corrections will be made to the eCRF.'"
                ],
                "confidence": "high"
              }
            }
          },
          "sdv_strategy": {
            "instanceType": "SDVStrategy",
            "overall_approach": "risk_based",
            "default_sdv_percentage": 20,
            "critical_data_100_percent": [
              "informed_consent",
              "eligibility_criteria",
              "primary_endpoint",
              "SAEs",
              "withdrawal_reason"
            ],
            "sdv_reduction_criteria": {
              "enabled": true,
              "minimum_subjects_enrolled": 5,
              "error_rate_threshold_percent": 2,
              "reduced_sdv_percentage": 10,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify criteria for reducing SDV. These values are derived from common risk-based monitoring practices where SDV intensity can be decreased at sites demonstrating high quality after an initial period.",
                  "supporting_context": [
                    "General industry standards for risk-based monitoring."
                  ],
                  "confidence": "low"
                }
              }
            },
            "sdv_escalation_criteria": {
              "error_rate_threshold_percent": 8,
              "escalated_sdv_percentage": 100,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify criteria for escalating SDV. These values are derived from common risk-based monitoring practices where SDV is increased to 100% at sites demonstrating poor data quality or high error rates.",
                  "supporting_context": [
                    "General industry standards for risk-based monitoring."
                  ],
                  "confidence": "low"
                }
              }
            },
            "remote_sdv_enabled": true,
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not contain an explicit Source Data Verification (SDV) strategy. This risk-based approach is derived based on modern clinical trial standards (ICH E6 R2). 100% SDV is inferred for critical data points essential for subject safety (consent, eligibility, SAEs) and trial integrity (primary endpoint, withdrawal). A default percentage is assumed for non-critical data.",
                "supporting_context": [
                  "Section 9.3, Page 93: 'An entry must also be made in the subject's dated source documents to confirm that informed consent was obtained...'",
                  "Section 10.2, Page 95: 'AbbVie (or their representatives) will also be allowed access to all source documents pertinent to the study in order to verify eCRF entries.'"
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_visits": {
            "instanceType": "MonitoringVisits",
            "site_initiation_visit": {
              "required": true,
              "timing": "Before first subject enrolled",
              "format": "on_site",
              "key_activities": [
                "protocol_training",
                "investigator_site_file_review",
                "EDC_training",
                "drug_accountability_training"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.5.2.2",
                  "page_number": 62,
                  "text_snippet": "Instructions for the handling of study supplies to the study site are available in the veliparib IB, study Dosing Cards and from participants at the Site Initiation Visit."
                }
              }
            },
            "routine_monitoring": {
              "on_site_visit_frequency": "risk_based_adaptive",
              "remote_monitoring_frequency": "monthly",
              "on_site_activities": [
                "ICF_review",
                "source_data_verification",
                "AE_SAE_review",
                "drug_accountability_check",
                "investigator_site_file_review"
              ],
              "remote_activities": [
                "centralized_data_review",
                "KRI_monitoring",
                "query_management"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.2",
                  "page_number": 93,
                  "text_snippet": "On-site monitoring will be performed before, during and after the trial to assure appropriate conduct of the trial in accordance with ICH GCP."
                }
              }
            },
            "triggered_visits": [
              {
                "id": "trigger-001",
                "trigger_type": "KRI_threshold_breach",
                "response_timeline_hours": 48,
                "actions": [
                  "remote_assessment_of_issue",
                  "targeted_SDV",
                  "on_site_visit_if_unresolved"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention triggered visits or KRIs. This is a standard component of a risk-based monitoring plan, where exceeding a KRI threshold would trigger a specific set of actions, potentially including a targeted on-site visit.",
                    "supporting_context": [
                      "General principles of risk-based quality management."
                    ],
                    "confidence": "low"
                  }
                }
              },
              {
                "id": "trigger-002",
                "trigger_type": "QTL_threshold_breach",
                "response_timeline_hours": 24,
                "actions": [
                  "immediate_site_contact",
                  "root_cause_analysis",
                  "CAPA_initiation"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention triggered visits or QTLs. This is a standard component of a risk-based monitoring plan. A breach of a Quality Tolerance Limit is a serious event requiring immediate response and investigation.",
                    "supporting_context": [
                      "General principles of risk-based quality management."
                    ],
                    "confidence": "low"
                  }
                }
              }
            ],
            "close_out_visit": {
              "timing": "after_LPLV",
              "timing_days_after_event": 45,
              "format": "on_site",
              "activities": [
                "final_SDV",
                "final_drug_accountability",
                "essential_document_collection",
                "archiving_preparation"
              ],
              "site_release_criteria": [
                "all_CRFs_complete",
                "all_queries_resolved",
                "final_IRB_report_submitted"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "67",
                  "page_number": 67,
                  "text_snippet": "An overall accountability of the study drug supplied by AbbVie will be performed and verified by the site monitor throughout the study and at the study site closeout visit."
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The monitoring visit structure is derived from explicit mentions of Site Initiation and Close-Out visits, and the general requirement for on-site monitoring during the trial, which implies routine visits.",
                "supporting_context": [
                  "Section 5.5.2.2, Page 62",
                  "Section 9.2, Page 93",
                  "Page 67"
                ],
                "confidence": "high"
              }
            }
          },
          "key_risk_indicators": [
            {
              "id": "KRI-001",
              "instanceType": "KeyRiskIndicator",
              "name": "Informed Consent Compliance",
              "category": "protocol_compliance",
              "metric": "Percentage of subjects with informed consent date after the start of any study procedure.",
              "data_source": "EDC",
              "review_frequency": "weekly",
              "threshold_green": "0%",
              "threshold_amber": ">0% to 1%",
              "threshold_red": ">1%",
              "action_amber": "Review specific subject data with site, confirm process.",
              "action_red": "Immediate site call, retrain on consent process, potential CAPA.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.3",
                  "page_number": 93,
                  "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject..."
                }
              }
            },
            {
              "id": "KRI-002",
              "instanceType": "KeyRiskIndicator",
              "name": "Primary Endpoint Data Availability",
              "category": "data_integrity",
              "metric": "Percentage of subjects with missing date of death or last known alive date 60 days post-expected collection.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<2%",
              "threshold_amber": "2-5%",
              "threshold_red": ">5%",
              "action_amber": "Follow up with site on outstanding survival data.",
              "action_red": "Escalate to project manager, implement targeted follow-up plan.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "4.0",
                  "page_number": 29,
                  "text_snippet": "The primary objective of the study is to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival... in LSP positive subjects"
                }
              }
            },
            {
              "id": "KRI-003",
              "instanceType": "KeyRiskIndicator",
              "name": "SAE Reporting Timeliness",
              "category": "patient_safety",
              "metric": "Percentage of SAEs not reported to the sponsor within 24 hours of site awareness.",
              "data_source": "Safety DB",
              "review_frequency": "weekly",
              "threshold_green": "0%",
              "threshold_amber": ">0% to 10%",
              "threshold_red": ">10%",
              "action_amber": "Review late reporting reason with site.",
              "action_red": "Retrain site on SAE reporting requirements, document deviation.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "6.1.2",
                  "page_number": 74,
                  "text_snippet": "If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a serious adverse event (SAE) within 24 hours of the site being made aware of the serious adverse event."
                }
              }
            },
            {
              "id": "KRI-004",
              "instanceType": "KeyRiskIndicator",
              "name": "Major Protocol Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Number of major protocol deviations per subject-month.",
              "data_source": "CTMS",
              "review_frequency": "monthly",
              "threshold_green": "<0.05",
              "threshold_amber": "0.05-0.1",
              "threshold_red": ">0.1",
              "action_amber": "Analyze trend and type of deviations for the site.",
              "action_red": "Triggered monitoring visit, root cause analysis, potential site hold on enrollment.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "7.0",
                  "page_number": 81,
                  "text_snippet": "Protocol Deviations. AbbVie does not allow intentional/prospective deviations from the protocol. The principal Investigator is responsible for complying with all protocol requirements..."
                }
              }
            },
            {
              "id": "KRI-005",
              "instanceType": "KeyRiskIndicator",
              "name": "Tumor Assessment Visit Compliance",
              "category": "protocol_compliance",
              "metric": "Percentage of required tumor assessment visits (C3D1, C5D1, etc.) missed or out of window.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<5%",
              "threshold_amber": "5-10%",
              "threshold_red": ">10%",
              "action_amber": "Review scheduling practices with site coordinator.",
              "action_red": "Retrain site on importance of assessment schedule for endpoint analysis.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "6",
                  "page_number": 6,
                  "text_snippet": "Tumor assessments will be performed at baseline prior to treatment on Cycle 3 Day 1 and Cycle 5 Day 1. After cessation of platinum doublet therapy, tumor assessments will be performed q9 weeks until 1 year after beginning treatment..."
                }
              }
            }
          ],
          "quality_tolerance_limits": [
            {
              "id": "QTL-001",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Informed Consent Major Deviations",
              "category": "informed_consent",
              "acceptable_limit": "0% of subjects with consent obtained after study start",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "1 subject",
              "alert_threshold_numeric": 1,
              "action_threshold": "1 subject",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Immediate investigation",
                "root_cause_analysis",
                "CAPA_initiation",
                "report_to_IRB_IEC"
              ],
              "escalation_path": [
                "project_manager",
                "sponsor_QA",
                "head_of_clinical_operations"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.3",
                  "page_number": 44,
                  "text_snippet": "Signed informed consent will be obtained from the subject before any study procedures are undertaken..."
                }
              }
            },
            {
              "id": "QTL-002",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Eligibility Criteria Major Deviations",
              "category": "eligibility",
              "acceptable_limit": "<2% of randomized subjects",
              "acceptable_limit_numeric": 0.02,
              "alert_threshold": "1% of subjects",
              "alert_threshold_numeric": 0.01,
              "action_threshold": "2% of subjects",
              "action_threshold_numeric": 0.02,
              "predefined_actions": [
                "Analyze deviation types",
                "review_screening_logs",
                "retrain_sites_on_key_criteria",
                "consider_protocol_clarification"
              ],
              "escalation_path": [
                "medical_monitor",
                "project_manager",
                "steering_committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol has extensive and specific inclusion/exclusion criteria. A QTL for eligibility is critical to ensure the integrity of the study population. The numeric thresholds are based on industry standards for acceptable levels of major deviations.",
                  "supporting_context": [
                    "Section 5.2.1, Pages 33-35: Inclusion Criteria",
                    "Section 5.2.2, Pages 36-37: Exclusion Criteria"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-003",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Primary Endpoint Data Integrity",
              "category": "endpoint_collection",
              "acceptable_limit": "<5% of subjects in the LSP+ subgroup are non-evaluable for the primary OS analysis due to missing data",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "2.5% of subjects",
              "alert_threshold_numeric": 0.025,
              "action_threshold": "5% of subjects",
              "action_threshold_numeric": 0.05,
              "predefined_actions": [
                "Investigate reasons for data loss",
                "implement enhanced follow-up procedures",
                "assess_impact_on_statistical_power"
              ],
              "escalation_path": [
                "lead_data_manager",
                "lead_statistician",
                "project_manager"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The primary endpoint is OS in the LSP+ subgroup. A critical quality factor is ensuring this data is complete. A QTL is established to monitor the rate of non-evaluable subjects, which could compromise the study's primary objective. The 5% limit is a standard threshold for acceptable data loss for a primary endpoint.",
                  "supporting_context": [
                    "Section 4.0, Page 29: 'The primary objective of the study is to assess if treatment with veliparib plus carboplatin and paclitaxel results in improved survival...in LSP positive subjects...'",
                    "Section 8.1.2.1, Page 83: 'The primary efficacy analysis will be a comparison of OS distributions...in LSP + subgroup.'"
                  ],
                  "confidence": "high"
                }
              }
            }
          ],
          "findings_management": {
            "instanceType": "FindingsManagement",
            "finding_categories": [
              {
                "id": "finding-cat-001",
                "category": "critical",
                "definition": "A finding that adversely affects the rights, safety, or well-being of the subjects and/or the quality and integrity of the data.",
                "response_timeline_days": 1,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This definition is derived from standard GCP definitions of a critical finding. The protocol's emphasis on safety (Section 6.0) and data integrity (Section 10.0, 11.0) supports this categorization.",
                    "supporting_context": [
                      "Section 6.0 Adverse Events",
                      "Section 7.0 Protocol Deviations"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "finding-cat-002",
                "category": "major",
                "definition": "A finding that could potentially affect the rights, safety, or well-being of the subjects or the quality and integrity of the data.",
                "response_timeline_days": 15,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This definition is derived from standard GCP definitions of a major finding. It represents a significant departure from the protocol that could impact study outcomes but is not immediately critical.",
                    "supporting_context": [
                      "Section 7.0 Protocol Deviations"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "finding-cat-003",
                "category": "minor",
                "definition": "A finding that is unlikely to affect subject safety or data integrity, but represents a departure from the protocol or GCP.",
                "response_timeline_days": 30,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This definition is derived from standard GCP definitions of a minor finding, representing administrative or procedural errors with low impact.",
                    "supporting_context": [
                      "Section 7.0 Protocol Deviations"
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "capa_process": {
              "capa_triggers": [
                "critical_finding",
                "repeated_major_finding",
                "QTL_breach",
                "systemic_issue_identified"
              ],
              "response_timeline_days": 30,
              "verification_required": true,
              "tracking_system": "Quality Management System",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not describe a formal CAPA process. This process is derived from standard quality management systems in clinical research, where significant or systemic issues (like critical findings or QTL breaches) trigger a formal corrective and preventive action plan.",
                  "supporting_context": [
                    "Section 7.0 Protocol Deviations",
                    "Section 9.2 Ethical Conduct of the Study"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "protocol_deviation_management": {
              "deviation_categories": [
                "major",
                "minor"
              ],
              "internal_reporting_timeline_days": 5,
              "irb_reporting_required": true,
              "irb_reporting_timeline_days": 10,
              "root_cause_analysis_required": true,
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "7.0",
                  "page_number": 81,
                  "text_snippet": "If a protocol deviation occurs (or is identified) after a subject has been enrolled, the principal Investigator is responsible for notifying Independent Ethics Committee (IEC)/Independent Review Board (IRB) regulatory authorities (as applicable), and the following AbbVie Clinical Monitor(s):"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The overall findings management framework is derived from the protocol's requirements for managing adverse events (Section 6.0) and protocol deviations (Section 7.0), structured according to standard industry practice.",
                "supporting_context": [
                  "Section 6.0 Adverse Events",
                  "Section 7.0 Protocol Deviations"
                ],
                "confidence": "high"
              }
            }
          },
          "monitoring_reports": {
            "submission_timeline_days": 10,
            "review_timeline_days": 5,
            "key_content": [
              "visit_summary",
              "action_item_status",
              "protocol_deviation_log",
              "SAE_reconciliation",
              "site_performance_assessment"
            ],
            "storage_location": "eTMF",
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not specify the content or timelines for monitoring reports. This information is derived from standard clinical operations procedures and GCP guidelines, which require timely reporting and review of monitoring activities.",
                "supporting_context": [
                  "Section 9.2 Ethical Conduct of the Study",
                  "Section 10.0 Source Documents and Case Report Form Completion"
                ],
                "confidence": "medium"
              }
            }
          },
          "provenance": {
            "kind": "derived",
            "derived": {
              "reasoning": "The overall monitoring plan is inferred from various sections of the protocol that describe monitoring activities, data handling, and quality assurance, but a single, consolidated monitoring plan section is not present.",
              "supporting_context": [
                "Section 9.2",
                "Section 10.2",
                "Section 11.0"
              ],
              "confidence": "high"
            }
          }
        },
        "rbqm": {
          "ract_register": {
            "critical_to_quality_factors": [
              {
                "ctq_id": "CTQ-001",
                "ctq_category": "Endpoint Integrity",
                "factor": "Accurate and complete collection of Overall Survival (OS) data, including date of randomization and date of death/last known alive.",
                "insight_type": "explicit",
                "clinical_reasoning": "OS is the primary efficacy endpoint for the LSP+ subgroup. Incomplete or inaccurate survival data could lead to biased results and an inconclusive trial.",
                "failure_mode": "Sites fail to conduct survival follow-up visits/calls, leading to loss to follow-up and censored data, reducing statistical power.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 30,
                "affected_stakeholders": [
                  "Patient",
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Clear protocol instructions for survival follow-up",
                  "Site training on the importance of OS data collection"
                ],
                "detective_controls": [
                  "Centralized monitoring reports tracking last contact dates"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.1.2.1",
                    "page_number": 83,
                    "text_snippet": "The primary efficacy analysis will be a comparison of OS distributions between the 120 mg of veliparib BID + carboplatin/paclitaxel and Investigators' choice of platinum therapy groups in LSP + subgroup."
                  }
                }
              },
              {
                "ctq_id": "CTQ-002",
                "ctq_category": "Patient Safety",
                "factor": "Timely and accurate reporting of Serious Adverse Events (SAEs).",
                "insight_type": "explicit",
                "clinical_reasoning": "Ensures ongoing safety assessment of the investigational product and allows for timely regulatory reporting and protection of study subjects.",
                "failure_mode": "Site staff are unaware of or fail to follow the 24-hour reporting timeline for SAEs, leading to delayed safety signal detection.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 30,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "SAE reporting training at SIV",
                  "Provision of clear reporting forms and contact details"
                ],
                "detective_controls": [
                  "Routine monitoring review of source documents for unreported SAEs"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.6.1",
                    "page_number": 79,
                    "text_snippet": "In the event of a serious adverse event, whether associated with study drug or not, the Investigator will notify the Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse event..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-003",
                "ctq_category": "GCP Compliance",
                "factor": "Enrollment of the correct patient population as defined by the inclusion/exclusion criteria.",
                "insight_type": "explicit",
                "clinical_reasoning": "The study population is specific (advanced non-squamous NSCLC, current/former smokers). Enrollment of ineligible subjects compromises data interpretability and study validity.",
                "failure_mode": "Sites misinterpret complex eligibility criteria (e.g., prior therapy washouts, specific mutations), leading to enrollment of ineligible subjects.",
                "severity_score": 4,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 36,
                "affected_stakeholders": [
                  "Patient",
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Detailed eligibility checklist",
                  "Medical monitor availability for eligibility questions"
                ],
                "detective_controls": [
                  "100% SDV of eligibility criteria for all subjects",
                  "Centralized review of screening data"
                ],
                "mitigation_hierarchy_level": "Detection",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.2",
                    "page_number": 33,
                    "text_snippet": "The study population will consist of adult subjects who are current or former smokers with cytologically or histologically confirmed locally advanced or metastatic non-squamous NSCLC..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-004",
                "ctq_category": "Data Quality",
                "factor": "Availability of high-quality tumor tissue for determination of Lung Subtype Panel (LSP) status.",
                "insight_type": "inferred",
                "clinical_reasoning": "The primary analysis is on the LSP+ subgroup. Failure to obtain sufficient, high-quality tissue samples for analysis will result in fewer evaluable subjects, threatening the primary objective.",
                "failure_mode": "Archived tissue samples are old, degraded, or insufficient in quantity, leading to a high rate of LSP test failure.",
                "severity_score": 5,
                "probability_score": 4,
                "detectability_score": 3,
                "risk_priority_number": 60,
                "affected_stakeholders": [
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Clear tissue collection and handling requirements in protocol/lab manual",
                  "Site training on sample requirements"
                ],
                "detective_controls": [
                  "Central lab tracking of sample receipt and QC checks"
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10",
                    "page_number": 10,
                    "text_snippet": "LSP status: Available archived tumor tissue will be used to determine the subjects' tumor LSP status with a commercially developed RNA seq based LSP classifier developed in partnership with Qiagen."
                  }
                }
              },
              {
                "ctq_id": "CTQ-005",
                "ctq_category": "GCP Compliance",
                "factor": "Maintenance of proper blinding and randomization procedures.",
                "insight_type": "explicit",
                "clinical_reasoning": "This is an open-label study, so blinding is not applicable. However, correct randomization is critical to prevent selection bias and ensure comparability between treatment arms.",
                "failure_mode": "Site staff do not use the IRT system correctly, leading to randomization errors or incorrect treatment assignment.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 2,
                "risk_priority_number": 20,
                "affected_stakeholders": [
                  "Sponsor",
                  "Patient"
                ],
                "preventive_controls": [
                  "Use of a validated central IRT system",
                  "Training on IRT system at SIV"
                ],
                "detective_controls": [
                  "Central monitoring of IRT logs and drug dispensing records"
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.3",
                    "page_number": 91,
                    "text_snippet": "The randomization numbers of the study will assign subjects in a 1:1 ratio to either the 120 mg of veliparib BID + carboplatin/paclitaxel treatment group or the Investigators' preferred platinum therapy treatment group."
                  }
                }
              },
              {
                "ctq_id": "CTQ-006",
                "ctq_category": "Operational Feasibility",
                "factor": "Adherence to the specified treatment regimen, including veliparib pre-dosing and chemotherapy administration.",
                "insight_type": "explicit",
                "clinical_reasoning": "The specific timing of veliparib administration relative to chemotherapy is part of the therapeutic hypothesis. Deviations could impact efficacy and safety outcomes.",
                "failure_mode": "Subjects are non-compliant with oral veliparib dosing at home, or sites delay chemotherapy, disrupting the intended schedule.",
                "severity_score": 4,
                "probability_score": 4,
                "detectability_score": 4,
                "risk_priority_number": 64,
                "affected_stakeholders": [
                  "Patient",
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Clear subject instructions and dosing diaries",
                  "Site reminders to subjects"
                ],
                "detective_controls": [
                  "Pill counts at monitoring visits",
                  "Review of chemotherapy administration records"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.1",
                    "page_number": 30,
                    "text_snippet": "Subjects randomized to receive veliparib will begin oral veliparib dosing 2 days prior to the start of the carboplatin/paclitaxel infusion on C1D-2 and will continue twice a day BID through C1D5 (7 consecutive days)."
                  }
                }
              }
            ],
            "emergent_systemic_risks": [
              {
                "risk_id": "ESR-001",
                "risk_type": "cross_domain",
                "risk_description": "High rate of LSP test failure due to poor quality or insufficient quantity of archived tumor tissue impacts the primary endpoint analysis and potentially biomarker research.",
                "discovery_reasoning": "Inferred from the dependency of the primary endpoint on LSP+ status and the known challenges with using archived tissue.",
                "affected_domains": [
                  "Endpoints",
                  "Data Collection",
                  "Subject Population"
                ],
                "trigger_conditions": "Manifests when central lab QC results show a test failure rate exceeding projections, impacting the number of subjects evaluable for the primary endpoint.",
                "probability": "Likely",
                "impact_severity": "Catastrophic",
                "affected_objectives": [
                  "Primary Efficacy"
                ],
                "quantitative_estimate": "Potential for >25% of samples to be non-evaluable, threatening statistical power.",
                "preventive_redesign": "Not applicable as the protocol is finalized. The design relies on archived tissue, which cannot be prospectively controlled.",
                "monitoring_approach": "Track sample submission and QC failure rates in real-time via a central lab dashboard.",
                "contingency_plan": "Discuss with statisticians amending the SAP to include analysis of the ITT population or other subgroups if the LSP+ population is insufficient.",
                "linked_ctq_ids": [
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10",
                    "page_number": 10,
                    "text_snippet": "Sample size consideration for OS analysis in LSP+ subgroup: Based on 452 subjects having tissue samples (assumed 76% LSP sample availability rate, out of 595 enrolled subjects), the below table provides the power and number of events..."
                  }
                }
              },
              {
                "risk_id": "ESR-002",
                "risk_type": "interaction_effect",
                "risk_description": "Variability in the 'Investigator's Choice' of standard chemotherapy in the control arm introduces heterogeneity, potentially masking or exaggerating the treatment effect of veliparib.",
                "discovery_reasoning": "Explicitly stated in the protocol design (Section 5.1), which allows three different platinum doublet options.",
                "affected_domains": [
                  "Study Design",
                  "Endpoints"
                ],
                "trigger_conditions": "Analysis reveals significant outcome differences between the different chemotherapy backbones within the control arm.",
                "probability": "Possible",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Primary Efficacy"
                ],
                "quantitative_estimate": "Could increase variance and reduce the power to detect a true difference by 10-15%.",
                "preventive_redesign": "The protocol mitigates this risk through stratification by the Investigator's preferred platinum therapy at randomization.",
                "monitoring_approach": "Monitor the distribution of chosen therapies across sites and countries to detect imbalances.",
                "contingency_plan": "Pre-specify subgroup analyses by control therapy type in the Statistical Analysis Plan to explore heterogeneity.",
                "linked_ctq_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.1",
                    "page_number": 30,
                    "text_snippet": "Subject randomization will be stratified by...the Investigators' preferred platinum therapy (carboplatin/paclitaxel versus cisplatin/pemetrexed versus carboplatin/pemetrexed)..."
                  }
                }
              },
              {
                "risk_id": "ESR-003",
                "risk_type": "cross_domain",
                "risk_description": "Misclassification of smoking status (current vs. former) at baseline could dilute the treatment effect in key subgroups and weaken the rationale for the study population.",
                "discovery_reasoning": "Inferred from the study's focus on smokers and stratification by this factor, combined with the reliance on subject self-reporting.",
                "affected_domains": [
                  "Subject Population",
                  "Data Collection"
                ],
                "trigger_conditions": "Post-hoc data analysis or audits reveal inconsistencies in smoking history documentation.",
                "probability": "Possible",
                "impact_severity": "Moderate",
                "affected_objectives": [
                  "Secondary Efficacy"
                ],
                "quantitative_estimate": "Potential misclassification of 5-10% of subjects.",
                "preventive_redesign": "Incorporate more objective measures like cotinine testing if feasible (not in this protocol).",
                "monitoring_approach": "Centralized data review for logical inconsistencies in smoking history fields.",
                "contingency_plan": "Conduct sensitivity analyses in the final statistical analysis to assess the impact of potential misclassification.",
                "linked_ctq_ids": [
                  "CTQ-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6",
                    "page_number": 6,
                    "text_snippet": "Subjects must be current smokers (defined as having > 100 smoking events lifetime and having smoked within the past year) or former smokers (defined as having > 100 smoking events lifetime and having not smoked within the past year)."
                  }
                }
              }
            ],
            "strategic_risk_indicators": [
              {
                "kri_id": "SKRI-001",
                "kri_type": "leading_indicator",
                "category": "Risk Velocity",
                "metric": "Rate of tumor tissue sample rejection at the central lab.",
                "rationale": "Provides an early warning of systemic issues with tissue sample quality or quantity, which directly threatens the feasibility of the primary endpoint analysis in the LSP+ population.",
                "predictive_value": "Predicts a future inability to meet the required number of evaluable subjects for the primary analysis, potentially leading to an underpowered study.",
                "calculation_formula": "(Number of samples failing QC / Total number of samples received) * 100",
                "data_sources": [
                  "Central Lab LIMS"
                ],
                "frequency": "Weekly",
                "thresholds": {
                  "green": {
                    "range": "<15%",
                    "interpretation": "Within expected range"
                  },
                  "amber": {
                    "range": "15-25%",
                    "interpretation": "Investigate common failure reasons and sites",
                    "escalation": "Clinical Team Lead"
                  },
                  "red": {
                    "range": ">25%",
                    "interpretation": "Systemic issue, immediate action required",
                    "escalation": "Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This KRI is derived from the critical dependency of the primary endpoint on successful LSP analysis of archived tissue. The protocol assumes a 76% sample availability rate, implying a ~24% failure/unavailability rate. This KRI directly monitors that assumption.",
                    "supporting_context": [
                      "Section 10, Page 10: 'Based on 452 subjects having tissue samples (assumed 76% LSP sample availability rate, out of 595 enrolled subjects)...'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-002",
                "kri_type": "leading_indicator",
                "category": "Operational Health",
                "metric": "Screen failure rate, specifically due to not meeting smoking history or tumor histology criteria.",
                "rationale": "A high screen failure rate for these key criteria indicates difficulty in identifying the target population, which can predict significant delays in enrollment.",
                "predictive_value": "Predicts failure to meet enrollment timelines and potential for protocol amendments to broaden eligibility.",
                "calculation_formula": "(Number of screen failures for key criteria / Total number of subjects screened) * 100",
                "data_sources": [
                  "EDC",
                  "CTMS"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<40%",
                    "interpretation": "Normal for oncology trials"
                  },
                  "amber": {
                    "range": "40-60%",
                    "interpretation": "Review screening logs for patterns",
                    "escalation": "Project Manager"
                  },
                  "red": {
                    "range": ">60%",
                    "interpretation": "Enrollment at risk, re-evaluate site selection/protocol criteria",
                    "escalation": "Sponsor Executive"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-003"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This KRI is derived from the highly specific population requirements (non-squamous histology, smoking history). These criteria are expected to lead to a significant number of screen failures, and monitoring this rate is crucial for managing enrollment timelines.",
                    "supporting_context": [
                      "Section 5.2.1, Page 33: 'Subject must have...non-squamous NSCLC.'",
                      "Section 5.2.1, Page 34: 'Subjects must be current smokers...or former smokers...'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-003",
                "kri_type": "leading_indicator",
                "category": "Quality Trajectory",
                "metric": "Rate of early treatment discontinuations for reasons other than progressive disease.",
                "rationale": "This is a leading indicator of potential tolerability issues with the veliparib combination that may not be fully captured by individual AE reports. It predicts overall subject retention and data completeness.",
                "predictive_value": "Predicts a higher-than-expected rate of missing data for later efficacy and QoL assessments, and may indicate an emerging safety concern.",
                "calculation_formula": "(Number of subjects discontinuing for non-PD reasons / Total randomized subjects) * 100",
                "data_sources": [
                  "EDC"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<10%",
                    "interpretation": "As expected"
                  },
                  "amber": {
                    "range": "10-15%",
                    "interpretation": "Review reasons for discontinuation",
                    "escalation": "Medical Monitor"
                  },
                  "red": {
                    "range": ">15%",
                    "interpretation": "Potential tolerability signal, requires formal safety review",
                    "escalation": "Safety Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-002",
                  "CTQ-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.4.1",
                    "page_number": 56,
                    "text_snippet": "Each subject will be withdrawn from the study or study treatment (as applicable) per Section 5.4.1 if any of the following occur: ... The subject experiences treatment toxicity which, in the Investigator's opinion, prohibits further therapy..."
                  }
                }
              }
            ],
            "strategic_summary": {
              "summary": "The primary strategic risk is the dependency on the quality and availability of archived tumor tissue to identify the LSP+ subgroup for the primary endpoint analysis. Secondary risks include operational complexity related to the 'Investigator's Choice' control arm and ensuring compliance with the specific dosing schedule of the experimental therapy in a sick patient population. Proactive monitoring of tissue sample quality and enrollment criteria is critical for success.",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This summary synthesizes the most critical risks identified throughout the protocol. The dependency on LSP status is paramount (Section 4.0, 8.1.2.1), the 'Investigator's Choice' introduces variability (Section 5.1), and the dosing schedule is complex (Section 5.1).",
                  "supporting_context": [
                    "Section 4.0",
                    "Section 5.1",
                    "Section 8.1.2.1",
                    "Section 10"
                  ],
                  "confidence": "high"
                }
              }
            }
          },
          "risk_governance": {
            "risk_assessment_matrix": {
              "scoring_methodology": {
                "probability_scale": {
                  "1": "Rare (<5%)",
                  "2": "Unlikely (5-20%)",
                  "3": "Possible (20-50%)",
                  "4": "Likely (50-80%)",
                  "5": "Almost Certain (>80%)"
                },
                "impact_scale": {
                  "1": "Negligible",
                  "2": "Minor",
                  "3": "Moderate",
                  "4": "Major",
                  "5": "Catastrophic"
                },
                "risk_levels": {
                  "1-4": "Low",
                  "5-9": "Medium",
                  "10-14": "High",
                  "15-25": "Critical"
                }
              },
              "identified_risks": [
                {
                  "risk_id": "RISK-004",
                  "risk_category": "Data Collection",
                  "risk_description": "Failure to obtain sufficient high-quality tumor tissue for LSP analysis, jeopardizing the primary endpoint.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 5,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": "CTQ-004",
                  "linked_mitigation_ids": [
                    "MIT-001"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.2.1",
                      "page_number": 7,
                      "text_snippet": "Subject must consent to provide archived tissue or cytology sample of NSCLC lesion (primary or metastatic) for analysis if available."
                    }
                  }
                },
                {
                  "risk_id": "RISK-006",
                  "risk_category": "Operational",
                  "risk_description": "Poor subject adherence to the oral veliparib dosing schedule, impacting the assessment of the treatment regimen.",
                  "risk_owner": "Site",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 4,
                    "score": 16,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-006",
                  "linked_mitigation_ids": [
                    "MIT-002"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.5.6",
                      "page_number": 66,
                      "text_snippet": "Unless otherwise directed by the Investigator, a subject will be considered compliant with study drug, veliparib, if 80% of the assigned dose is taken during a cycle. Compliance below 80% will require counseling of the subject by study site personnel."
                    }
                  }
                },
                {
                  "risk_id": "RISK-003",
                  "risk_category": "Subject Population",
                  "risk_description": "High rate of screen failures due to restrictive eligibility criteria, leading to significant enrollment delays.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 3,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 3,
                    "impact": 3,
                    "score": 9,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": "CTQ-003",
                  "linked_mitigation_ids": [
                    "MIT-003"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "This risk is derived from the extensive and highly specific inclusion/exclusion criteria, which are common in oncology but increase the likelihood of screen failures and slow enrollment.",
                      "supporting_context": [
                        "Section 5.2.1 Inclusion Criteria",
                        "Section 5.2.2 Exclusion Criteria"
                      ],
                      "confidence": "high"
                    }
                  }
                }
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not contain a risk assessment matrix. This structure and its contents are derived by identifying key risks from the protocol text (e.g., reliance on tissue samples, complex dosing) and applying a standard risk scoring methodology.",
                  "supporting_context": [
                    "General principles of risk-based quality management."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "mitigation_strategies": [
              {
                "mitigation_id": "MIT-001",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "control_type": "Preventive",
                "control_category": "Site Training",
                "strategy_description": "Implement mandatory, detailed training for site staff on tumor tissue block/slide requirements, including age, size, and handling procedures, prior to site activation.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of training records; monitoring of initial sample QC results from first enrolled subjects at each site.",
                "verification_frequency": "Per site activation",
                "resource_requirements": "Development of training materials, CRA time for training delivery.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This mitigation strategy is derived as a standard and necessary control for the identified risk of poor tissue quality. The protocol requires tissue collection, implying that sites must be trained on the specific requirements.",
                    "supporting_context": [
                      "Section 5.3.1.3, Page 52: 'Tissue Collection. Subjects must consent to provide available archival tumor...for analysis.'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-002",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "control_type": "Detective",
                "control_category": "Monitoring",
                "strategy_description": "Monitors to perform meticulous review of subject dosing diaries and conduct pill counts at every routine monitoring visit to assess compliance.",
                "implementation_phase": "Conduct",
                "responsible_party": "Monitor",
                "effectiveness_rating": "High",
                "verification_method": "Review of monitoring reports for compliance assessment sections.",
                "verification_frequency": "Per monitoring visit",
                "resource_requirements": "Monitor time during visits.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.5.6",
                    "page_number": 66,
                    "text_snippet": "Subjects will be instructed to return all veliparib bottles (empty, partially filled or full) to the study site personnel prior to each cycle... The site staff will document the bottles returned and the number of capsules per bottle on the appropriate form."
                  }
                }
              },
              {
                "mitigation_id": "MIT-003",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "control_type": "Detective",
                "control_category": "Central Monitoring",
                "strategy_description": "Centralized monitoring team to review screen failure logs weekly to identify sites with disproportionately high failure rates or specific problematic criteria.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of central monitoring reports and meeting minutes.",
                "verification_frequency": "Weekly",
                "resource_requirements": "Central monitor FTE, data analytics platform.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.3.1.1",
                    "page_number": 44,
                    "text_snippet": "Subjects will be considered screen failures if the informed consent has been signed and a study-specific procedure has been performed...but subject does not randomize into the study. The reason for screen failure will be documented..."
                  }
                }
              }
            ],
            "safety_signal_detection": {
              "statistical_methods": [
                {
                  "method_id": "SSD-001",
                  "method_name": "AE Incidence Review",
                  "method_description": "Regular review of adverse event incidence rates, severity, and seriousness, comparing treatment arms.",
                  "application": "Ongoing monitoring of the safety profile of veliparib in combination with chemotherapy.",
                  "data_requirements": [
                    "EDC safety data",
                    "MedDRA coding"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.1.8",
                      "page_number": 88,
                      "text_snippet": "Statistical Analysis of Safety. Statistical analyses of safety data described below will be performed for three study population separately: LSP+ subgroup, LSP– subgroup, entire study population."
                    }
                  }
                }
              ],
              "stopping_rules": [],
              "dsmb_interface": {
                "dsmb_required": false,
                "meeting_frequency": "N/A",
                "review_scope": [],
                "unblinding_criteria": "N/A",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "A comprehensive search of the protocol for terms such as 'DSMB', 'DMC', 'Data Safety Monitoring Board', or 'Independent Data Monitoring Committee' yielded no results. The absence of any mention of such a committee indicates one is not planned for this study.",
                    "supporting_context": [
                      "Absence of a DSMB/DMC section in the protocol."
                    ],
                    "confidence": "high"
                  }
                }
              }
            },
            "issue_management_cascade": {
              "level_1": "Site identifies issue, attempts local resolution, informs Monitor.",
              "level_2": "Monitor escalates to Clinical Team Lead (CTL) if unresolved or significant.",
              "level_3": "CTL involves Medical Monitor for clinical/safety issues or other functional leads (Data Management, Stats) as needed.",
              "level_4": "Significant issues impacting study integrity, timelines, or budget are escalated to the Project Manager and Sponsor Leadership.",
              "level_5": "Critical safety or ethical issues may require reporting to regulatory authorities and/or IRB/IEC.",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not define an issue escalation pathway. This cascade is derived from standard clinical trial operational procedures. It incorporates roles mentioned in the protocol, such as the Investigator, Monitor, and Medical Monitor, into a logical hierarchy.",
                  "supporting_context": [
                    "Section 7.0, Page 81: Mentions notifying the AbbVie Clinical Monitor for deviations.",
                    "Section 6.6.1, Page 79: Provides contact information for the Oncology Safety Management Team for safety concerns."
                  ],
                  "confidence": "medium"
                }
              }
            }
          },
          "technology_config": {
            "edc_system": "Rave (Medidata)",
            "irt_system": "Interactive Response Technology (IRT) system for randomization and drug supply management.",
            "etmf_system": "Standard electronic trial master file system.",
            "safety_db": "Standard pharmacovigilance safety database.",
            "rbqm_platform": "Centralized monitoring platform for KRI tracking and data analytics.",
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The EDC and IRT systems are explicitly named. The other systems (eTMF, Safety DB, RBQM Platform) are inferred as standard components required to execute a trial of this nature and to fulfill the data collection and reporting requirements described.",
                "supporting_context": [
                  "Section 10.2, Page 95: 'The CRF data for this study are being collected with an electronic data capture (EDC) system called Rave® provided by the technology vendor Medidata Solutions Incorporated...'",
                  "Section 49, Page 49: 'An Interactive Response Technology system (IRT) will be utilized to register subjects.'"
                ],
                "confidence": "high"
              }
            }
          },
          "provenance": {
            "kind": "derived",
            "derived": {
              "reasoning": "The protocol does not use the term 'RBQM' but implements its principles. The entire RBQM section is a structured interpretation of the risks inherent in the study design, endpoints, and procedures described throughout the protocol, particularly in sections on objectives, population, procedures, and safety.",
              "supporting_context": [
                "Section 4.0 Study Objectives",
                "Section 5.0 Investigational Plan",
                "Section 6.0 Adverse Events",
                "Section 8.0 Statistical Methods"
              ],
              "confidence": "high"
            }
          }
        },
        "extraction_statistics": {
          "has_monitoring_approach": true,
          "has_sdv_strategy": true,
          "has_monitoring_visits": true,
          "kri_count": 5,
          "qtl_count": 3,
          "ctq_count": 6,
          "emergent_risk_count": 3,
          "mitigation_strategy_count": 3,
          "identified_risks_count": 3,
          "has_ract_register": true,
          "has_risk_governance": true
        },
        "provenance": {
          "kind": "derived",
          "derived": {
            "reasoning": "The overall quality management plan is derived from the protocol's explicit requirements for monitoring, adherence to GCP/ICH, safety reporting, and data collection. These elements are synthesized into a structured quality management framework, with specific modern components like KRIs and QTLs inferred as best practices for executing the protocol's intent.",
            "supporting_context": [
              "Section 9.2, Page 93: Ethical Conduct of the Study",
              "Section 6.0, Page 73: Adverse Events",
              "Section 7.0, Page 81: Protocol Deviations",
              "Section 10.0, Page 94: Source Documents and Case Report Form Completion"
            ],
            "confidence": "high"
          }
        }
      },
      "_agentDocumentation": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including monitoring approach (RBQM),\n    KRIs, quality tolerance limits, and audit procedures. Essential for CTMS monitoring\n    configuration.",
        "scope": "- Monitoring approach (on-site, remote, centralized)\n    - Risk-based quality management (RBQM)\n    - Key Risk Indicators (KRIs)\n    - Quality Tolerance Limits (QTLs)\n    - Source data verification extent\n    - Audit procedures\n    - CAPA management",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan",
          "Appendix: RBQM Plan"
        ],
        "keyInsights": [
          {
            "name": "Monitoring Approach",
            "description": "On-site, remote, centralized monitoring strategy",
            "dataPath": "monitoring_approach",
            "downstreamUses": [
              "CTMS monitoring setup",
              "CRA allocation",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "high"
          },
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Quality Tolerance Limits",
            "description": "QTLs with actions when exceeded",
            "dataPath": "qtls[]",
            "downstreamUses": [
              "Quality dashboard configuration",
              "Sponsor alerts",
              "CAPA triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring visit schedules",
          "Set up KRI dashboards and thresholds",
          "Generate monitoring plan templates",
          "Configure central monitoring alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json"
      }
    },
    "withdrawalProcedures": {
      "moduleId": "withdrawal_procedures",
      "instanceType": "WithdrawalProcedures",
      "data": {
        "id": "WP-001",
        "instanceType": "WithdrawalProcedures",
        "name": "Withdrawal and Discontinuation Procedures",
        "description": "Procedural specifications for subject withdrawal and discontinuation",
        "discontinuation_types": [
          {
            "id": "DT-001",
            "type_name": {
              "code": "TREATMENT_DISCONTINUATION",
              "decode": "Treatment Discontinuation"
            },
            "definition": "Subjects who discontinue treatment prior to reaching an event of disease progression are to continue assessments until disease progression.",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "5.4.1",
              "page_number": 56,
              "text_snippet": "Subjects who complete therapy or who discontinue treatment prior to reaching an event of disease progression are to continue assessments until disease progression. Refer to Section 5.3.1 for more details."
            }
          },
          {
            "id": "DT-002",
            "type_name": {
              "code": "STUDY_WITHDRAWAL",
              "decode": "Study Withdrawal"
            },
            "definition": "Subject discontinuation from the study without reaching a protocol-defined endpoint.",
            "allows_continued_followup": false,
            "provenance": {
              "section_number": "5.4.1",
              "page_number": 56,
              "text_snippet": "When subject discontinuation from the study (without reaching a protocol-defined endpoint) is planned, the Investigator is to notify the AbbVie medical monitor or the clinical team representative (Section 7.0) via telephone as soon as possible (provided, in each case, subject care and safety are not compromised)."
            }
          }
        ],
        "consent_withdrawal": {
          "right_to_withdraw": "Each subject has the right to withdraw from study treatment at any time. In addition, the Investigator may discontinue a subject from the study treatment at any time for any reason if the Investigator considers it necessary. The subject decides to withdraw consent for any reason.",
          "withdrawal_process": "The reason(s) for the discontinuation from the study will be recorded and assessments will be performed per Table 2.",
          "data_handling_options": [
            {
              "option": {
                "code": "RETAIN_ALL",
                "decode": "Retain all data"
              },
              "description": "Data collected up to the point of withdrawal will be retained and used in the study analysis. Pharmacogenetic samples will be retained for research."
            }
          ],
          "sample_handling": "AbbVie will store the DNA samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on ABT-888 (or drugs of this class) continues but no longer than 20 years.",
          "consequences": "Subjects may withdraw consent for any reason without penalty.",
          "provenance": {
            "section_number": "5.4",
            "page_number": 56,
            "text_snippet": "Each subject has the right to withdraw from study treatment at any time. In addition, the Investigator may discontinue a subject from the study treatment at any time for any reason if the Investigator considers it necessary... The subject decides to withdraw consent for any reason."
          }
        },
        "discontinuation_visit": {
          "timing": "The visit at which an investigator identifies disease progression or at which a subject meets other criteria for study discontinuation will be considered the Final Visit. It is preferable that Final Visit procedures be conducted prior to the initiation of another anticancer therapy.",
          "timing_days_from_last_dose": null,
          "required_assessments": [
            {
              "id": "ASS-001",
              "assessment_type": {
                "code": "PHYSICAL_EXAM",
                "decode": "Physical Examination"
              },
              "assessment_name": "Physical Exam (including weight)",
              "mandatory": true
            },
            {
              "id": "ASS-002",
              "assessment_type": {
                "code": "VITAL_SIGNS",
                "decode": "Vital Signs"
              },
              "assessment_name": "Vital Signs",
              "mandatory": true
            },
            {
              "id": "ASS-003",
              "assessment_type": {
                "code": "QUESTIONNAIRE",
                "decode": "Questionnaire"
              },
              "assessment_name": "Performance Status (ECOG)",
              "mandatory": true
            },
            {
              "id": "ASS-004",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory"
              },
              "assessment_name": "Documentation of Non-Childbearing Status or Pregnancy Test",
              "mandatory": true
            },
            {
              "id": "ASS-005",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory"
              },
              "assessment_name": "Chemistry/Hematology",
              "mandatory": true
            },
            {
              "id": "ASS-006",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory"
              },
              "assessment_name": "Urinalysis",
              "mandatory": true
            },
            {
              "id": "ASS-007",
              "assessment_type": {
                "code": "IMAGING",
                "decode": "Imaging"
              },
              "assessment_name": "Tumor Assessments",
              "mandatory": true
            },
            {
              "id": "ASS-008",
              "assessment_type": {
                "code": "QUESTIONNAIRE",
                "decode": "Questionnaire"
              },
              "assessment_name": "QoL Questionnaires",
              "mandatory": true
            },
            {
              "id": "ASS-009",
              "assessment_type": {
                "code": "AE_REVIEW",
                "decode": "Adverse Event Review"
              },
              "assessment_name": "Adverse Event and Concomitant Medication Assessment",
              "mandatory": true
            }
          ],
          "documentation_requirements": [
            "The reason(s) for the discontinuation from the study will be recorded."
          ],
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 57,
            "text_snippet": "The visit at which an investigator identifies disease progression or at which a subject meets other criteria for study discontinuation will be considered the Final Visit. The reason(s) for the discontinuation from the study will be recorded and assessments will be performed per Table 2."
          }
        },
        "post_discontinuation_followup": {
          "safety_followup": {
            "duration_days": 30,
            "duration_description": "Subjects who have a Final Visit within 30 days of therapy will have one Follow-Up Visit approximately 30 days after the last dose of study drug.",
            "assessments": [
              "Physical Exam",
              "Vital Signs",
              "Performance Status (ECOG)",
              "Chemistry/Hematology",
              "Adverse Event and Concomitant Medication Assessment"
            ],
            "contact_method": {
              "code": "IN_PERSON",
              "decode": "In-person visit"
            }
          },
          "survival_followup": {
            "required": true,
            "frequency": "at 2-month intervals (or as requested by sponsor to support data analysis)",
            "duration": "beginning at the last clinical assessment and continuing until the endpoint of death, the subject has become lost to follow-up, or AbbVie terminates the study.",
            "information_collected": [
              "Survival status",
              "Post-study anti-cancer therapy information"
            ]
          },
          "ae_followup": {
            "ongoing_ae_followup": true,
            "followup_until": "a satisfactory clinical resolution of the laboratory results or adverse event is achieved"
          },
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 57,
            "text_snippet": "Subjects who have a Final Visit within 30 days of therapy will have one Follow-Up Visit approximately 30 days after the last dose of study drug... If a subject is discontinued from the study with an ongoing adverse event or an unresolved clinically significant laboratory result, the site will attempt to provide follow-up until a satisfactory clinical resolution of the laboratory results or adverse event is achieved."
          }
        },
        "lost_to_followup": {
          "definition": "The protocol does not provide a specific definition for lost to follow-up, but lists it as a reason to end survival follow-up.",
          "missed_visits_threshold": null,
          "contact_attempts_required": null,
          "contact_methods": [],
          "documentation_required": [],
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 57,
            "text_snippet": "Subjects no longer undergoing clinical assessments will have survival information reported at 2-month intervals (or as requested by sponsor to support data analysis) beginning at the last clinical assessment and continuing until the endpoint of death, the subject has become lost to follow-up, or AbbVie terminates the study."
          }
        },
        "replacement_strategy": {
          "allows_replacement": false,
          "replacement_conditions": [
            {
              "discontinuation_reason": "Any",
              "replacement_allowed": false
            }
          ],
          "timing_cutoff": "Discontinued subjects will not be replaced.",
          "randomization_handling": null,
          "stratification_maintenance": false,
          "provenance": {
            "section_number": "5.4",
            "page_number": 56,
            "text_snippet": "Discontinued subjects will not be replaced."
          }
        },
        "administrative_withdrawal": {
          "reasons": [
            {
              "id": "AWR-001",
              "reason_type": {
                "code": "SPONSOR_DECISION",
                "decode": "Sponsor Decision"
              },
              "description": "AbbVie may terminate this study prematurely, either in its entirety or at any study site, for reasonable cause."
            },
            {
              "id": "AWR-002",
              "reason_type": {
                "code": "INVESTIGATOR_DECISION",
                "decode": "Investigator Decision"
              },
              "description": "The Investigator may also terminate the study at his/her site for reasonable cause."
            },
            {
              "id": "AWR-003",
              "reason_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "description": "The study is stopped due to safety concerns."
            }
          ],
          "notification_requirements": "If the Sponsor has decided to prematurely discontinue the study, the Sponsor will promptly notify in writing each Investigator as well as regulatory authorities. Each Investigator must promptly notify the enrolled subjects of the premature discontinuation and administer appropriate treatments.",
          "irb_notification": true,
          "provenance": {
            "section_number": "5.4.2",
            "page_number": 58,
            "text_snippet": "AbbVie may terminate this study prematurely, either in its entirety or at any study site, for reasonable cause provided that written notice is submitted in advance of the intended termination. The Investigator may also terminate the study at his/her site for reasonable cause, after providing written notice to AbbVie in advance of the intended termination. Advance notice is not required by either party if the study is stopped due to safety concerns."
          }
        },
        "data_retention": {
          "retention_period_years": 20,
          "retention_policy": "Pharmacogenetic and biospecimen samples will be retained for up to but no longer than 20 years.",
          "analysis_populations": [
            {
              "population": {
                "code": "SAFETY",
                "decode": "Safety Population"
              },
              "inclusion_criteria": "Subjects who were randomized but did not receive study drug will not be included in the analyses of safety."
            },
            {
              "population": {
                "code": "ITT",
                "decode": "Intent-to-Treat Population"
              },
              "inclusion_criteria": "For OS and PFS analyses, data from withdrawn subjects will be censored according to protocol-specified rules, implying their inclusion in the analysis set."
            }
          ],
          "provenance": {
            "section_number": "5.3.7",
            "page_number": 55,
            "text_snippet": "The samples will be retained while research on veliparib (or drugs of this class) continues for up to but no longer than 20 years."
          }
        },
        "retention_strategies": {
          "prevention_measures": [],
          "incentives": [],
          "re_consent_procedures": null,
          "provenance": {
            "section_number": "5.5.6",
            "page_number": 66,
            "text_snippet": "Unless otherwise directed by the Investigator, a subject will be considered compliant with study drug, veliparib, if 80% of the assigned dose is taken during a cycle. Compliance below 80% will require counseling of the subject by study site personnel."
          }
        },
        "provenance": {
          "section_number": "5.4",
          "page_number": 55,
          "text_snippet": "5.4 Removal of Subjects from Therapy or Assessment"
        }
      },
      "_agentDocumentation": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures including types of withdrawal, required\n    assessments, and follow-up requirements. Important for EDC disposition forms and\n    protocol deviation tracking.",
        "scope": "- Discontinuation types (treatment vs study)\n    - Consent withdrawal procedures\n    - Early termination visit requirements\n    - Survival follow-up\n    - Lost to follow-up procedures\n    - Protocol deviation handling",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          },
          {
            "name": "Follow-up Requirements",
            "description": "Post-discontinuation follow-up procedures",
            "dataPath": "followup_requirements",
            "downstreamUses": [
              "EDC follow-up forms",
              "Site procedures",
              "Survival tracking"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition and early termination forms",
          "Configure survival follow-up tracking",
          "Set up protocol deviation categorization"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json"
      }
    },
    "imagingCentralReading": {
      "moduleId": "imaging_central_reading",
      "instanceType": "ImagingCentralReading",
      "data": {
        "id": "NCT02264990-imaging-central-reading",
        "instanceType": "ImagingCentralReading",
        "name": "NCT02264990 Imaging & Central Reading",
        "description": "Tumor assessment and imaging specifications for Protocol M14-359.",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers"
        },
        "response_criteria": {
          "primary_criteria": "RECIST",
          "criteria_version": "1.1",
          "secondary_criteria": [],
          "modifications": null,
          "provenance": {
            "section_number": "Appendix H",
            "page_number": 114,
            "text_snippet": "Response criteria will be assessed using RECIST (version 1.1). Changes in the measurable lesions over the course of therapy must be evaluated using the criteria listed below."
          }
        },
        "imaging_modalities": [
          {
            "modality_id": "IMG-001",
            "modality_type": "CT",
            "body_regions": [
              "chest",
              "abdomen"
            ],
            "contrast_required": true,
            "contrast_type": "IV contrast",
            "slice_thickness": "≤ 5 mm",
            "technical_requirements": "Conventional CT should be performed with cuts of 5 mm or less in slice thickness contiguously. A scale should be incorporated into all radiographic measurements. If a subject is unable to undergo a CT scan with IV contrast due to allergy or renal insufficiency, a non-contrast CT may be performed.",
            "preferred_modality": true,
            "provenance": {
              "section_number": null,
              "page_number": 116,
              "text_snippet": "Conventional CT should be performed with cuts of 5 mm or less in slice thickness contiguously. This applies to tumors of the chest and abdomen. A scale should be incorporated into all radiographic measurements. ... If prior to enrollment, it is known a subject is not able to undergo CT scans with IV contrast due to allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI should be used to evaluate the subject at baseline and follow-up should be guided by the tumor"
            }
          },
          {
            "modality_id": "IMG-002",
            "modality_type": "MRI",
            "body_regions": [
              "brain"
            ],
            "contrast_required": null,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "To be performed on any subject with signs or symptoms suggesting CNS involvement by tumor. A CT scan can be used if MRI is contraindicated.",
            "preferred_modality": false,
            "provenance": {
              "section_number": null,
              "page_number": 49,
              "text_snippet": "A baseline MRI (or CT if MRI is contraindicated) of the brain is to be performed on any subject with signs or symptoms suggesting CNS involvement by tumor."
            }
          },
          {
            "modality_id": "IMG-003",
            "modality_type": "Ultrasound",
            "body_regions": [],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "Ultrasound (US) should not be used to measure tumor lesions for accurate objective response evaluation.",
            "preferred_modality": false,
            "provenance": {
              "section_number": null,
              "page_number": 116,
              "text_snippet": "For accurate objective response evaluation, ultrasound (US) should not be used to measure tumor lesions."
            }
          }
        ],
        "assessment_schedule": {
          "baseline_window": "Within 28 days (inclusive) of randomization.",
          "on_treatment_frequency": "Tumor assessments will be performed on Cycle 3 Day 1 and Cycle 5 Day 1.",
          "first_assessment_timing": "Cycle 3 Day 1",
          "post_treatment_schedule": "After cessation of platinum doublet therapy, tumor assessments will be performed q9 weeks until 1 year after beginning treatment (C1D-2) (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death.",
          "confirmatory_scan_required": false,
          "confirmatory_scan_window": null,
          "assessment_timepoints": [
            "Baseline",
            "Cycle 3 Day 1",
            "Cycle 5 Day 1",
            "Post-treatment: every 9 weeks for 1 year",
            "Post-treatment (after 1 year): every 12 weeks until progression or death"
          ],
          "provenance": {
            "section_number": null,
            "page_number": 6,
            "text_snippet": "Tumor assessments will be performed at baseline prior to treatment on Cycle 3 Day 1 and Cycle 5 Day 1. After cessation of platinum doublet therapy, tumor assessments will be performed q9 weeks until 1 year after beginning treatment (C1D-2) (or beyond 1 year until maintenance therapy is discontinued), then q12 weeks until radiographic progression or death."
          }
        },
        "lesion_requirements": {
          "provenance": {
            "section_number": "Appendix H",
            "page_number": 114,
            "text_snippet": "Response criteria will be assessed using RECIST (version 1.1). Changes in the measurable lesions over the course of therapy must be evaluated using the criteria listed below.\nEligibility\nSubjects with measurable disease at baseline can have objective tumor response evaluated by RECIST (version 1.1). Measurable disease is defined by the presence of at least one measurable lesion."
          },
          "measurable_disease_definition": "Presence of at least one measurable lesion. Measurable lesions are those that can be accurately measured in at least one dimension with a minimum size of ≥ 10 mm longest diameter (CT scan slice thickness no greater than 5 mm) or 10 mm caliper measurement by clinical exam.",
          "target_lesion_minimum_size": "≥ 10 mm",
          "lymph_node_criteria": "To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in short axis when assessed by CT scan. Pathological lymph nodes with ≥ 10 to < 15 mm short axis are considered non-target lesions.",
          "max_target_lesions": 5,
          "max_target_lesions_per_organ": 2,
          "non_target_lesion_definition": "All other lesions, including small lesions (longest diameter < 10 mm) as well as truly non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung and also abdominal masses that are not confirmed and followed by imaging techniques.",
          "non_measurable_disease": [
            "Blastic bone lesions",
            "Leptomeningeal disease",
            "Ascites",
            "Pleural/pericardial effusion",
            "Inflammatory breast disease",
            "Lymphangitic involvement of skin or lung",
            "Abdominal masses not confirmed by imaging",
            "Cystic lesions defined as simple cysts"
          ]
        },
        "response_categories": [
          {
            "category_code": "CR",
            "category_name": "Complete Response",
            "definition": "The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. For non-target lesions, disappearance of all non-target lesions and normalization of tumor marker level.",
            "target_lesion_criteria": "Disappearance of all target lesions.",
            "non_target_lesion_criteria": "Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm short axis).",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "Appendix H",
              "page_number": 118,
              "text_snippet": "Complete Response (CR): The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm."
            }
          },
          {
            "category_code": "PR",
            "category_name": "Partial Response",
            "definition": "At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.",
            "target_lesion_criteria": "At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.",
            "non_target_lesion_criteria": "Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "Appendix H",
              "page_number": 118,
              "text_snippet": "Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters."
            }
          },
          {
            "category_code": "PD",
            "category_name": "Progressive Disease",
            "definition": "At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (baseline or after) or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, unequivocal progression of existing non-target lesions.",
            "target_lesion_criteria": "At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (baseline or after). The sum must also demonstrate an absolute increase of at least 5 mm.",
            "non_target_lesion_criteria": "Unequivocal progression of existing non-target lesions.",
            "new_lesion_criteria": "Appearance of one or more new lesions.",
            "provenance": {
              "section_number": "Appendix H",
              "page_number": 118,
              "text_snippet": "Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started (baseline or after) or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm."
            }
          },
          {
            "category_code": "SD",
            "category_name": "Stable Disease",
            "definition": "Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started (baseline or after).",
            "target_lesion_criteria": "Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.",
            "non_target_lesion_criteria": "Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "Appendix H",
              "page_number": 118,
              "text_snippet": "Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started (baseline or after)."
            }
          }
        ],
        "central_reading": {
          "bicr_required": false,
          "bicr_purpose": null,
          "reading_methodology": null,
          "reader_qualifications": null,
          "blinding_requirements": null,
          "adjudication_process": null,
          "vendor_name": null,
          "turnaround_time": null,
          "provenance": {
            "section_number": "6",
            "page_number": 6,
            "text_snippet": "Radiographic information will be collected to determine response according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Toxicities will be graded at each study visit according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0."
          }
        },
        "image_submission": {
          "submission_method": null,
          "format_requirements": null,
          "anonymization_requirements": null,
          "submission_timeline": null,
          "quality_requirements": null,
          "provenance": {
            "section_number": "48",
            "page_number": 48,
            "text_snippet": "A CT scan of the full chest and abdomen (with image of liver and adrenal glands) will be used in the evaluation of tumor responses, as per Table 2... Magnetic resonance imaging (MRI) can be conducted in cases where local laws/requirements mandate, but should have Sponsor approval prior to performing the MRI."
          }
        },
        "special_assessments": [
          {
            "assessment_id": "SA-001",
            "assessment_name": "Brain MRI/CT",
            "purpose": "To confirm absence of CNS metastases in subjects with signs or symptoms of CNS involvement.",
            "methodology": "Standard clinical MRI or CT if MRI is contraindicated.",
            "schedule": "At screening assessment for symptomatic subjects.",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 34,
              "text_snippet": "8. Subject must have no history of brain metastases or evidence of CNS tumors at screening assessment. Subjects with signs or symptoms of CNS involvement will undergo MRI (or CT scan if MRI is contraindicated) to confirm absence of CNS metastases."
            }
          }
        ],
        "immune_related_criteria": {
          "irecist_used": false,
          "pseudoprogression_handling": null,
          "confirmation_requirements": null,
          "treatment_beyond_progression": null,
          "provenance": {
            "section_number": "Appendix H",
            "page_number": 114,
            "text_snippet": "Response criteria will be assessed using RECIST (version 1.1). Changes in the measurable lesions over the course of therapy must be evaluated using the criteria listed below."
          }
        },
        "extraction_statistics": {
          "has_response_criteria": true,
          "has_bicr": false,
          "has_immune_criteria": false,
          "modality_count": 3,
          "response_category_count": 4
        }
      },
      "_agentDocumentation": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications including response criteria (RECIST, RANO),\n    imaging modalities, central reading requirements, and adjudication procedures.\n    Essential for oncology and imaging-endpoint studies.",
        "scope": "- Response assessment criteria (RECIST 1.1, iRECIST, RANO)\n    - Imaging modalities and protocols\n    - Central vs local reading\n    - Reader blinding\n    - Adjudication procedures\n    - Image acquisition specifications\n    - Timepoints and windows",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter",
          "Appendix: Central Reading Manual"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Imaging Schedule",
            "description": "Tumor assessment timepoints and windows",
            "dataPath": "imaging_schedule",
            "downstreamUses": [
              "Visit schedule programming",
              "Site calendars",
              "Imaging upload tracking"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high"
          },
          {
            "name": "Central Reading",
            "description": "Independent central review configuration",
            "dataPath": "central_reading",
            "downstreamUses": [
              "Imaging vendor requirements",
              "Reader training",
              "Adjudication workflows"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows",
          "Create imaging CRFs in EDC",
          "Generate imaging charter requirements"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json"
      }
    },
    "pkpdSampling": {
      "moduleId": "pkpd_sampling",
      "instanceType": "PKPDSampling",
      "data": {
        "id": "NCT02264990-pkpd-sampling",
        "instanceType": "PKPDSampling",
        "name": "NCT02264990 PK/PD Sampling",
        "description": "Pharmacokinetic and pharmacodynamic sampling requirements for Veliparib in Non-Small Cell Lung Cancer",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers"
        },
        "pk_sampling": {
          "pk_sampling_required": true,
          "pk_sampling_purpose": "To characterize the pharmacokinetics of veliparib, support population PK modeling, and analyze in LSP-defined populations.",
          "provenance": {
            "section_number": null,
            "page_number": 9,
            "text_snippet": "Pharmacokinetic/Pharmacogenetics: Blood samples for pharmacokinetics of veliparib will be collected at designated timepoints throughout the study and will be analyzed in LSP-defined populations as well as the entire study population."
          },
          "analytes": [
            {
              "analyte_id": "ANALYTE-001",
              "analyte_name": "veliparib",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "provenance": {
                "section_number": "5.3.2.2",
                "page_number": 53,
                "text_snippet": "Plasma concentrations of veliparib will be determined using validated methods under the supervision of the Drug Analysis Department at AbbVie."
              }
            },
            {
              "analyte_id": "ANALYTE-002",
              "analyte_name": "veliparib metabolite(s)",
              "analyte_type": "metabolite",
              "matrix": "plasma",
              "provenance": {
                "section_number": "5.3.2.2",
                "page_number": 53,
                "text_snippet": "Plasma concentrations of veliparib metabolite(s) may be determined using validated or non-validated methods."
              }
            }
          ],
          "sampling_schedule": [
            {
              "schedule_id": "SCHED-001",
              "visit_name": "Cycle 1 Day -2",
              "timepoints": [
                {
                  "timepoint_name": "1h post AM dose",
                  "nominal_time": "1h"
                },
                {
                  "timepoint_name": "2h post AM dose",
                  "nominal_time": "2h"
                },
                {
                  "timepoint_name": "3h post AM dose",
                  "nominal_time": "3h"
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": "Table 4",
                "page_number": 43,
                "text_snippet": "Veliparib PK Sampling C1D-2 -- 1, 2, 3 h"
              }
            },
            {
              "schedule_id": "SCHED-002",
              "visit_name": "Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h"
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": "Table 4",
                "page_number": 43,
                "text_snippet": "Veliparib PK Samplinga C2D1, C3D1, C4D1. 0 ha"
              }
            }
          ],
          "intensive_pk_visits": [
            "Cycle 1 Day -2"
          ],
          "sparse_pk_visits": [
            "Cycle 2 Day 1",
            "Cycle 3 Day 1",
            "Cycle 4 Day 1"
          ],
          "sample_volume": "Approximately 3 mL"
        },
        "pk_parameters": {
          "primary_parameters": [
            "CL/F",
            "V/F"
          ],
          "calculation_method": "Nonlinear mixed effect modeling",
          "provenance": {
            "section_number": "5.3.5",
            "page_number": 54,
            "text_snippet": "A nonlinear mixed effect modeling analysis will be conducted to estimate the population pharmacokinetic parameters of veliparib including apparent oral clearance (CL/F) and volume of distribution (V/F). Additional parameters may be calculated if useful in the interpretation of the data."
          }
        },
        "population_pk": {
          "pop_pk_planned": true,
          "modeling_approach": "Nonlinear mixed effect modeling",
          "covariates": [],
          "objectives": "To estimate the population pharmacokinetic parameters of veliparib.",
          "provenance": {
            "section_number": "5.3.5",
            "page_number": 54,
            "text_snippet": "A nonlinear mixed effect modeling analysis will be conducted to estimate the population pharmacokinetic parameters of veliparib including apparent oral clearance (CL/F) and volume of distribution (V/F)."
          }
        },
        "pd_assessments": {
          "pd_assessments_required": true,
          "provenance": {
            "section_number": null,
            "page_number": 10,
            "text_snippet": "Pharmacodynamic: Research to find biomarkers that may serve as surrogates for clinical endpoints in future veliparib studies or that may be predictive of veliparib activity will be conducted. Serum, plasma, blood and tissue samples will be collected at designated time points throughout the study."
          },
          "pd_biomarkers": [
            {
              "biomarker_id": "BIOMARKER-001",
              "biomarker_name": "Plasma Markers",
              "biomarker_type": "exploratory",
              "matrix": "plasma",
              "sampling_schedule": "C1D-2 (Pre-dose), C3D1 (Pre-dose), Final Visit",
              "purpose": "To evaluate known and novel markers (nucleic acids, peptides/proteins and/or metabolites) of disease status.",
              "provenance": {
                "section_number": "5.3.1.3",
                "page_number": 52,
                "text_snippet": "Pharmacodynamic correlative studies are exploratory in nature. Serum, plasma and tissue specimens may be utilized to evaluate known and novel markers (nucleic acids, peptides/proteins and/or metabolites) of disease status."
              }
            },
            {
              "biomarker_id": "BIOMARKER-002",
              "biomarker_name": "Serum Markers",
              "biomarker_type": "exploratory",
              "matrix": "serum",
              "sampling_schedule": "C1D-2 (Pre-dose), C3D1 (Pre-dose), Final Visit",
              "purpose": "To evaluate known and novel markers (nucleic acids, peptides/proteins and/or metabolites) of disease status.",
              "provenance": {
                "section_number": "5.3.1.3",
                "page_number": 52,
                "text_snippet": "Pharmacodynamic correlative studies are exploratory in nature. Serum, plasma and tissue specimens may be utilized to evaluate known and novel markers (nucleic acids, peptides/proteins and/or metabolites) of disease status."
              }
            },
            {
              "biomarker_id": "BIOMARKER-003",
              "biomarker_name": "Genetic lesions",
              "biomarker_type": "exploratory",
              "matrix": "archival tumor tissue",
              "sampling_schedule": "Screening or C1D-2",
              "purpose": "To identify potential associations with subject outcome or to better characterize the disease (e.g., amplification, chromosomal loss, mutational/methylation).",
              "provenance": {
                "section_number": "5.3.7",
                "page_number": 55,
                "text_snippet": "Biospecimens collected may be evaluated for genetic lesions whether they occur by amplification, chromosomal loss and/or mutational/methylation with the intent of identifying potential associations with subject outcome or to better characterize the disease."
              }
            },
            {
              "biomarker_id": "BIOMARKER-004",
              "biomarker_name": "DNA repair proteins (e.g., ERCC1, XPF)",
              "biomarker_type": "exploratory",
              "matrix": "archival tumor tissue",
              "sampling_schedule": "Screening or C1D-2",
              "purpose": "To explore the relationship between tumor response and/or disease status.",
              "provenance": {
                "section_number": "5.3.7",
                "page_number": 55,
                "text_snippet": "Biospecimens may be evaluated for levels of biomarkers including nucleic acids, proteins/peptides and metabolites. For example protein analysis of relevant proteins, including but not limited to, DNA repair proteins, such as ERCC1 and XPF, may be performed on tumor tissue obtained from each consented subject."
              }
            }
          ],
          "pk_pd_relationship": "Exploratory analysis of the relationship between tumor response and/or disease status and biomarkers."
        },
        "immunogenicity": {
          "ada_testing_required": false,
          "provenance": {
            "section_number": "5.3.4",
            "page_number": 54,
            "text_snippet": "AbbVie will assess adverse events, laboratory data, ECGs and vital signs throughout the study. Adverse events intensity and laboratory evaluation changes will be assessed by utilizing NCI CTCAE version 4.0. (Immunogenicity is not mentioned in the protocol)."
          }
        },
        "sample_handling": {
          "processing_requirements": "Plasma: Centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw. Serum: Clot formation, centrifugation, transfer to cryovials and freezing should be accomplished in less than 90 minutes from the time of blood draw.",
          "storage_conditions": "Frozen (as per the study specific laboratory manual)",
          "provenance": {
            "section_number": "5.3.1.3",
            "page_number": 52,
            "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL (Baseline and Final Visit) or 6 mL (all other timepoints) of blood will be collected... The complete process of centrifugation, transfer to cryovial and freezing should be accomplished in less than 1 hour from the time of blood draw.\nBlood Collection for Serum Markers\nApproximately 5 mL of blood will be collected..."
          }
        },
        "special_populations": {
          "provenance": {
            "section_number": null,
            "page_number": 7,
            "text_snippet": "11. Subject must have adequate bone marrow, renal and hepatic function as follows:\n! Renal function: serum calculated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula... \n! Hepatic function: AST and ALT ≤ 2.5 × ULN unless liver metastases are present, then AST and ALT < 5.0 × ULN; bilirubin ≤ 1.5 × ULN... (No specific PK studies in special populations are described)."
          }
        },
        "extraction_statistics": {
          "has_pk_sampling": true,
          "has_pd_assessments": true,
          "has_immunogenicity": false,
          "has_population_pk": true,
          "analyte_count": 2,
          "biomarker_count": 4,
          "total_pk_timepoints": 6
        }
      },
      "_agentDocumentation": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications including\n    timepoints, bioanalytical methods, and population PK requirements. Essential for\n    clinical pharmacology studies and bioanalytical lab setup.",
        "scope": "- PK sampling timepoints (intensive, sparse)\n    - PD biomarker sampling\n    - Bioanalytical methods and assay validation\n    - Population PK specifications\n    - Drug concentration thresholds\n    - Sample handling for PK",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule",
          "Appendix: Bioanalytical Methods"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          },
          {
            "name": "Bioanalytical Methods",
            "description": "Assay methods, LLOQ, validated ranges",
            "dataPath": "bioanalytical_methods[]",
            "downstreamUses": [
              "Bioanalytical lab requirements",
              "Sample stability planning",
              "CSR content"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides",
          "Set up PK timepoint tracking in EDC",
          "Generate population PK analysis specifications"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json"
      }
    }
  },
  "provenanceSummary": {
    "totalPagesReferenced": 81,
    "pageRange": [
      1,
      118
    ],
    "sectionPageCounts": {
      "studyMetadata": 9,
      "studyDesign": 8,
      "endpointsEstimandsSAP": 11,
      "adverseEvents": 9,
      "safetyDecisionPoints": 6,
      "concomitantMedications": 5,
      "biospecimenHandling": 5,
      "laboratorySpecifications": 15,
      "informedConsent": 19,
      "proSpecifications": 8,
      "dataManagement": 8,
      "siteOperationsLogistics": 21,
      "qualityManagement": 18,
      "withdrawalProcedures": 5,
      "imagingCentralReading": 8,
      "pkpdSampling": 9
    },
    "pageToSections": {
      "1": [
        "studyMetadata",
        "endpointsEstimandsSAP",
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "2": [
        "studyMetadata"
      ],
      "4": [
        "studyMetadata",
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "5": [
        "studyMetadata",
        "siteOperationsLogistics"
      ],
      "6": [
        "studyMetadata",
        "proSpecifications",
        "qualityManagement",
        "imagingCentralReading"
      ],
      "7": [
        "studyMetadata",
        "informedConsent",
        "qualityManagement",
        "pkpdSampling"
      ],
      "8": [
        "studyMetadata"
      ],
      "9": [
        "proSpecifications",
        "pkpdSampling"
      ],
      "10": [
        "laboratorySpecifications",
        "qualityManagement",
        "pkpdSampling"
      ],
      "27": [
        "informedConsent"
      ],
      "28": [
        "informedConsent"
      ],
      "29": [
        "endpointsEstimandsSAP",
        "informedConsent",
        "qualityManagement"
      ],
      "30": [
        "studyDesign",
        "endpointsEstimandsSAP",
        "informedConsent",
        "qualityManagement"
      ],
      "31": [
        "studyDesign",
        "informedConsent"
      ],
      "33": [
        "studyMetadata",
        "studyDesign",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "34": [
        "laboratorySpecifications",
        "imagingCentralReading"
      ],
      "35": [
        "laboratorySpecifications"
      ],
      "36": [
        "concomitantMedications"
      ],
      "37": [
        "concomitantMedications"
      ],
      "38": [
        "concomitantMedications",
        "informedConsent"
      ],
      "39": [
        "concomitantMedications"
      ],
      "40": [
        "concomitantMedications"
      ],
      "41": [
        "laboratorySpecifications",
        "informedConsent",
        "proSpecifications",
        "dataManagement"
      ],
      "42": [
        "informedConsent"
      ],
      "43": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "44": [
        "qualityManagement"
      ],
      "45": [
        "siteOperationsLogistics"
      ],
      "46": [
        "laboratorySpecifications"
      ],
      "47": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "48": [
        "laboratorySpecifications",
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "49": [
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "50": [
        "proSpecifications",
        "siteOperationsLogistics"
      ],
      "51": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "proSpecifications",
        "dataManagement"
      ],
      "52": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "53": [
        "endpointsEstimandsSAP",
        "biospecimenHandling",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "54": [
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "55": [
        "informedConsent",
        "withdrawalProcedures",
        "pkpdSampling"
      ],
      "56": [
        "safetyDecisionPoints",
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "57": [
        "withdrawalProcedures"
      ],
      "58": [
        "withdrawalProcedures"
      ],
      "59": [
        "studyDesign",
        "siteOperationsLogistics"
      ],
      "61": [
        "siteOperationsLogistics"
      ],
      "62": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "63": [
        "studyMetadata",
        "siteOperationsLogistics"
      ],
      "64": [
        "siteOperationsLogistics"
      ],
      "65": [
        "studyDesign",
        "dataManagement"
      ],
      "66": [
        "siteOperationsLogistics",
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "67": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "68": [
        "informedConsent"
      ],
      "70": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "71": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "72": [
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "73": [
        "adverseEvents",
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "74": [
        "adverseEvents",
        "qualityManagement"
      ],
      "75": [
        "adverseEvents"
      ],
      "76": [
        "adverseEvents"
      ],
      "77": [
        "adverseEvents"
      ],
      "79": [
        "adverseEvents",
        "informedConsent",
        "qualityManagement"
      ],
      "80": [
        "adverseEvents"
      ],
      "81": [
        "adverseEvents",
        "qualityManagement"
      ],
      "82": [
        "endpointsEstimandsSAP"
      ],
      "83": [
        "endpointsEstimandsSAP",
        "qualityManagement"
      ],
      "84": [
        "endpointsEstimandsSAP",
        "proSpecifications"
      ],
      "85": [
        "endpointsEstimandsSAP",
        "dataManagement"
      ],
      "86": [
        "endpointsEstimandsSAP"
      ],
      "88": [
        "endpointsEstimandsSAP",
        "qualityManagement"
      ],
      "89": [
        "endpointsEstimandsSAP",
        "adverseEvents",
        "dataManagement"
      ],
      "91": [
        "qualityManagement"
      ],
      "92": [
        "siteOperationsLogistics"
      ],
      "93": [
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "95": [
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "96": [
        "informedConsent",
        "dataManagement"
      ],
      "98": [
        "siteOperationsLogistics"
      ],
      "103": [
        "siteOperationsLogistics"
      ],
      "106": [
        "informedConsent"
      ],
      "108": [
        "proSpecifications"
      ],
      "110": [
        "proSpecifications"
      ],
      "113": [
        "studyDesign",
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "114": [
        "imagingCentralReading"
      ],
      "116": [
        "imagingCentralReading"
      ],
      "118": [
        "imagingCentralReading"
      ]
    }
  },
  "agentDocumentation": {
    "description": "Agent documentation for downstream system automation. Each agent's documentation describes its purpose, key insights, downstream system integrations, and automation use cases.",
    "agents": {
      "pro_specifications": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome (PRO) and clinical outcome assessment (COA)\n    specifications including instruments, ePRO system configuration, and compliance\n    requirements. Essential for ePRO/eCOA vendor configuration.",
        "scope": "- PRO instruments (questionnaires, scales)\n    - ePRO/eCOA system configuration\n    - ClinRO instruments (clinician-rated)\n    - ObsRO instruments (observer-rated)\n    - PerfO instruments (performance outcomes)\n    - Daily diaries\n    - Administration timing and windows\n    - Compliance thresholds\n    - Scoring and MCID definitions",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments",
          "Appendix: PRO Administration Guide"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "ePRO System Configuration",
            "description": "Vendor, platform, alerts, reminders, compliance thresholds",
            "dataPath": "epro_system",
            "downstreamUses": [
              "ePRO vendor requirements",
              "Device configuration",
              "Integration specs"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "Assessment Schedule",
            "description": "Timepoints, windows, recall periods for each instrument",
            "dataPath": "pro_instruments[].schedule",
            "downstreamUses": [
              "ePRO scheduling",
              "Compliance alerts",
              "Site calendars"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts",
          "Generate site PRO administration training",
          "Create PRO endpoint analysis specifications",
          "Configure reminder schedules"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json"
      },
      "arms_design": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical"
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical"
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical"
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json"
      },
      "withdrawal_procedures": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures including types of withdrawal, required\n    assessments, and follow-up requirements. Important for EDC disposition forms and\n    protocol deviation tracking.",
        "scope": "- Discontinuation types (treatment vs study)\n    - Consent withdrawal procedures\n    - Early termination visit requirements\n    - Survival follow-up\n    - Lost to follow-up procedures\n    - Protocol deviation handling",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          },
          {
            "name": "Follow-up Requirements",
            "description": "Post-discontinuation follow-up procedures",
            "dataPath": "followup_requirements",
            "downstreamUses": [
              "EDC follow-up forms",
              "Site procedures",
              "Survival tracking"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition and early termination forms",
          "Configure survival follow-up tracking",
          "Set up protocol deviation categorization"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json"
      },
      "safety_decision_points": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json"
      },
      "laboratory_specifications": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, normal ranges, eligibility-related lab\n    criteria, and lab-triggered dose modifications. Critical for central lab setup\n    and EDC lab data entry configuration.",
        "scope": "- Laboratory panels (hematology, chemistry, urinalysis, etc.)\n    - Individual tests with units and methods\n    - Eligibility-related lab criteria\n    - Lab-triggered dose modifications\n    - Hepatotoxicity monitoring (Hy's Law)\n    - Central vs local lab requirements\n    - Special lab tests (biomarkers, pharmacogenomics)",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications",
          "Appendix: Laboratory Reference Ranges"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical"
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Lab-Triggered Actions",
            "description": "Lab thresholds triggering dose holds/modifications",
            "dataPath": "lab_triggered_actions[]",
            "downstreamUses": [
              "EDC lab alerts",
              "Medical monitor dashboards",
              "Site guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry with units and ranges",
          "Create eligibility screening lab checklists",
          "Configure lab alert thresholds in EDC",
          "Generate hepatotoxicity monitoring workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json"
      },
      "site_operations_logistics": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements including equipment, training, drug supply,\n    and vendor coordination. Supports site initiation planning and CTMS configuration.",
        "scope": "- Site equipment requirements\n    - Training requirements\n    - Drug storage and handling\n    - IP accountability procedures\n    - Vendor coordination\n    - Site qualification criteria\n    - Document requirements",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements",
          "Appendix: Training Guide"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium"
          },
          {
            "name": "Training Requirements",
            "description": "Required site training modules",
            "dataPath": "training_requirements[]",
            "downstreamUses": [
              "LMS configuration",
              "Site initiation tracking",
              "Delegation logs"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments",
          "Create equipment requirement lists",
          "Set up IP accountability workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json"
      },
      "endpoints_estimands_sap": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json"
      },
      "pkpd_sampling": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications including\n    timepoints, bioanalytical methods, and population PK requirements. Essential for\n    clinical pharmacology studies and bioanalytical lab setup.",
        "scope": "- PK sampling timepoints (intensive, sparse)\n    - PD biomarker sampling\n    - Bioanalytical methods and assay validation\n    - Population PK specifications\n    - Drug concentration thresholds\n    - Sample handling for PK",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule",
          "Appendix: Bioanalytical Methods"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          },
          {
            "name": "Bioanalytical Methods",
            "description": "Assay methods, LLOQ, validated ranges",
            "dataPath": "bioanalytical_methods[]",
            "downstreamUses": [
              "Bioanalytical lab requirements",
              "Sample stability planning",
              "CSR content"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides",
          "Set up PK timepoint tracking in EDC",
          "Generate population PK analysis specifications"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json"
      },
      "quality_management": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including monitoring approach (RBQM),\n    KRIs, quality tolerance limits, and audit procedures. Essential for CTMS monitoring\n    configuration.",
        "scope": "- Monitoring approach (on-site, remote, centralized)\n    - Risk-based quality management (RBQM)\n    - Key Risk Indicators (KRIs)\n    - Quality Tolerance Limits (QTLs)\n    - Source data verification extent\n    - Audit procedures\n    - CAPA management",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan",
          "Appendix: RBQM Plan"
        ],
        "keyInsights": [
          {
            "name": "Monitoring Approach",
            "description": "On-site, remote, centralized monitoring strategy",
            "dataPath": "monitoring_approach",
            "downstreamUses": [
              "CTMS monitoring setup",
              "CRA allocation",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "high"
          },
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Quality Tolerance Limits",
            "description": "QTLs with actions when exceeded",
            "dataPath": "qtls[]",
            "downstreamUses": [
              "Quality dashboard configuration",
              "Sponsor alerts",
              "CAPA triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring visit schedules",
          "Set up KRI dashboards and thresholds",
          "Generate monitoring plan templates",
          "Configure central monitoring alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json"
      },
      "adverse_events": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical"
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical"
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json"
      },
      "data_management": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications including EDC configuration, CDISC standards,\n    data quality requirements, and database lock procedures. Guides EDC setup and\n    data management planning.",
        "scope": "- EDC system requirements\n    - CDISC standards (CDASH, SDTM, ADaM versions)\n    - Data entry timelines\n    - Query management\n    - Database lock procedures\n    - Source data verification requirements\n    - Data transfer specifications",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "EDC Requirements",
            "description": "EDC system specifications, vendor requirements",
            "dataPath": "edc_system",
            "downstreamUses": [
              "EDC vendor selection",
              "System configuration",
              "User setup"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          },
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          },
          {
            "name": "Data Entry Timelines",
            "description": "Expected data entry windows after visit",
            "dataPath": "data_entry_timelines",
            "downstreamUses": [
              "KRI configuration",
              "Site metrics",
              "Query aging rules"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "medium"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines and alerts",
          "Set up CDISC standards compliance checks",
          "Generate data management plan templates",
          "Configure query management workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json"
      },
      "biospecimen_handling": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements.\n    Essential for central lab setup, biobank configuration, and site laboratory\n    manual generation.",
        "scope": "- Specimen types and collection requirements\n    - Tube types, volumes, and handling\n    - Processing instructions (centrifugation, aliquoting)\n    - Storage conditions (temperature, duration)\n    - Shipping requirements (courier, temperature monitoring)\n    - Central lab vs local lab procedures\n    - Biobanking/future research samples",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual",
          "Appendix: Sample Handling Instructions"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical"
          },
          {
            "name": "Processing Instructions",
            "description": "Centrifugation, aliquoting, timing requirements",
            "dataPath": "processing_instructions[]",
            "downstreamUses": [
              "Site training materials",
              "Lab manual generation",
              "Quality checks"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          },
          {
            "name": "Shipping Requirements",
            "description": "Temperature, courier, documentation for specimen transport",
            "dataPath": "shipping_requirements",
            "downstreamUses": [
              "Logistics planning",
              "Courier configuration",
              "Chain of custody"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals",
          "Set up shipping logistics and temperature monitoring",
          "Design sample collection CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json"
      },
      "study_metadata": {
        "agentId": "study_metadata",
        "displayName": "Study Metadata",
        "instanceType": "Study",
        "wave": 0,
        "priority": 0,
        "purpose": "Extracts foundational study-level metadata that all other agents depend on.\n    This agent runs first and provides the context (protocol ID, phase, therapeutic area,\n    population characteristics) that enables accurate extraction by downstream agents.",
        "scope": "- Protocol identification (NCT, EudraCT, IND numbers)\n    - Study phase, type, and design overview\n    - Sponsor information\n    - Target population characteristics (disease, age, sex, biomarkers)\n    - Key milestones and timelines\n    - Design metadata (randomization, blinding, enrollment targets)",
        "keySectionsAnalyzed": [
          "Title Page / Cover",
          "Synopsis",
          "Section 1: Introduction and Background",
          "Section 3: Study Objectives",
          "Section 4: Study Design",
          "Section 5: Study Population"
        ],
        "keyInsights": [
          {
            "name": "Protocol Identifiers",
            "description": "NCT number, EudraCT, IND numbers for regulatory cross-referencing",
            "dataPath": "studyIdentifiers[]",
            "downstreamUses": [
              "CTMS study registration",
              "Regulatory submission linking",
              "ClinicalTrials.gov sync"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical"
          },
          {
            "name": "Study Phase",
            "description": "Clinical trial phase with NCI Thesaurus code",
            "dataPath": "studyPhase",
            "downstreamUses": [
              "Regulatory pathway determination",
              "Site qualification criteria",
              "Budget estimation"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical"
          },
          {
            "name": "Target Population",
            "description": "Disease, age range, sex, biomarker requirements, performance status",
            "dataPath": "studyPopulation",
            "downstreamUses": [
              "Site feasibility scoring",
              "Patient recruitment targeting",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Study Milestones",
            "description": "Screening period, enrollment duration, treatment duration, follow-up",
            "dataPath": "studyMilestones",
            "downstreamUses": [
              "CTMS timeline configuration",
              "Site contract milestones",
              "Resource planning"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high"
          },
          {
            "name": "Design Metadata",
            "description": "Randomization ratio, blinding type, target enrollment, countries",
            "dataPath": "studyDesignInfo",
            "downstreamUses": [
              "IRT configuration",
              "Drug supply planning",
              "Regulatory strategy"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System",
          "Interactive Response Technology",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Pre-populate EDC study header and demographics forms",
          "Configure CTMS study record with identifiers and milestones",
          "Set IRT enrollment caps by country/region",
          "Generate ClinicalTrials.gov registration data",
          "Auto-configure site feasibility questionnaires"
        ],
        "integration": {
          "dependsOn": [],
          "enriches": [
            "arms_design",
            "endpoints_estimands_sap",
            "eligibility_criteria"
          ],
          "crossReferences": [
            "quality_management",
            "data_management"
          ]
        },
        "cdiscDomains": [
          "DM",
          "DS"
        ],
        "regulatoryRelevance": "Foundation for ICH M11 sections 1-5, CTD Module 5",
        "schemaFile": "study_metadata_schema.json"
      },
      "imaging_central_reading": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications including response criteria (RECIST, RANO),\n    imaging modalities, central reading requirements, and adjudication procedures.\n    Essential for oncology and imaging-endpoint studies.",
        "scope": "- Response assessment criteria (RECIST 1.1, iRECIST, RANO)\n    - Imaging modalities and protocols\n    - Central vs local reading\n    - Reader blinding\n    - Adjudication procedures\n    - Image acquisition specifications\n    - Timepoints and windows",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter",
          "Appendix: Central Reading Manual"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical"
          },
          {
            "name": "Imaging Schedule",
            "description": "Tumor assessment timepoints and windows",
            "dataPath": "imaging_schedule",
            "downstreamUses": [
              "Visit schedule programming",
              "Site calendars",
              "Imaging upload tracking"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high"
          },
          {
            "name": "Central Reading",
            "description": "Independent central review configuration",
            "dataPath": "central_reading",
            "downstreamUses": [
              "Imaging vendor requirements",
              "Reader training",
              "Adjudication workflows"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows",
          "Create imaging CRFs in EDC",
          "Generate imaging charter requirements"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json"
      },
      "concomitant_medications": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical"
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high"
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json"
      },
      "informed_consent": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements including study risks, benefits,\n    alternatives, and special consent requirements. Supports ICF template generation\n    and IRB submission preparation.",
        "scope": "- Key risks (common, serious, unknown)\n    - Potential benefits\n    - Treatment alternatives\n    - Compensation and costs\n    - Confidentiality provisions\n    - Genetic/biobanking consent elements\n    - Optional sub-study consents\n    - Witness requirements",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form",
          "Protocol Synopsis (Risks/Benefits)"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical"
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high"
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs in EDC",
          "Prepare IRB submission packages",
          "Configure biobank consent tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json"
      }
    },
    "downstreamSystemCoverage": {
      "Electronic Patient-Reported Outcomes": [
        "pro_specifications"
      ],
      "Electronic Clinical Outcome Assessment": [
        "pro_specifications"
      ],
      "Electronic Data Capture": [
        "pro_specifications",
        "arms_design",
        "withdrawal_procedures",
        "safety_decision_points",
        "laboratory_specifications",
        "endpoints_estimands_sap",
        "pkpd_sampling",
        "quality_management",
        "adverse_events",
        "data_management",
        "biospecimen_handling",
        "study_metadata",
        "imaging_central_reading",
        "concomitant_medications",
        "informed_consent"
      ],
      "Interactive Response Technology": [
        "arms_design",
        "safety_decision_points",
        "study_metadata"
      ],
      "Interactive Web Response System": [
        "arms_design"
      ],
      "Randomization & Trial Supply Management": [
        "arms_design"
      ],
      "Drug Supply Management": [
        "arms_design"
      ],
      "Clinical Trial Management System": [
        "withdrawal_procedures",
        "site_operations_logistics",
        "quality_management",
        "adverse_events",
        "data_management",
        "study_metadata"
      ],
      "Safety Database (Pharmacovigilance)": [
        "safety_decision_points",
        "adverse_events",
        "concomitant_medications"
      ],
      "Central Laboratory": [
        "laboratory_specifications",
        "pkpd_sampling",
        "biospecimen_handling"
      ],
      "Trial Master File": [
        "site_operations_logistics",
        "informed_consent"
      ],
      "Regulatory Submission Systems": [
        "endpoints_estimands_sap",
        "study_metadata",
        "informed_consent"
      ],
      "Biospecimen Repository": [
        "biospecimen_handling"
      ],
      "Central Imaging": [
        "imaging_central_reading"
      ]
    },
    "automationCategories": {
      "EDC Form Design & Edit Checks": [
        {
          "agent": "pro_specifications",
          "insight": "PRO Instruments",
          "priority": "critical"
        },
        {
          "agent": "pro_specifications",
          "insight": "ePRO System Configuration",
          "priority": "critical"
        },
        {
          "agent": "withdrawal_procedures",
          "insight": "Discontinuation Types",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "AE Collection Period",
          "priority": "critical"
        },
        {
          "agent": "data_management",
          "insight": "EDC Requirements",
          "priority": "high"
        },
        {
          "agent": "data_management",
          "insight": "Data Entry Timelines",
          "priority": "medium"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Required Premedications",
          "priority": "high"
        },
        {
          "agent": "informed_consent",
          "insight": "Optional Consents",
          "priority": "high"
        }
      ],
      "Visit Schedule Programming": [
        {
          "agent": "pro_specifications",
          "insight": "Assessment Schedule",
          "priority": "high"
        },
        {
          "agent": "withdrawal_procedures",
          "insight": "Follow-up Requirements",
          "priority": "medium"
        },
        {
          "agent": "study_metadata",
          "insight": "Study Milestones",
          "priority": "high"
        },
        {
          "agent": "imaging_central_reading",
          "insight": "Imaging Schedule",
          "priority": "high"
        }
      ],
      "Randomization Configuration": [
        {
          "agent": "arms_design",
          "insight": "Study Arms",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Stratification Factors",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Design Metadata",
          "priority": "critical"
        }
      ],
      "Drug Supply & Kit Management": [
        {
          "agent": "arms_design",
          "insight": "Dosing Regimens",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Drug Supply Configuration",
          "priority": "high"
        }
      ],
      "Safety Monitoring Rules": [
        {
          "agent": "arms_design",
          "insight": "Dose Modification Rules",
          "priority": "high"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Dose Reduction Levels",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Decision Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Stopping Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Organ-Specific Adjustments",
          "priority": "high"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Lab-Triggered Actions",
          "priority": "high"
        },
        {
          "agent": "quality_management",
          "insight": "Key Risk Indicators",
          "priority": "high"
        },
        {
          "agent": "quality_management",
          "insight": "Quality Tolerance Limits",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "SAE Criteria",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "Reporting Timelines",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "AESI List",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "DLT Criteria",
          "priority": "high"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Drug Interactions",
          "priority": "high"
        }
      ],
      "Laboratory Panel Configuration": [
        {
          "agent": "laboratory_specifications",
          "insight": "Laboratory Panels",
          "priority": "critical"
        },
        {
          "agent": "pkpd_sampling",
          "insight": "PK Sampling Schedule",
          "priority": "high"
        },
        {
          "agent": "pkpd_sampling",
          "insight": "Bioanalytical Methods",
          "priority": "medium"
        },
        {
          "agent": "biospecimen_handling",
          "insight": "Specimen Collection Requirements",
          "priority": "critical"
        },
        {
          "agent": "biospecimen_handling",
          "insight": "Processing Instructions",
          "priority": "high"
        },
        {
          "agent": "biospecimen_handling",
          "insight": "Shipping Requirements",
          "priority": "high"
        }
      ],
      "Eligibility Verification": [
        {
          "agent": "laboratory_specifications",
          "insight": "Eligibility Lab Criteria",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Target Population",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Prohibited Medications",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Washout Requirements",
          "priority": "critical"
        }
      ],
      "Site Training Materials": [
        {
          "agent": "site_operations_logistics",
          "insight": "Equipment Requirements",
          "priority": "medium"
        },
        {
          "agent": "site_operations_logistics",
          "insight": "Training Requirements",
          "priority": "medium"
        },
        {
          "agent": "quality_management",
          "insight": "Monitoring Approach",
          "priority": "high"
        }
      ],
      "CDISC Data Standards Mapping": [
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Primary Endpoints",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Estimands",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Analysis Populations",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Statistical Methods",
          "priority": "high"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Subgroup Analyses",
          "priority": "medium"
        },
        {
          "agent": "data_management",
          "insight": "CDISC Standards",
          "priority": "high"
        },
        {
          "agent": "imaging_central_reading",
          "insight": "Response Criteria",
          "priority": "critical"
        },
        {
          "agent": "imaging_central_reading",
          "insight": "Central Reading",
          "priority": "high"
        }
      ],
      "Regulatory Document Generation": [
        {
          "agent": "study_metadata",
          "insight": "Protocol Identifiers",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Study Phase",
          "priority": "critical"
        },
        {
          "agent": "informed_consent",
          "insight": "Key Risks",
          "priority": "critical"
        }
      ]
    },
    "integrationGraph": {
      "nodes": [
        {
          "id": "pro_specifications",
          "displayName": "PRO/eCOA Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "arms_design",
          "displayName": "Treatment Arms & Study Design",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "withdrawal_procedures",
          "displayName": "Withdrawal Procedures",
          "wave": 2,
          "priority": 2
        },
        {
          "id": "safety_decision_points",
          "displayName": "Safety Decision Points",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "laboratory_specifications",
          "displayName": "Laboratory Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "site_operations_logistics",
          "displayName": "Site Operations & Logistics",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "endpoints_estimands_sap",
          "displayName": "Endpoints, Estimands & SAP",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "pkpd_sampling",
          "displayName": "PK/PD Sampling",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "quality_management",
          "displayName": "Quality Management",
          "wave": 2,
          "priority": 1
        },
        {
          "id": "adverse_events",
          "displayName": "Adverse Events",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "data_management",
          "displayName": "Data Management",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "biospecimen_handling",
          "displayName": "Biospecimen Handling",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "study_metadata",
          "displayName": "Study Metadata",
          "wave": 0,
          "priority": 0
        },
        {
          "id": "imaging_central_reading",
          "displayName": "Imaging & Central Reading",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "concomitant_medications",
          "displayName": "Concomitant Medications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "informed_consent",
          "displayName": "Informed Consent Elements",
          "wave": 1,
          "priority": 1
        }
      ],
      "edges": [
        {
          "source": "study_metadata",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "pro_specifications",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "depends_on"
        },
        {
          "source": "arms_design",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "pkpd_sampling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "biospecimen_handling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "arms_design",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "withdrawal_procedures",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "safety_decision_points",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "safety_decision_points",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "laboratory_specifications",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "laboratory_specifications",
          "type": "depends_on"
        },
        {
          "source": "laboratory_specifications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "site_operations_logistics",
          "type": "depends_on"
        },
        {
          "source": "site_operations_logistics",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "site_operations_logistics",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "imaging_central_reading",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pkpd_sampling",
          "type": "depends_on"
        },
        {
          "source": "pkpd_sampling",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "quality_management",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "adverse_events",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "safety_decision_points",
          "type": "cross_references"
        },
        {
          "source": "adverse_events",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "depends_on"
        },
        {
          "source": "data_management",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "biospecimen_handling",
          "type": "depends_on"
        },
        {
          "source": "biospecimen_handling",
          "target": "laboratory_specifications",
          "type": "enriches"
        },
        {
          "source": "biospecimen_handling",
          "target": "pkpd_sampling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "imaging_central_reading",
          "type": "depends_on"
        },
        {
          "source": "imaging_central_reading",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "concomitant_medications",
          "type": "depends_on"
        },
        {
          "source": "concomitant_medications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "concomitant_medications",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "concomitant_medications",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "informed_consent",
          "type": "depends_on"
        },
        {
          "source": "informed_consent",
          "target": "adverse_events",
          "type": "cross_references"
        }
      ]
    }
  }
}